



ANNUAL REPORT- 2019-2020



A D V E N T
ADVENT PHARMA LIMITED



TABLE OF CONTENTS

Letter of Transmittal	01
Notice of the 13 th Annual General Meeting	02
Corporate Profile	03
Brief History of the Company	04
Vision, Mission and Values Statement	05
Board of Directors and Management of the Company	06
Brief Profile of the Board of Directors	07
Message From The Chairman	09
Message From The Managing Director	10
Directors' Report to the Shareholders	11
Financial Highlights	22
Factory View	24
Managing Director & CFO's Declaration to the Board of Directors	27
Certificate of Compliance of Corporate Governance	28
Report on Compliance of Corporate Governance Guidelines	29
Information Relating to Capital Structure	41
Audit Committee Report	42
Nomination and Remuneration Committee Report	44
Status of Credit Rating	46
Application of International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs)	46
Auditors' Report and Audited Financial Statements	47
Proxy Form & Attendance Slip	116

Letter of Transmittal

The Shareholders
Bangladesh Securities and Exchange Commission (BSEC)
Registrar of Joint Stock Companies & Firms (RJSC)
Dhaka Stock Exchange Limited
Chittagong Stock Exchange Limited

Subject: Annual Report for the year ended 30th June 2020.

Dear Sir(s),

We are pleased to enclose herewith a copy of the Annual Report together with the Audited Financial Statements including Statement of Financial Position as at 30 June 2020, Statement of Profit or Loss and Other Comprehensive Income, Statement of Cash Flows, Statement of Changes in Equity for the year ended on 30 June, 2020, along with notes thereon of Advent Pharma Limited for your kind information and record.

Thanking you

Sincerely Yours,

Sd/-
Md. Ikramul Islam
Company Secretary

Advent Pharma Limited

Rupayan Karim Tower, Level # 10, 80, Kakrail
V.I.P. Road, Ramna, Dhaka-1000,
Factory: Plot # B 50-54, BSCIC Industrial Estate, Dhamrai, Dhaka.

Notice of the 13th Annual General Meeting (AGM)

Notice is hereby given to all the Shareholders of Advent Pharma Limited that the 13th Annual General Meeting (AGM) of the Company will be held on virtual platform on Thursday, December 17, 2020 at 11.00 a.m.

AGENDA

01. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 30 June 2020, together with the report of the Directors' and Auditors' thereon.
02. To declare dividend as recommended by the Board of Directors.
03. To elect/re-elect Directors as per Articles of Association of the Company.
04. To appoint/re-appoint Statutory Auditors of the Company and professionals for compliance of Corporate Governance Code and fix their remuneration.
05. To appoint of new Managing Director.
06. To transact any other business with the permission of the Chair.

By order of the Board

Dated: Dhaka
December 03, 2020

Sd/-
Md. Ikramul Islam
Company Secretary

Note:

01. The Shareholders whose names will appear in the Share Register of the Company or Depository Register of CDBL as on the Record Date i.e. November 19, 2020 will be eligible to attend the 13th Annual General Meeting (AGM) and qualify for the dividend.
02. A member entitled to attend and vote at the Annual General Meeting may appoint a Proxy to attend and vote in his/her behalf. Proxy form must be affixed with requisite revenue stamp and must be submitted at the Head office of the Company, not more than 48 hours before the time fixed for the meeting.
03. Shareholders are requested to update their BO account with ETIN in their respective Brokerage House to avoid deduction of 15% tax instead of 10% for individuals as per Section 54 of the amended Income Tax Ordinance, 1984.

N.B: In compliance with Bangladesh Securities and Exchange Commission's Circular No. SEC/CMRRCD/2009-193/154 dated October 24, 2013, no gift/gift coupon/food box/benefit in cash or in kind shall be distributed/paid to the Shareholders for attending the 13th Annual General Meeting.

CORPORATE PROFILE

Name of the Company	: Advent Pharma Limited
Legal Status	: A Public Company limited by shares registered under companies Act, 1994 and listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited.
Date of Incorporation	: C-65459(2951)/2007 dated: 25.01.2007
Converted into Public Limited Company	: 07-May-2016
Commencement of Commercial Operation	: 01-March -2013
Production Capacity	: Bolus Products (in Pcs): 15.87 Million Pcs/Year Powder Products (in Kg): 1.18 Million Kg/Year Liquid Products (in Litre): 1.39 Litre/Year
Registered Office & Factory	: Plot # B 50-54 BSCIC Industrial Estate, Dhamrai, Dhaka.
Corporate Office	: Rupayan Karim Tower, Level # 10, 80, Kakrail, V.I.P. Road, Ramna, Dhaka-1000.
Nature of Business	: The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms.
Authorized Capital	: BDT 1,000 million
Paid Up Capital	: BDT 830.06 million
Date of Approval for IPO	: January 11, 2018
Date of Listing with DSE	: April 01, 2018
Date of Listing with CSE	: March 28, 2018
Principal Bankers	: Islami Bank Bangladesh Ltd, New Market Br, Dhaka. DBBL, Satmasjid Road Br, IFIC Bank Ltd, Dhanmondi Br, Shahjalal-Islami Bank Ltd, Satmasjid Road Br., Midland Bank Ltd, Dilkusha Br.
External Auditors	: Ahmed Zaker & Co., Chartered Accountants Green City Edge (Level-10), 89 Kakrail, Dhaka-1000.
Tax Consultants & Legal Advisor	: Nasir Uddin Ahmed, M. Com (Mgt.), L.L.B 48 & 49 Kakrail, Sky View Mamta Center, A-2 (2nd Floor), Dhaka-1000.
Credit Rating Agency	: Alpha Credit Rating Ltd. Sadharan Bima Bhavan-2 (8th floor), 139 Motijheel C/A, Dhaka-1000.
Company's Website	: www.adventpharmabd.com
Email	: adventpharmaltd.bd@gmail.com

BRIEF HISTORY OF THE COMPANY

Advent Pharma Limited (APL) is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock such as powder, bolus and liquid dosage forms. APL has earned a reputation as a successful animal health medicine manufacturer over the last few years.

Advent Pharma Limited was incorporated as a Private Limited Company on 25th January, 2007 and subsequently converted into a Public Limited Company on 7th May 2016 under Companies Act 1994 with the Registrar of Joint Stock Companies and Firms, Dhaka, Bangladesh under the Companies Act, 1994. The Certificate of Incorporation number is C-65459(2951)/2007.

The Company started its commercial operation on March 01, 2013. The Company gets consent for IPO (Initial Public Offering) as on January 11, 2018 from Bangladesh Securities and Exchange Commission. Accordingly the company listed with CSE (Chittagong Stock Exchange Ltd) as on March 28, 2018 and listed with DSE (Dhaka Stock Exchange Ltd) as on April 01, 2018. Advent Pharma Limited starts its trade from April 12, 2018 at DSE (Dhaka Stock Exchange Ltd) and CSE (Chittagong Stock Exchange Ltd).

Vision Statement

To become the market leader of the veterinary pharmaceutical industry through increased productivity advanced technological application with quality on the strengths of our well experienced professionals.

Mission Statement

To meet up the market needs through a closer working relationship and maintaining quality customer service. To provide maximum value to our customers, and communities.

OUR VALUES

- Quality
- Customer Focus
- Accountability
- Transparency
- Innovation
- Continuous Improvement

Brief description of business strategy;

APL's key strategic objectives are to:

The Company is committed to manufacture products with strict adherence to the Drug Administration Guideline. The aim of the promoters is to generate opportunity of employment, significant contribution to GDP and help to develop Forward & Backward linkage in the country. The management of the company has the following objectives:

1. To be dedicated for the production of animal health care drugs;
2. To fulfill the increasing demand of animal health care drugs in the national market with high quality products;
3. To make the project a model plant of producing animal health care products of highest quality and excellence in competitive price.

BOARD OF DIRECTORS AND MANAGEMENT OF THE COMPANY

Board of Directors

Mr. A.K.M Shafiqul Alam, LLB (Nominee Director of Blue Agro Tech Ltd.)	Chairman
Mrs. Faria Binta Alam	Managing Director
Mr. Wajhi Ahmed	Director
Mrs. Kazi Rina Alam	Director
Mr. Md. Tazul Islam	Director
Mr. Mohammad Towhidul Islam (Nominee Director of Horipur Feed Ltd.)	Director
Mr. Asif Iqbal Chowdhury (Nominee Director of Farmers Hopes Ltd.)	Director
Mr. Mohammed Salim, MBA, FCMA	Independent Director
Mr. Sheikh Karimuzzaman	Independent Director

Audit Committee

Mr. Mohammed Salim, MBA, FCMA Independent Director	Chairman
Mr. Sheikh Karimuzzaman Independent Director	Member
Mr. Asif Iqbal Chowdhury (Nominee Director of Farmers Hopes Ltd.)	Member
Mr. Ikramul Islam Company Secretary	Member Secretary

Nomination and Remuneration Committee (NRC)

Mr. Mohammed Salim, MBA, FCMA Independent Director	Chairman
Mr. A.K.M Shafiqul Alam (Nominee Director of Blue Agro Tech Ltd.)	Member
Mr. Mohammad Towhidul Islam (Nominee Director of Horipur Feed Ltd.)	Member
Mr. Ikramul Islam Company Secretary	Member Secretary

BRIEF OF THE BOARD OF DIRECTORS

Mr. A.K.M Shafiqul Alam, LLB

Chairman

Mr. Advocate A.K.M Shafiqul Alam, son of Mr. Abdus Salam was born in illustrious family on March 01, 1952 at Dhaka, Bangladesh. He completed the degree of LLB and started advocacy in the supreme court of Bangladesh. He has over 44 years working experiences in the field law practicing. He is the Nominee Director of Blue Agro Tech Ltd.

Faria Binta Alam,

Managing Director

Faria Binta Alam was born in famous Muslim family in Bangladesh in the year 1986. She has LLM degree and she is a practicing lawyer in the Supreme Court of Bangladesh. Mrs. Faria is highly proficient and result-oriented professional lawyer with around 7 years of experience in the practicing field.

Mrs. Faria is a member of Panel Lawyers in Standard Bank Ltd. as well as in NCC Bank and she has the privilege to be a Legal Adviser of Hotel Royal Palace Pvt. Ltd.

Wajhi Ahmed,

Director

Wajhi Ahmed was born in a very prominence Muslim family at Dhaka in Bangladesh in the year 1961. He has a long track of 33 years' successful experiences in handling and managing the commercial, financial and marketing segments of Gaco Pharmaceutical, a renowned pharmaceutical manufacturing enterprise of the country. He was the Director of the said organization that deals in manufacturing of pharmaceutical products for human consumptions.

Kazi Rina Alam,

Director

Kazi Rina Alam was born an eminence Muslim family in Bangladesh in the year 1959. She has successful long experience of running and managing SME level business enterprise dealing with handicrafts and promotional gift items.

Md. Tazul Islam,

Director

Md. Tazul Islam, son of Sundor Ali was born in illustrious family on May 08, 1956 at Comilla, Bangladesh. Basically, he was a Diploma Engineer over 33 years' business experiences.

Mohammad Towhidul Islam,

Director (Nominee Director of Horipur Feed Ltd.)

Mohammad Towhidul Islam was born in 1987 in illustrious family of Bangladesh. He obtained BBA from Presidency University & MBA (major in Finance) from BRAC University. He is also partly qualified in Institute of Chartered Accounts in Bangladesh (ICAB). He has 12 years working experiences in Philip Morris International (PMI) and Rahman Rahman-Huq, a member firm of KPMG International.

Asif Iqbal Chowdhury,

Director (Nominee Director of Farmers Hopes Ltd.)

Asif Iqbal Chowdhury, son of late Mafizul Islam Chowdhury was born in illustrious family of Gaibandha, Bangladesh in the year 1971. He obtained BSS under Dhaka University and has over 15 years' business experiences.

**Mohammed Salim,
Independent Director**

Mohammed Salim, FCMA, MBA (UK), MIPA (AUS), CMA(USA), the independent director of Advent Pharma Ltd. was born in October 31, 1963 in Bhola, Bangladesh. With his vast educational qualifications, he has over 28 years' professional experiences in the field of Financial Management, General Management, Financial Analysis, Project financing, Company Law, Budgeting & forecasting, etc. Out of his 28 years working experiences, he served as a General Manager (Finance) of about 10 years at Power Grid Company of Bangladesh Ltd.

**Shekh Karimuzzaman,
Independent Director**

Sheikh Karimuzzaman was born in a respectable Muslim family at Dhaka in the year 1968. He completed his Master of Laws (LLM) from Southeast University in the year 2007. He started practice in the Supreme Court of Bangladesh in the year 2010. He also completed BA (Hon's.) MA in English from Dhaka University in the year 1990. Out of this, He also achieved the degree of Master of Human Rights from Dhaka International University in the year 2006. He is a social worker as well.



MESSAGE FROM THE CHAIRMAN

Bismillahir Rahmanir Rahim

Respected Members, Shareholders and Other Stakeholders,

Assalamualaikum

It is a great pleasure for me to be here with you at the 13th Annual General Meeting of Advent Pharma Limited. On behalf of the Board of Directors and myself, I express my heartfelt thanks and profound gratitude to you for your support and confidence. It is also my privilege to present you Company's Annual Report for the Year ended June 30, 2020 along with our business performance. We are always trying to create the value for investment of the shareholders who have pledge their trust on us over the years.

Advent Pharma Ltd. performed very well during the year 2019-2020. We believe that our endeavors and team work have enabled the Company to maintain its profitability under competitive industry scenario.

In 2019-2020, the Company didn't maintain its growth in Profit comparing to the previous year due to COVID-19 pandemic in the worldwide and repeated flood. It is expected that we will try to recover this situation in the coming year. Based on performance and business results the Board has recommended 10% Stock dividend for the year 2019-2020.

Advent Pharma Limited recognizes that its people are its most valuable asset. Accordingly, the Company continued its programs for development of its human resources being the key contributor to Company's success. We value the contributions of our employees to the organization and adopted policy to reward them accordingly.

At Advent Pharma Ltd. we are working for a better future for our stakeholders, customers, employees and society at large. At this occasion, I would like to thank the employees, without whose efforts and commitments we would not have earned such a strong business position. I would also like to extend my gratitude to the Bangladesh Securities & Exchange Commission, Dhaka Stock Exchange Limited, Chittagong Stock Exchange Limited, Registrar of Joint Stock Companies and Firms, National Board of Revenue, Central Depository Bangladesh Limited and our numerous shareholders for their valuable guidance, support and cooperation at the time of our needs. Our commitment is to attain our cherished mission through execution of prudent business strategies while ensuring that we contribute positively towards the furtherance of our national economy.

Yours sincerely

Sd/-

A.K.M Shafiqul Alam, LLB
Chairman



MESSAGE FROM THE MANAGING DIRECTOR

Bismillahir Rahmanir Rahim

It is a great pleasure and privilege for me to attend this 13th Annual General Meeting of Advent Pharma Limited along with our distinguished shareholders. I am delighted to announce that 2019-2020 has been a successful year for the Company though there has been impact of COVID-19 and flood. During this year the Company has also maintained its volume of revenue and profitability under highly competitive industry scenario by means of improvement in the quality of products and customer satisfaction.

As we have mentioned in the last few years, achieving double-digit growth year after year in the pharmaceutical business is becoming quite a challenge due to the paucity of new pharmaceutical products in the world. We have also stressed that in this environment of low R&D productivity, it has become increasingly important to efficiently utilize the full potential of existing product portfolio. To this end, we have implemented and piloted a number of ideas over the last four years. I shall elaborate on the progress of our strategic actions later in this statement. We have attempted to analyze the underlying factors for growth in the Bangladesh pharmaceutical market. While economic development is undoubtedly a key determinant of market growth, it is not straightforward to quantify the relationship of an exogenous factor such as GDP growth rate, with market growth because of the preponderance of a variety of factors influencing performance. However, endogenous growth, which is the growth that pharmaceutical companies foster through various promotional campaigns are much easier to identify and analyze. Looking at the performance of each molecule, it is clear that the prospects of endogenous growth remain good in Bangladesh.

I believe that the dedication and commitment of all our employees towards our customers have been the main driving force in our successful performance. Accordingly, I would thank our devoted workforce and would expect their similar dedication in future. At the same time, I would also like to thank the members of the Board of Directors for their continued support to the Management of the Company. I also acknowledge with gratitude the relentless backing and cooperation of our numerous stakeholders and earnestly thank them for their continued trust and confidence on us.

Thanking You

Sd/-

Faria Binta Alam
Managing Director

DIRECTORS' REPORT

Bismillahir Rahmanir Rahim

Dear Shareholders

Assalamualaikum

On behalf of the Board of Directors of Advent Pharma Limited, I welcome you all to the 13th Annual General Meeting. It is a pleasure to present you the Audited Financial Statements of the Company for the year ended June 30, 2020, Auditors' Report and the Directors' Report thereon Corporate Governance along with Company's performance and other matters in terms of Companies Act 1994, listing regulations of DSE and CSE, the guidelines issued by Bangladesh Securities and Exchange Commission (BSEC) and International Accounting Standards and other applicable rules & regulations.

Background

Advent Pharma Limited was incorporated as a Private Limited Company on 25th January, 2007 and subsequently converted into a Public Limited Company on 7th May 2016 under Companies Act 1994 with the Registrar of Joint Stock Companies and Firms, Dhaka, Bangladesh under the Companies Act, 1994. The Certificate of Incorporation number is C-65459(2951)/2007. The Company started its commercial operation on March 01, 2013.

The Company gets consent for IPO (Initial Public Offering) as on January 11, 2018. Accordingly the company listed with CSE (Chittagong Stock Exchange Ltd) as on March 28, 2018 and listed with DSE (Dhaka Stock Exchange Ltd) as on April 01, 2018. Advent Pharma Limited starts its trade from April 12, 2018 at DSE (Dhaka Stock Exchange Ltd) and CSE (Chittagong Stock Exchange Ltd).

Revenue

The Company attained a growth of - 11.29% during the year 2019-2020 as against 51.99% during the previous year 2018-2019. The national pharma market growth and that of the company during the past few years are given below:

Year	National Market Growth Rate	Company's Growth Rate
2015-2016	15.18%	30.40%
2016-2017	35.29%	24.86%
2017-2018	10.94%	38.94%
2018-2019	13.60%	51.99%
2019-2020	10.63%	-11.29%
Average	16.19%	32.30%

Source: IMS Report, 2020

The operating financial results of the Company for the year 2019-2020 as compared to previous year are summarized hereunder:

Particular	2019-20	2018-19
Turnover	534,027,579	601,966,497
Gross Profit	306,976,352	283,819,921
Financial Expenses	6,006,104	5,741,191
Other Income	10,817,225	6,935,771
Net Profit Before Tax (NPBT)	161,509,212	211,960,605
Provision for Taxation	44,454,754	53,556,967
Net Profit After Tax (NPAT)	117,054,459	158,403,638
Gross Margin (Turnover)	42.52%	47.15%
Net Margin Before Tax	30.24%	35.21%
Net Margin After Tax	21.92%	26.31%
Earnings Per Share (EPS) BDT.	1.41	2.10
Number of Shares used to compute EPS	83,006,000	75,460,000

Industry outlook and possible future developments in the industry

Pharmaceutical sector of Bangladesh has been among those few countable sectors for which Bangladesh is proud of at the international level. This industry is the second largest contributor to the government exchequer. As per Director General of Drug Administration, there are roughly 272 licensed Companies in this sector, mainly dealing with the Production of human drugs. As per report published in the Financial Express on 09 Jan 2017, Local companies account for 97% of the drug sales in the local market, catering to a population of 160 million, while the remaining 3% is imported. There was lack of due attention for the livestock sector in Bangladesh by the public and Private investors until the early 1990s. However, during the last 20 years both the public and private investment in livestock sector is quite remarkable. A considerable number of dairy farms, poultry farms have started growing up.


Bangladesh is an agricultural country and livestock is playing a key factor for developing agricultural sector. Animal health care drug of high quality with affordable price is the prime need of the hour to develop livestock sector. Analyzing the size and ever increasing demand of the market for all types of medicines, feed additives (Vitamins, Minerals, amino acids, etc.), biological, implants and related Products for livestock and companion animals, it is clearly evident that animal health Products has a bright marketing Prospect in Bangladesh.

The promoters of Advent Pharma Ltd. have visualized exploring the opportunities and invested in this sector in order to fulfill the increasing demand of Veterinary drugs and nutritional supplements in the existing local Market. We will make full use of the market scope, our business potentials and dynamics to benefit over-proportionally from the accelerating economic growth, while always keeping in mind the interests of our shareholders.


The company has been operating in the market for a long time with reputation and commitment. With long experience in pharmaceutical manufacturing, we are confident and believe that we can hold on to our reputation as a quality manufacturer.

The production process at the factory has three steps inputs to derive three types of dosage forms i.e. Bolus, Powder and Liquid. The production process has many interdependencies from each part of the process. An overview of the production process is provided below in Production Flow Chart:


A. Process Flow Sheet for Manufacture of Liquid Preparation



B. Process Flow Sheet for Manufacture of Powder Preparation



C. Process Flow Sheet for Manufacture of Bolus (Tablet)



Segment Reporting

The company operates only in one segment that is the pharmaceuticals manufacturing through the process of Manufacture of Liquid Preparation, Powder Preparation and Bolus (Tablet).

Investment Planning

Company is pursuing with a prudent plan for investment in capital assets and working capital in line with the goal of the company or a suitable place.

Risk and Concerns

Changes in the existing global or national policies can have either positive or negative impacts for the company. Any scarcity or price hike of raw materials due to change in policy in the international market might hamper the production and profitability. Changes in forex rates might also affect the pricing and thereby the profitability of the Company.

The performance of the company may also be affected negatively by the political and economic instability both in Bangladesh and worldwide.

Similarly, risks and concern of the industry depends on the Government policies as well. However, pharmaceuticals industry being the potential industry have always enjoyed special consideration from all the successive Governments and expectation is that it will continue to enjoy similar care and consideration from policy makers in the future. Unless any policy change that may negatively and materially affect the industry as a whole, the business of the company is expected not to be affected in the short run.

Discussion on cost of goods sold, gross margin and net profit margin

Profit from Operation	30-June-20		30-June-19	
	Amount	Percentage	Amount	Percentage
Turnover	534,027,579	100%	601,966,497	100%
Cost of Goods Sold	306,976,352	57.48%	318,146,576	52.85%
Gross Profit	227,051,227	42.52%	283,819,921	47.15%
Net Profit for the year	117,054,459	21.92%	158,403,638	26.31%

Discussion on continuity of extra-ordinary gain or loss

Extraordinary gains or losses refer to infrequent and unusual gain or loss and which is not part of the Company's ordinary/day to day operations. As to the Company, there was no such gain or loss during the year under reporting.

Related party transactions

Related party transactions are presented in note no.34.00 of the notes to the financial statements.

Significant variance of financial statements

Advent Pharma Ltd. Is veterinary medicine producer. Due to COVID-19 pandemic and flood, our sales has decreased and materials price has increased in the market for interruption of Import. On the other hand carrying cost also has increased. In this year we got approval another 17 new products product from drug administration and Department of Live Stock Services. For this we have spent some amount of money for product development. All of this reason net profit after tax has decreased, earnings per share and net operating cash flow per share has also decreased in the same line.

Utilization of IPO fund

Purpose as per prospectus	As per prospectus	Utilized up to 30 June, 2018	Utilized during 2018-2019	Utilized during 2019-2020	Total Unutilized
Acquisition of Machineries & Equipment	81,430,800	-	29,924,522	51,506,278	-
Construction of Building and Other Civil Works	100,069,200	1,027,800	92,089,910	6,951,490	-
IPO Expenses	18,500,000	18,198,305	-	301,695	-
Total	200,000,000	19,226,105	122,014,432	58,759,463	-

The company raised Tk. 200,000,000 divided into 2,000,000 ordinary shares of Tk. 10 each through IPO on March 13, 2018. The company utilized Tk. 81,430,800 for the purpose of acquisition of Machineries and Equipment, Tk. 100,069,200 for the purpose of construction of Building and other civil works and Tk. 18,500,000 for IPO expenses up to June 30, 2020 as certified by independent auditor, AHMAD & AKHTAR, Chartered Accountants, Habib Sarwar & Co., Chartered Accountants and Artisan, Chartered Accountants.

The utilization for the purpose of construction of building and other civil works has been recognized as capital work in progress in note # 5, Acquisition of Machineries and Equipment has been recognised in note # 04, and the IPO expenses included in the printing and stationery expenses to the financial statements.

Compliance of Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018.

Board Size:

The number of Directors in the board of Directors of the company is nine (09) including two (02) Independent Director that is line with notification given by BSEC.

Independent Directors

In terms of the provision under Corporate Governance Code(CGC), the Boards of Directors has appointed Mr. Mohammed Salim, MBA, FCMA as Independent Directors of the company as on dated 05 January 2017 for a period of three years and Mr. Sheikh Karimuzzaman as Independent Directors of the company as on 25 November 2018 for a period of three years. They are well versed and experienced person.

Qualification of Independence Director

Mohammed Salim, MBA, FCMA

Independent Director

Mohammed Salim, FCMA, MBA (UK), MIPA (AUS), CMA (USA), the independent director of Advent Pharma Ltd. was born in October 31, 1963 in Bhola, Bangladesh. With his vast educational qualifications, he has over 28 years' professional experiences in the field of Financial Management, General Management, Financial Analysis, Project financing, Company Law, Budgeting & forecasting, etc. Out of his 28 years working experiences, he served as a General Manager (Finance) of about 10 years at Power Grid Company of Bangladesh Ltd. He is the successful president of The Institution of Cost and Management Accountants of Bangladesh (ICMAB).

Sheikh Karimuzzaman,

Independent Director

Sheikh Karimuzzaman was born in a respectable Muslim family at Dhaka in the year 1968. He completed his Master of Laws (LLM) from Southeast University in the year 2007. He started practice in the Supreme Court of Bangladesh in the year 2010. He also completed BA (Hon's.) MA in English from Dhaka University in the year 1990. Out of this, He also achieved the degree of Master of Human Rights from Dhaka International University in the year 2006. He is a social worker as well.

Chief Financial Officer, Company Secretary, Head of Internal Audit

As per corporate governance code of BSEC, the company has allocated the responsibilities of the officials as follows:

Chief Financial Officer	: Mr.Md. Mohsin Mia
Company Secretary	: Mr. Md. Ikramul Islam
Head of Internal Audit	: Mr. Md. Ali Reza Zohurul Islam

Audit Committee

The Audit Committee, as a sub-committee of the Board has been constituted with the Independent Director Mr. Mohammed Salim, MBA, FCMA as Chairman and two other Directors as members. The company Secretary acts as Member Secretary to the Audit Committee. This committee assists the Board of the company in ensuring that the financial statements reflect true and fair view of the state of affairs of the Company. Audit Committee is responsible to the Board of Directors and its roles and responsibilities are clearly set forth. The roles and functions of the Audit Committee have been stated in the annual audit committee report and it is annexed herewith.

Nomination and Remuneration Committee (NRC)

The Nomination and Remuneration Committee (NRC), as a sub-committee of the Board of Director has been constituted with three board of directors with one Independent Director Mr. Mohammed Salim, MBA, FCMA as Chairman and two other Directors as members. The company Secretary acts as Member Secretary to the Committee. The Nomination and Remuneration Committee assists the Board in formulation of the nomination policy and criteria for determining qualifications, experiences and independence of the directors. The committee also assists the board in setting policy for attractive remuneration package for the directors in line with their appropriate performance and industry benchmark. The roles and functions of the Nomination and Remuneration Committee have been stated in the annual Nomination and Remuneration Committee report and it is annexed herewith.

External Statutory Auditors

The BSEC guidelines are being strictly followed in engaging statutory Audit for the Company.

Maintaining a website

The company has been maintaining an official website www.adventpharmabd.com which is linked with the website of the stock exchange.

Subsidiary Company

The company has no subsidiary company whatsoever.

Duties of Managing Director and CFO

The provision of BSEC regulations have been compiled in the Annual Report.

Reporting and Compliance of Corporate Governance Code

Status of compliance with the conditions imposed by the Commission's Notification No BSEC/CMRRCD /2006-158/207/Admin/80 dated 03June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969.

Directors' Appointment and Re-Appointment

With regard to the appointment, retirement and re-appointment of directors, the company is governed as per Companies Act. 1994 and other related legislations. Accordingly, the following Directors of the Board will retire at the annual general meeting and be eligible to offer themselves for re-election:

1. KaziRinaAlam
2. Mohammad Towhidul Islam (Nominee Director of Horipur Feed Ltd.)

Shareholding pattern

The shareholding of directors at the end of 30 June, 2020 is shown as bellow:

	Name of the shareholders	Position	Shares held	%
i.	Parent/Subsidiary/Associated companies and other related parties			
ii.	Directors:			
	WAJHI AHMED	Managing Director	1,839,200	2.22 %
	KAZI RINA ALAM	Director	1,694,000	2.04 %
	FARIA BINTA ALAM	Director	1,669,800	2.01 %
	MD. TAZUL ISLAM	Director	1,694,000	2.04 %
	BLUE AGRO TECH LTD	Director	5,844,300	7.04 %
	HORIPUR FEED LTD.	Director	5,841,275	7.04 %
	FARMERS HOPES LIMITED	Director	5,844,300	7.04 %
	MOHAMMAD JAWAID YAHYA	Sponsor director	1,669,800	2.01 %
	MOHAMMED SALIM	Independent Director	-	-
	SHEKH KARIMUZZAMAN	Independent Director	-	-
iii.	Managing Director, Chief Financial Officer, Company Secretary, Head of Internal Audit and their Spouse and Minor Children:			
	WAJHI AHMED	Managing Director	1,839,200	2.22 %
	MD. MOHSIN MIA	Chief Financial Officer	-	-
	MD. IKRAMUL ISLAM	Company Secretary	-	-
	MD. ALI REZA ZOHURUL ISLAM	Head of Internal Audit	-	-
iv.	Executives:		-	-
v.	Shareholders holding 10% or more voting interest in the company:	-	-	-

Directors involved in other Companies:

Sl.	Name	Position in APL	Involvement with Other Companies	
			Companies	Position
1	Wajhi Ahmed	Managing Director	Not involved in other organization	-
2	Mohammad JawaidYahya	Sponsor Director		-
3	Kazi Rina Alam	Director		-
4	FariaBintaAlam	Director		-
5	A.K.M ShafiquAlam (Nominee Director of Blue Agro Tech Ltd.)	Chairman	Blue Agro Tech Ltd.	Director
6	Md. Tazul Islam	Director	Horipur Feed Limited	Managing Director
7	Mohammad Towhidul Islam (Nominee Director of Horipur Feed Ltd.)	Director	Horipur Feed Limited	Director
8	Asif Iqbal Chowdhury (Nominee Director of Farmers Hope Ltd.)	Director	Farmers Hope Ltd.	Chairman
9	Mohammed Salim	Independent Director	Asian Centre for Management and Information Technology Limited.	Director
10	Shekh Karimuzzaman	Independent Director	-	-

Board Meeting and Attendance

During the year, 6 (Six) nos. of Board Meetings were held. The attendance record of the directors is as given below:

Name of Directors	Attendance
A.K.M. Shafiqul Alam	6
Wajhi Ahmed	6
Kazi Rina Alam	6
Faria Binta Alam	6
Md. Tazul Islam	6
Mohammad Towhidul islam	6
Asif Iqbal Chowdhury	6
Mohammed Salim	6
Sheikh Karimuzzaman	6

Director's remuneration

Director's remuneration is shown in the note no. 34.01 of the notes to the Financial Statements.

Directors' Statement on Financial Reports

In accordance with the Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03June, 2018 the Directors are pleased to confirm the following:

- The financial statements together with the notes thereon have been drawn up in conformity with the Companies Act, 1994 and the Securities and Exchange Rules, 1987. These statements present fairly the company's state of affairs, the result of its operations, cash flows and changes in equity.
- Proper books of accounts of the company have been maintained.
- Appropriate accounting policies have been applied consistently in preparation of the financial statements and the accounting estimates are based on reasonable and prudent judgment.
- International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as applicable in Bangladesh have been followed in the preparation of the financial statements.
- The system of internal control is sound and has been implemented and monitored effectively.
- Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.
- The key operating and financial data for the last five years have been presented in page 22.
- No Bonus or stock dividend has been or shall be declared as interim dividend.

Going Concern

While approving the financial statements, the directors have made appropriate enquiries and analysed the significant financial, operating as well as other indicators for enabling them to understand the ability of the company to continue its operation for a foreseeable period. Directors are convinced and have a reasonable expectation that the company has adequate resources to continue its operation consistently for the foreseeable future. Therefore the company adopted the going concern basis in preparing the financial statements.

Significant deviation of Operating Result

Advent Pharma Ltd. is veterinary medicine producer. Due to COVID-19 pandemic and flood, our sales has decreased and materials price has increased in the market for interruption of Import. On the other hand carrying cost also has increased. In this year we got approval another 17 new products product from drug administration and Department of Live Stock Services. For this we have spent some amount of money for product development. All of this reason net profit after tax has decreased earnings per share and net operating cash flow per share has also decreased in the same line.

Dividend

The Board of Directors has recommended 10% Stockdividend.

Particulars	2020	2019
Profit available for appropriation		
Profit/loss after Tax	117,054,459	158,403,638
Un-appropriated profit brought forward from previous year	264,034,442	187,950,804
Total Amount available for appropriation	381,088,901	346,354,442
Appropriation		
Closing Retained Earnings at year end (Before proposed final dividend)	381,088,901	346,354,442
Proposed Dividend for the year 2020 (10%stock)	83,006,000	90,552,000
Retained Earnings after proposed dividend	298,082,901	255,802,442

Statutory Auditors

The Auditors of the Company, M/S Ahmed Zaker&Co., Chartered Accountants, Green City Edge (Level-10), 89 Kakrail, Dhaka-1000, Bangladesh, has carried out the audit of the company for the year ended 30 June, 2020. They were appointed as Statutory Auditor in 12th AGM. The Auditors M/S Ahmed Zaker&Co., Chartered Accountants express their unwillingness to conduct the next year Audit as on 20 October 2020. The Board accepted the resignation of existing auditor M/S Ahmed Zaker&Co., Chartered Accountants and Audit committee recommended appointing Artisan Chartered Accountants as an Statutory auditor and the Board of Directors also agree in their Board Meeting held on 28 October, 2020, after getting expression their interest to work as auditor for the year ended June 30, 2021 with the remuneration of TK. 2,30,000/= (Taka Two Lac Thirty Thousand only) including VAT. As per regulation 15 (2) & (3) of DSE and CSE (listing) regulations, 2015 Company will be placed in the forthcoming 13th AGM for shareholder's approval and fixation of their fees.

Professionals for Compliance of Corporate Governance Code

The board has appointed M/S. Poddar and Associates, Cost and Management Accountants, 6/A/1 Segun bagicha Ground Floor), Dhaka-1000, Bangladesh, for the year 2020-2021 as professional for Corporate GovernanceCode and be placed before the shareholders for approval and fixation of fees.

Acknowledgment

The Company expresses its sincere thanks and gratitude to the respected shareholders, valued clients, suppliers, banks and well-wishers home and aboard for their wholehearted co-operation and active support.

We are thankful to the Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange Limited (DSE), Chittagong Stock Exchange Limited (CSE), Registrar of Joint Stock Companies &Firms (RJSCF), Central Depository Bangladesh Limited (CDBL), Government and private sector Organizations and other stakeholders for extending co-operation and support to our company.

Thanks are also due to all directors, all executives, officers, staff and workers of the company for their excellent, sincere, dedicated efforts in achieving company's target during the year.

I, on behalf of the board of directors, take the opportunity to inform you that we welcome any suggestions and opinion to improve our company performance and financial stability.

Thanking you.

On behalf of the Board of Directors

Sd/-

Mr. A.K.M Shafiqul Alam, LLB

Chairman

Management Discussion and Analysis on Financial Position and Performance

Bangladesh has been enjoying a strong macroeconomic stability for a decade. Constant 6% plus economic growth has been witnessed in this decade. However, since December 2019 the world has been facing Covid-19 which affected economic activities and human life as well. As of November 19, 2020, roughly 5.68 crore people around the world have been affected by Covid-19 and almost 13.6 lac people passed away because of Corona virus. Presently, the world has been recovering from the shock of Covid-19 that halted business and life. In this backdrop, Bangladesh has registered GDP growth of 5.24% in the FY 2019-20. Per Capita Income has been increasing as well from the last year and it stands USD 2064 in FY 2019-20. Because of Covid-19, both Export and Import have been shrunk in FY 2019-20. Export are getting impetus since August 2020 after reopening the business in worldwide. Remittance has been gearing up with record amount in this pandemic period. This is because of initiatives taken earlier by the Government in providing 2% cash incentive. Now, our foreign currency reserve crossed USD 40 billion, which is tremendous for the country.

For last five financial years the company generated moderate growth in sales except 2019-2020. In 2016(18 Months), sales stood Tk. 330,967,356 and now in 2020 sales stand Tk. 534,027,579. In line with sales, net profit after tax had been increased from around Tk. 41,328,007 in 2016(18 Months) to Tk. 117,054,459 in 2020. In the last five financial years, net operating cash flow per share was positive. In the backdrop of above scenario, it indicates the company is moving forward and it has good promise in the long run.

Accounting policy and estimation for preparing financial statements have been remained same as it was before. Hence, there is no effect in this regard.

As per report published in the Financial Express on 09 Jan 2017, Local companies account for 97% of the drug sales in the local market, catering to a population of 160 million, while the remaining 3% is imported.

There was lack of due attention for the livestock sector in Bangladesh by the public and Private investors until the early 1990s. However, during the last 20 years both the public and private investment in livestock sector is quite remarkable. A considerable number of dairy farms, poultry farms have started growing up.

Advent Pharma Ltd. have visualized exploring the opportunities and invested in this sector in order to fulfill the increasing demand of Veterinary drugs and nutritional supplements in the existing local Market.



__Sd/-____

Faria Binta Alam
Managing Director

FINANCIAL HIGHLIGHTS

Operational Result	Amount in Taka				
	30 June 2020	30 June 2019	30 June 2018	30 June 2017	30 June 2016 (18 Months)
Turnover	534,027,579	601,966,497	396,048,274	285,059,543	330,967,356
Gross Profit	227,051,227	283,819,921	173,532,438	128,368,344	137,554,821
Profit from Operation	164,773,552	223,026,912	102,057,103	81,759,008	72,515,373
Net Profit before tax	161,509,212	211,960,605	94,611,028	74,906,779	63,581,549
Net Profit after Tax	117,054,459	158,403,638	86,877,032	48,689,408	41,328,007
Financial Position	30 June 2020	30 June 2019	30 June 2018	30 June 2017	30 June 2016 (18 Months)
Non-Current Assets	1,105,545,263	931,180,917	685,286,322	562,066,136	247,264,764
Current Assets	266,232,759	276,465,072	327,475,163	165,204,383	79,791,496
Shareholder's Equity	1,120,590,279	1,018,634,442	873,950,804	605,272,077	170,482,669
Current Liability	132,750,779	102,897,663	72,096,752	55,664,895	44,678,229
Long Term Liability	118,436,964	86,113,884	66,713,929	66,333,547	111,895,362
Key Financial Ratio	30 June 2020	30 June 2019	30 June 2018	30 June 2017	30 June 2016 (18 Months)
Current Ratio	2.01	2.69	4.54	2.97	1.79
Quick Ratio	1.24	1.63	3.31	1.55	1.03
Debt to Equity Ratio	0.04	0.03	0.06	0.07	0.26
Net Income Ratio (%)	21.92%	26.31%	21.94%	17.08%	12.49%
Return on Equity (%)	10.45%	15.55%	11.75%	12.55%	35.90%
Earnings Per Share	1.41	2.10	1.59	1.49	3.75

FINANCIAL HIGHLIGHTS IN THE FORM OF GRAPHICAL REPRESENTATION



Factory View

Pictures of Factory, machineries, manufacturing process and products:





Our Newly Introduced Products:

Following Product has included in our portfolio during the year 2019-2020

SI NO	Name of Product	Presentation
1	Acipure Plus	100 & 500 ml Bottle
2	Adtetra Powder	500 gm Sachet
3	AdzymeLiquide	100 ml & 500 ml Bottle
4	Greenphose DCP Super	1 kg Sachet
5	Levo Super	100 ml Bottle
6	Nutrain	100 & 500 ml Bottle
7	Superior Syn Biotech	100 & 500 ml Bottle
8	Tilfos	100 ml Bottle

ADVENT PHARMA LIMITED
Declaration by Managing Director and CFO

Date: October 28, 2020

The Board of Directors

Advent Pharma Limited
Green Homes, Bloc-A, House # 10/7
Iqbal Road, Mohammadpur, Dhaka
Factory: Plot # B 50-54, BSCIC Industrial Estate,
Dhamrai, Dhaka.

Subject: Declaration on Financial Statements for the year ended on June 30, 2020.

Dear Sirs,

Pursuant to the condition No. 1(5) (xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- (1) The financial Statements of Advent Pharma Limited for the year ended on June 30, 2020 have been prepared in compliance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
- (2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- (3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- (4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- (5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- (6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:-

- (i) We have reviewed the financial statements for the year ended on 30 June 2020 and state that to the best of our knowledge and belief:
 - (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

Sd /-
FariaBintaAlam
Managing Director

Sd /-
Md. Mohsin Mia
Chief Financial Officer (CFO)

CERTIFICATE ON CORPORATE GOVERNANCE COMPLIANCE

Report to the Shareholders of Advent Pharma Limited on compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by Advent Pharma Limited for the year ended on June 30, 2020. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission except under conditions number 1(7)(a)&1(7)(b);
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws ; and
- (d) The governance of the company is satisfactory.

Place: Dhaka.
Dated: 2nd December 2020

Sd/-
Podder& Associates
Cost & Management Accountants

Annexure-C

[Certificate as per condition No. 1(5) (xxvii)]

Advent Pharma Limited Status of Compliance with the Corporate Governance Code (CGC)

Status of compliance with the conditions imposed by the Commission's Notification No.BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9)

Condition No.	Title	Compliance Status (Put \checkmark in the appropriate column)		Remarks (IF ANY)
		Complied	Not Complied	
1	Board of Directors			
1(1)	Size of the Board of Directors			
	The total number of the board members of the company shall not be less than 5 (five) and more than 20 (twenty)	\checkmark		The APL's Board is comprised of 9 Directors including the Managing Director
1(2)	Independent Directors			
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors.	\checkmark		02 out of 9 Directors are appointed as independent Director
1(2)(b)	For the purpose of this clause 'independent director' means a director-			
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	\checkmark		The independent Directors have declare their compliances
1(2)(b)(ii)	who is no a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid up shares of the company on the basis of family relationship and his or her family members shall not hold above mentioned shares in the company;	\checkmark		
1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	\checkmark		
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	\checkmark		
1(2)(b)(v)	who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	\checkmark		
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	\checkmark		

1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	√		
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	√		
1(2)(b)(ix)	who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI);	√		
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	√		
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM);	√		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days;	√		No vacancy occurred during the reporting period
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only.	√		
1(3)	Qualification of Independent Director			
1(3)(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to business;	√		
1(3)(b)	Independent Director shall have following qualifications			
1(3)(b)(i)	Business leader who is or was a promoter or director of an unlisted company having minimum paid up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association;	-		
1(3)(b)(ii)	Corporate leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	-		N/A
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or law;	√		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law;	-		N/A

1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	√		
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	√		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission;			No such issue arose
1(4)	Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director and/ or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	√		
1(4)(b)	The Managing Director (MD) and/ or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	√		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the chairperson and the Managing Director and/ or Chief Executive Officer;	√		
1(4)(e)	In the absence of the chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		No such incident arose yet
1(5)	The Directors' Report to Shareholders:	The Director's report complies with the guideline		
	The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the companies Act, 1994 (Act No. XVIII of 1994):-	√		
1(5)(i)	An industry outlook and possible future developments in the industry;	√		
1(5)(ii)	The Segment-wise or product-wise performance;	√		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√		
1(5)(v)	A discussion on continuity of any Extra-Ordinary activities and their implications (gain or loss);	√		
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	-		N/A

1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc;			No such matter to explain
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performance and Annual Financial statements;			No such event arose
1(5)(x)	A statement of remuneration paid to the directors including independent directors	√		Independent Directors have not received any remuneration
1(5)(xi)	The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√		
1(5)(xii)	Proper books of account of the issuer company have been maintained;	√		
1(5)(xiii)	Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√		
1(5)(xiv)	International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	√		
1(5)(xv)	The system of internal control is sound in design and has been effectively implemented and monitored;	√		
1(5)(xvi)	Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1(5)(xvii)	There is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	√		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	√		
1(5)(xix)	Key operating and financial data of at least preceding 5 (five) years shall be summarized;	√		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;	√		The Company has declared 10% stock dividend
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	-		N/A
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	√		
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:-			
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	√		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	√		
1(5)(xxiii)(c)	Executives; and	√		

1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	√		No shareholder holding 10% or more share of the Company
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:-			
1(5)(xxiv)(a)	a brief resume of the director	√		
1(5)(xxiv)(b)	nature of his or her expertise in specific functional areas;	√		
1(5)(xxiv)(c)	names of companies in which the person also holds the directorship and the membership of committees of the Board;	√		
1(5)(xxv)	A Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on:			
1(5)(xxv)(a)	accounting policies and estimation for preparation of financial statements;	√		
1(5)(xxv)(b)	changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	-		N/A
1(5)(xxv)(c)	comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√		
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√		
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	√		
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company;	√		
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	√		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	√		
1(6)	Meetings of the Board of Directors:			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	√		
1(7)	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer			

1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;		√	
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.		√	
2	Governance of Board of Directors of Subsidiary Company APL does not have any subsidiary Company			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	-	-	N/A
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;	-	-	N/A
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	-	-	N/A
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	-	-	N/A
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	-	-	N/A
3	Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)			
3(1)	Appointment			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	√		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	√		
3(2)	Requirement to attend Board of Directors' Meetings:			
	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board provided that CS, CFO and HIAC shall not attend such part of a meetings of the Board relating to their personal matter.	√		

3(3)	Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	-		
3(3)(a)(i)	these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√		
3(3)(a)(ii)	these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members	√		
3(3) (c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	√		
4	Board of Directors' Committee:- For ensuring good governance in the company, the Board shall have at least following subcommittees:			
4(i)	Audit Committee	√		
4(ii)	Nomination and Remuneration Committee	√		
5	Audit Committee			
5(1)	Responsibility to the Board of Directors			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	√		
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	√		
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	√		
5(2)	Constitution of the Audit Committee			
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	√		
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	√		
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	√		
5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		

5(2)(e)	The company secretary shall act as the secretary of the Committee;	√		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	√		
5(3)	Chairperson of the Audit Committee			
5(3)(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	√		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM);	√		
5(4)	Meeting of the Audit Committee			
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year	√		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√		
5(5)	Role of Audit Committee: The Audit Committee shall:-			
5(5)(a)	Oversee the financial reporting process;	√		
5(5)(b)	monitor choice of accounting policies and principles;	√		
5(5)(c)	monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√		
5(5)(d)	oversee hiring and performance of external auditors;	√		
5(5)(e)	hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	√		
5(5)(f)	review along with the management, the annual financial statements before submission to the Board for approval;	√		
5(5)(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√		
5(5)(h)	review the adequacy of internal audit function;	√		
5(5)(i)	review the Management's Discussion and Analysis before disclosing in the Annual Report;	√		
5(5)(j)	review statement of all related party transactions submitted by the management;	√		
5(5)(k)	review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	√		
5(5)(l)	oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	√		

5(5)(m)	oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission:	-		N/A
5(6)	Reporting of the Audit Committee			
5(6)(a)	Reporting to the Board of Directors			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	√		
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board on the following findings, if any:-			
5(6)(a)(ii)(a)	report on conflicts of interests;			No such Incidence arose
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;			No such Incidence arose
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;			No such Incidence arose
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such Incidence arose
5(6)(b)	Reporting to the Authorities:			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.			No such reportable incidence arose
5(7)	Reporting to the Shareholders and General Investors:			
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	√		
6	Nomination and Remuneration Committee (NRC)			
6(1)	Responsibility to the Board of Directors			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a subcommittee of the Board;	√		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	√		
6(2)	Constitution of the NRC			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	√		
6(2)(b)	All members of the Committee shall be non-executive directors;	√		

6(2) (c)	Members of the Committee shall be nominated and appointed by the Board;	√		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	-		No such case in arose
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	-		No such occurrence during the year
6(2)(g)	The company secretary shall act as the secretary of the Committee;	√		In Practice
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	√		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	√		
6(3)	Chairperson of the NRC			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	√		
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders.	√		
6(4)	Meeting of the NRC			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	√		
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√		
6(5)	Role of the NRC			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	√		
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board;	√		

6(5)(b)(i)	formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:	√		
6(5)(b)(i)(a)	the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√		
6(5)(b)(i)(b)	the relationship of remuneration to performance is clear and meets appropriate performance benchmarks;	√		
6(5)(b)(i)(c)	remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	√		
6(5)(b)(ii)	devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√		
6(5)(b)(iii)	identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	√		
6(5)(b)(iv)	formulating the criteria for evaluation of performance of independent directors and the Board;	√		
6(5)(b)(v)	identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	√		
6(5)(b)(vi)	developing, recommending and reviewing annually the company's human resources and training policies;	√		
6(5) (c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual Report.	√		
7	External or Statutory Auditors			
7(1)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:-	-		
7(1)(i)	appraisal or valuation services or fairness opinions;	√		
7(1)(ii)	financial information systems design and implementation;	√		
7(1)(iii)	book-keeping or other services related to the accounting records or financial statements;	√		
7(1)(iv)	broker-dealer services;	√		
7(1)(v)	actuarial services;	√		
7(1)(vi)	internal audit services or special audit services;	√		
7(1)(vii)	any service that the Audit Committee determines;	√		
7(1)(viii)	audit or certification services on compliance of corporate governance as required under condition No. 9(1);	√		
7(1)(ix)	any other service that creates conflict of interest.	√		
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company	√		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (AGM or EGM) to answer the queries of the shareholders.	√		

8	Maintaining a website by the Company			
8(1)	The company shall have an official website linked with the website of the stock exchange.	√		
8(2)	The company shall keep the website functional from the date of listing.	√		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	√		
9	Reporting and Compliance of Corporate Governance			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	√		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	√		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	√		

Sd/-
Faria Binta Alam
Managing Director


Information Relating to Company Capital

Advent Pharma Limited was incorporated as a Private Limited Company on 25th January, 2007 and subsequently converted into a Public Limited Company on 7th May 2016 under Companies Act 1994 with the Registrar of Joint Stock Companies and Firms, Dhaka, Bangladesh under the Companies Act, 1994. The Certificate of Incorporation number is C-65459(2951)/2007. The company has been operating in the market for a long time with reputation and commitment. The company has long experience in pharmaceutical manufacturing in Bangladesh. The Company started its business with paid up Capital TK. 2.50 million and now its existing paid up capital stands at 830.06 million. Authorized Capital of the Company is TK. 1000 million in 2017 the Company raised its paid up capital by TK. 200 million through IPO. The Company is listed with DSE and CSE. The Capital Structure of the Company is the nominated as under:

Particulars	Amount in Taka	Percentage
Sponsor & Director	: 260,966,750/-	31.44 %
Institution	: 162,193,724/-	19.77 %
Public	: 406,899,526/-	48.79 %
	830,060,000/-	100.00 %

The Range of Shareholding as on 30 June, 2020

Particulars of Investors	Number of Share	Percentage of Shareholding (%)
1 to 500 Shares	211,532	0.25
501 to 5,000 shares	3,188,008	3.84
5,001 to 10,000 shares	2,597,216	3.13
10,001 to 20,000 shares	3,102,268	3.74
20,001 to 30,000 shares	2,223,021	2.68
30,001 to 40,000 shares	1,125,898	1.36
40,001 to 50,000 shares	1,218,552	1.47
50,001 to 100,000 shares	4,896,610	5.90
100,001 to 1,000,000 shares	22,899,075	27.59
Over 1,000,000	41,543,820	50.05
Total	83,006,000	100.000



Audit Committee Report (for the year ended 30 June 2020)

Dear Shareholders,

Advent Pharma Limited established an audit committee as a sub-committee of the Board of Directors and they assist the Board of Directors in fulfilling its oversight responsibilities and ensuring that the financial statement reflects true and fair view.

Composition of Audit Committee

As per requirements of BSEC circular, The Board of Directors of Advent Pharma Limited formed an Audit Committee headed by Company's Independent Director Mr. Mohammed Salim, MBA, FCMA. The Committee is composed of 3 (three) members of the Board. The members of the Audit Committee are as follows:

Audit Committee

Mr. Mohammed Salim, MBA, FCMA Independent Director	Chairman
Mr. Sheikh Karimuzzaman Independent Director	Member
Mr. Asif Iqbal Chowdhury (Nominee Director of Farmers Hopes Ltd.)	Member
Md. Ikramul Islam Company Secretary	Member Secretary

Meeting and Attendance

During the year 2019-2020, under review the Audit Committee of Advent Pharma Limited conduct 5 (Five) meetings.

Audit Meeting Attended by Members

Name	Position	Meeting Attended
Mr. Mohammed Salim, MBA, FCMA Independent Director	Chairman	5
Mr. Sheikh Karimuzzaman Independent Director	Member	4
Mr. Asif Iqbal Chowdhury	Member	5
Md. Ikramul Islam	Member Secretary	5

The Role and Responsibilities of the Audit Committee

The Role and Responsibilities of the Audit committee are clearly mentioned in the Compliance of Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 condition no 5.5. The key responsibilities of the Audit committee are as follows.

- (a) Oversee the financial reporting process;
- (b) monitor choice of accounting policies and principles;
- (c) monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;
- (d) oversee hiring and performance of external auditors;
- (e) hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;

- (f) review along with the management, the annual financial statements before submission to the Board for approval;
- (g) review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;
- (h) review the adequacy of internal audit function;
- (i) review the Management's Discussion and Analysis before disclosing in the Annual Report;
- (j) review statement of all related party transactions submitted by the management;
- (k) review Management Letters or Letter of Internal Control weakness issued by statutory auditors;
- (l) oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and
- (m) oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission: Provided that the management shall disclose to the Audit Committee about the uses or applications of the proceeds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a quarterly basis, as a part of their quarterly declaration of financial results: Provided further that on an annual basis, the company shall prepare a statement of the proceeds utilized for the purposes other than those stated in the offer document or prospectus for publication in the Annual Report along with the comments of the Audit Committee.

The Committee during the period under report met four times and its activities includes the followings:

- The financial statements of the quarterly, half yearly and the full year were reviewed by the committee and subsequently recommended to the Board for adoption consideration and circulation as per the requirement of Bangladesh Securities & Exchange Commission.
- The committee also reviewed the audited financial statements of the Company for the year ended June 30, 2020 this reviews incorporated the accounting policies and key judgments and estimates underpinning financial statements as disclosed in Notes to the Accounts.
- The committee also reviewed the work of the internal audit department and made suggestions for improvement.
- The committee reviewed the compliance with existing laws and regulations.
- Approved the internal audit plan.
- Reviewed the effectiveness and independence of the Statuary auditors and recommended re-appointment of external auditors.

Sd/-

On behalf of the Committee
Mr. Mohammed Salim, MBA, FCMA
Chairman, Audit Committee

Nomination and Remuneration Committee Report (for the year ended 30 June 2020)

Dear Shareholders,

The Company has formed a Nomination and Remuneration Committee (NRC) as per notification no. BSEC/CMRRCD/2006-158/207/Admin/80 Dated 3 June 2018.

Members of NRC:

The committee consists of 3 (Three) members; which is as follows:

- | | |
|---|------------------|
| 1. Mr. Mohammed Salim, MBA, FCMA
(Independent Director) | Chairman |
| 2. Mr. A.K.M Shafiqul Alam
(Nominee Director of Blue Agro Tec Ltd.) | Member |
| 3. Mr. Mohammad Towhidul Islam
(Nominee Director of Horipur Feed Ltd.) | Member |
| 4. Md. Ikramul Islam | Member Secretary |

The main role of the Committee is to assist and advice the Board on the Company's remuneration policy for the Board and Key management personnel, drive diversity and inclusion in the organization, guide standards of behavior and culture code, ensure appropriate process for performance-related pay in order to motivate and retain executives and ensure that the company is able to attract the best talent in the market in order to maximize shareholder value.

During the year 2019-2020, the Committee held 1(One) meeting, complying with the requirement of at least one meeting to be held during the year.

NRC Meeting Attendance record of the Members

Name	Position	Meeting Attended
Mr. Mohammed Salim, MBA, FCMA Independent Director	Chairman	1
Mr. A.K.M Shafiqul Alam (Nominee Director of Blue Agro Tec Ltd.)	Member	1
Mr. Mohammad Towhidul Islam (Nominee Director of Horipur Feed Ltd.)	Member	1
Md. Ikramul Islam	Member Secretary	1

Terms of Reference:

The terms of reference of the committee as set out by the Nomination and Remuneration Committee which was adopted by the Board during the year under review. The committee shall oversee, among others, the following matters and shall recommend the following for review and/or approval of the Board, as the case may be:

- i. The criteria for determining qualifications, positive attributes and independence of a director
- ii. A policy relating to the remuneration of the directors, top level executive, considering the following:
 - a. The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors to run the company successfully;
 - b. The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
 - c. Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- iii. A policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background

- iv. The plan in relation to identification of persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;
- v. The criteria for evaluation of performance of independent directors and the Board;
- vi. The plan or proposal on company's needs for employees at different levels and the selection, transfer or and promotion criteria/ principles; and
- vii. The annual exercise on the developments, recommendations and review of the company's human resources and training policies;

Major Activities during the year:

During the year under review, the Committee carried out the following activities:

- a. Reviewed and ratified the uniform Code of Conduct for the Company which would is also applicable to members of the Board and key management personnel or top-level executives which was adopted by the Board.
- b. Reviewed the available document of the Company which underlies all aspects of individual and collective performance and functioning of the Company.
- c. Reviewed the core human resources principles and philosophy of the Company including recruitment, performance evaluation across all levels of members and talent value proposition of the Company.

The NRC Committee expressed their sincere thanks to the members of the Board and Management of the Company for their support in carrying out its duties and responsibilities effectively. The Committee will proceed to function by adopting and adhering to a calendar or plan for the year and monitor progress on the same.

On behalf of the Committee

sd/-

Mohammed Salim, MBA, FCMA

Chairman

Nomination and Remuneration Committee

Credit Rating

Advent Pharma Limited has been rated as BBB+ (Pronounced as Triple B Plus) long term credit rating and ST-3 Short term credit rating by Alpha Credit Rating Limited based on audited financial statements up to 30 June, 2019, Bank liability position as on 11 November, 2019 and other available information up to the date of rating declaration. The date of rating was on 21 November, 2019. The outlook on the rating is Stable.

Long Term Rating	Short Term Rating	Outlook	Date of Validity
BBB+	ST-3	Stable	20 November, 2020

Alpha Credit Rating Limited considered financial performance, scale of business, quality of financial statements and data presentation, management's relationship with different parties or stakeholders' of the business, managements' business experience and other qualitative factors, increased revenue & profitability, good ROA & ROE, adequate finance cost payment ability, positive CRO, increasing net asset value, good control efficiency, audit report, low dependency on external facilities, most of the updated compliances, sound liquidity position, good working capital management, improved cash conversion cycle, sufficient collateral coverage, efficient managerial effort of the directors while assigning the rating that reflects the strengths of the company which has long operating history, moderate to high revenue growth.

Application of International Financial Reporting Standards (IFRSs) and Internal Accounting Standards (IASs)

Name of the Accounting Standards	Ref. No.	Status of Application
Presentation of Financial Statements	IAS-1	Applied
Inventories	IAS-2	Applied
Statement of Cash Flows	IAS-7	Applied
Accounting Policies, Changes in Accounting Estimates and Errors	IAS-8	Applied
Events after the Reporting Period	IAS-10	Applied
Income Taxes	IAS-12	Applied
Property, Plant and Equipment	IAS-16	Applied
Employee Benefits	IAS-19	Applied
Borrowing Costs	IAS-23	Applied
Related Party Disclosures	IAS-24	Applied
Financial Instruments: Presentation	IAS-32	Applied
Earnings Per Share	IAS-33	Applied
Impairment of Assets	IAS-36	Applied
Provisions, Contingent Liabilities and Contingent Assets	IAS-37	Applied
Financial Instruments: Recognition & Measurement	IAS-39	Applied
Financial Instruments: Disclosures	IFRS-7	Applied
Operating Segments	IFRS-8	Applied
Financial Instruments	IFRS-9	Applied
Revenue from Contracts with Customers	IFRS-15	Applied
Leases	IFRS-16	Applied

**Independent Auditors' Report
To the shareholders of
Advent Pharma Limited
Report on the Audit of the Financial Statements.**

Opinion

We have audited the financial statements of **Advent Pharma Limited (“the Company”)**, which comprise the Statement of Financial Position as at 30 June 2020, and Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at 30 June 2020, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) where practicable, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye Laws. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matters

Without qualifying our opinion, we draw attention on the matters disclosed:

1. As disclosed in Note: 4.00, during the year, the company made addition of BDT 53,434,378 against Plant and machinery and Building of BDT 150,778,461 but supporting documentations was not sufficient. The company did not maintain fixed assets register properly with details containing information such as identification number of assets held, date of acquisition cost of purchase, category of assets, accumulated depreciation, etc. Due to lack of such update records, existence, completeness and accuracy of the said fixed assets was not traceable.
2. The company reported BDT 14,627,525 which was payable against dividend as on 30 June 2020. Upon comparing these outstanding balances with the corresponding bank account held by the company, we noted the said bank account had a balance of BDT 81,294 not sufficient as on the reporting date to settle outstanding payable against dividend.
3. During the audit at the company, we noted that the company made some payments against purchase and expenses in cash mode instead of A/C payee cheque or bank transfer which indicates violation of Income tax ordinance 1984 guideline.
4. As per the section 234 of the Bangladesh Labour Act, 2006, “Establishment of Workers profit participation Fund and Welfare fund” - every company is to pay, within 9 (nine) months of the close of every year 5% of profit before tax and transfer to respective participatory fund, welfare fund and workers welfare foundation fund established under section 14 at the ratio of 80:10:10. But the company did not make payment last year BDT 11,982,914.

5. The company reported accounts receivable tk. 118,236,156. A substantial amount of total dues of Tk. 118,236,156 is doubtful of recovery, but no provision has been made in these financial statements for the doubtful receivable amount.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statement of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	Our response to the risk
Revenue recognition	
<p>During the year, the Company recognized sales turnover of BDT 534,027,579 which has decreased by BDT (67,938,918) as compared with previous year.</p> <p>Sales revenue recognized by the Company as per IFRS: 15, 'Revenue from Contracts with Customers' & Company Policy. Revenue is recognized based on point of delivery and when relevant performance obligations are satisfied. The company adopted IFRS: 15 'Revenue from Contracts with Customers' for first time during the year.</p> <p>We considered sales revenue as an item of significant audit areas during our audit because of its predominance in determining the financial performance of the Company</p>	<p>Our audit procedures included the following to test the design and operating effectiveness of key control focusing on:</p> <ul style="list-style-type: none"> • Segregation of duties in invoice creation and modification. • Timing of revenue recognition considering step by step procedure. <p>Our substantive procedures in relation to revenue recognition and measurement comprise the following:</p> <ul style="list-style-type: none"> • Obtaining understanding and documenting the process of revenue recognition and measurement followed by the Company. • Tracing performance obligations stipulated and contract value in the contract with invoice and delivery challan issued to evaluate point of recognition and measurement. • Testing occurrence and accuracy of sales revenue recognized by inspecting source documents such as contract made with the customer, delivery challan and VAT challan. • Assessing accuracy and comparing revenue recognized during the year with VAT returns submitted to VAT authority; • Finally assessing the appropriateness and presentation of disclosure notes with IFRS 15: Revenue from contracts with customers.
See note no. 22, Revenue in the financial statements	
Valuation of closing inventories	
<p>Closing inventories aggregating to BDT 67,886,459 was recognized in the statement of financial position as on 30 June 2020. Compared with previous year, this has decreased by BDT (2,923,693).</p> <p>Closing inventories were all held at factory premises of the Company. Since determining valuation of these inventories involves management judgements which results in estimation uncertainty, we considered this an area of significant audit attention to be emphasized during the audit.</p>	<p>Our audit responses comprise the following procedures:</p> <ul style="list-style-type: none"> • Evaluating the design and implementation of key inventory control operating across factory premises. • Attending and observing the physical inventory at the reporting date. • Evaluating compliance with instructions of management count procedures during the count. • Inspecting physical stock counting report as on 30 June 2020 and reconciling count results to closing

	<p>inventories listings and performing test count on selected items to test completeness, accuracy and existence of inventories.</p> <ul style="list-style-type: none"> Reviewing composition of cost of inventories comprising raw materials, work-in-process and finished goods and comparing net realizable value on selected samples to test their valuation.
See note no. 7, Inventories in the financial statements	
Property, plant and equipment	
<p>Property, plant and equipment (PPE) was carried at BDT 1,098,601,145 representing over 80% of total assets of the company as on 30 June 2020. The company reported addition to PPE of BDT 286,988,605 during the year.</p> <p>Property, plant and equipment (PPE) are subject to recognition and measurement criteria only after satisfactorily meeting relevant requirement as per IAS 16: Property, plant and equipment, we identified this element of the assets as an area with higher risk of material misstatement which would require significant audit attention during our audit.</p> <p>The company is also required to perform assessment for impairment when there is condition which suggests indication of assets being impaired.</p>	<p>Our audit procedures performed during the audit to address the risks identified consist of the following:</p> <ul style="list-style-type: none"> Obtaining and documenting detailed understanding regarding procurement process of PPE and identified relevant control points and their implementation. Reviewing recognition, measurement and valuation basis of PPE in compliance with requirement of IAS 16: Property, plant and equipment. Inspecting supporting documents against the acquisition of PPE made during the year to test their accuracy, valuation and ownership in the financial statements. Assessing the appropriateness and presentation of disclosures notes to the financial statements with the requirement of IAS 16 and other relevant IFRSs.
See note no. 4, Property, plant and equipment in the financial statements	
Measurement of current year income tax and deferred tax	
<p>During the year, the Company recognized current year income tax of Tk. 10,025,596 and deferred tax Tk. 34,429,158 respectively in the statement of profit or loss and other comprehensive income. Both of these expenses have increased significantly compared to corresponding expense recognized in the last year.</p> <p>Determination of both current year income tax and deferred tax involves compliance with the Income Tax Ordinance (ITO) 1984 and latest finance act along with IAS 12: Income Tax, there is a higher risk of material misstatement that amount charged in profit or loss might be over/understated.</p>	<p>Our audit responses adopted during the audit to address the risk identified comprise the following:</p> <ul style="list-style-type: none"> Obtained and documented management procedures involved in determining both current year income tax and deferred tax. Obtained understanding and reviewed relevant section of the ITO and SRO to test the accuracy of rate applied by the Company. Reviewed rate of depreciation used in determining tax depreciation in compliance with the latest finance act which is used to determine taxable profit and deferred tax. Re-performed detailed calculation of current year income tax and deferred tax as given by the Company. Inspected latest assessment order completed and compared amount of tax paid by the Company with amount recognized in the financial statements.

See note no. 21 & 16, income tax & deferred tax expenses in the financial statements	
Bank Loan	
<p>As referred note no 14 & 15 in the financial statement the company recognized Long Term Borrowings of BDT 24,040,250 and Short-term Borrowings of BDT 23,358,077 respectively at their reporting date.</p> <p>Loan liability borrowings from bank were considered a key audit matter because this external form of credit facilities availed by the company require fulfillment of several terms and require fulfillment of several terms and conditions as mentioned in loan sanction letter issued by lending bank.</p>	<ul style="list-style-type: none"> • Our substantive audit procedure adopted during the audit includes the following test or details • Inspecting relevant board minutes in support of bank loan reported in the financial statement. • Agreeing outstanding balances with confirmation letter received from the bank. • Agreeing finance costs charged by the company with loan statements provided by bank to test accuracy and completeness of expenses in relation to bank loan

Other Matter

Due to the outbreak of global pandemic “Covid-19” declared by the World Health Organization (WHO) and subsequent spread of the virus resulting in deteriorating situation in Bangladesh during the conduct of audit at the company, our audit procedures were mainly tailored to the material areas of the financial statements with more emphasis placed on obtaining documentary evidence from the company and testing their accuracy using the online platforms and limited physical verification to avoid the risk of getting contacted the virus and safety of audit team members.

Other Information

Management is responsible for the other information. The other information comprises all the information in the annual report other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The companies Act, 1994 require the management to ensure effective internal audit, internal control and risk management functions of the company.

In preparing the financial statements, management is responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company’s financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercised professional judgment and maintained professional skepticism throughout the audit. We also:

- Identified and assessed the risks of material misstatement of the financial statements, whether due to fraud or error, designed and performed audit procedures responsive to those risks, and obtained audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtained an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in circumstances.
- Evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Concluded on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluated the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and event in a manner that achieves fair presentation.
- Obtained sufficient appropriate audit evidence regarding the financial information of the entity to express an opinion on the financial statements. We are solely responsible for our audit opinion.

We communicated with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit.

We also provided those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicated with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determined those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We described these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determined that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, and the Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts and records as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) The Statement of Financial Position, Statement of Profit or Loss and Other Comprehensive Income of the Company dealt with by the report are in agreement with the books of account and returns;
- d) The expenditures incurred were for the purposes of the Company's business.
- e) The company adopted IFRS: 15 'Revenue from Contracts with Customers' & IFRS 16: 'Leases' for first time during the year.

Place: Dhaka
Dated: 28 October, 2020

Sd/-
Ahmed Zaker & Co.
(Zabed A Mridha, FCA)
Chartered Accountants
Partner

Advent Pharma Ltd.
Statement of Financial Position
As at June 30, 2020

Particulars	Notes	Amount in Taka	
		30-June-2020	30-June-2019
ASSETS			
NON-CURRENT ASSETS		1,104,525,308	931,180,917
Property, Plant and Equipment	4.00	1,098,601,145	844,729,863
Capital Work in Progress (Building Construction)	5.00	5,924,163	86,451,054
Right of use Assets	6.00	1,019,955	-
CURRENT ASSETS		266,232,759	276,465,072
Inventories	7.00	67,886,459	70,810,152
Trade and Other Receivable	8.00	118,236,156	78,850,747
Advances, Deposits and Pre-payments	9.00	33,771,482	38,061,290
Investment in FDR	10.00	40,000,000	80,000,000
Cash and Cash Equivalents	11.00	6,338,662	8,742,883
Total Assets		1,371,778,022	1,207,645,989
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,120,590,279	1,018,634,442
Share Capital	12.00	830,060,000	754,600,000
Retained Earnings	13.00	290,530,279	264,034,442
NON-CURRENT LIABILITIES		118,436,964	86,113,884
Long Term Borrowings - Net of Current Portion	14.00	16,516,175	19,114,798
Deferred Tax Liabilities	16.00	101,428,244	66,999,086
Liabilities for lease net current maturity	18.00	492,545	-
CURRENT LIABILITIES		132,750,779	102,897,663
Current Portion of Long Term Borrowings	14.00	7,912,963	7,912,963
Payable to IPO Applicants		109,355	129,355
Short Term Borrowings	15.00	23,358,077	7,235,622
Trade and other payables	17.00	23,896,162	12,630,812
Liabilities for Lease-current maturity	18.00	649,231	-
Liabilities for expenses	19.00	6,110,913	4,083,317
Liability for contribution to WPPF	20.00	21,344,569	11,982,914
Provision for Current Tax	21.00	49,369,509	58,922,680
Total Liabilities		251,187,743	189,011,547
Total Shareholders' Equity and Liabilities		1,371,778,022	1,207,645,989
Net Asset Value (NAV) per Share	30.00	13.50	13.50

The accompanying notes (01 to 38) form an integral part of this financial statement and are to be read in conjunction therewith.

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Sd/-
Managing Director

Sd/-
Chairman

Dated: October 28, 2020
Place: Dhaka

Sd/-
Ahmed Zaker & Co.
Chartered Accountants

Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended June 30, 2020

Particulars	Notes	Amount in Taka	
		July 01, 2019 to June 30, 2020	July 01, 2018 to June 30, 2019
A Revenues	22.00	534,027,579	601,966,497
B Cost of Sales	23.00	(306,976,352)	(318,146,576)
C Gross Profit		227,051,227	283,819,921
Operating Expenses		(62,277,675)	(60,793,009)
D Administrative expenses	24.00	(25,588,030)	(24,502,073)
Selling & Marketing Expenses	25.00	(36,689,645)	(36,290,936)
E Operating Profit		164,773,552	223,026,912
Non Operating Expenses		(6,006,104)	(5,741,191)
F Financial Expenses	26.00	(6,006,104)	(5,741,191)
G Other Income	27.00	10,817,225	6,935,771
H Loss on disposal on Fixed Assets	28	-	(1,662,857)
I Profit Before W.P.P.F		169,584,673	222,558,635
J Expenses for W.P.P.F	20.00	(8,075,461)	(10,598,030)
K Profit Before Tax		161,509,212	211,960,605
L Income Tax Expenses		(44,454,754)	(53,556,967)
Current Tax	21.00	(10,025,596)	(29,817,062)
Deferred Tax	16.00	(34,429,158)	(23,739,905)
M Net Profit After Tax		117,054,459	158,403,638
N Other Comprehensive Income		-	-
O Total Comprehensive Income		117,054,459	158,403,638
P Adjusted Earnings per Share (EPS)	29.00	1.41	1.91
Basic Earnings per Share (EPS)	29.00	1.41	2.10

The accompanying notes (01 to 38) form an integral part of this financial statement and are to be read in conjunction therewith.

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Sd/-
Managing Director

Sd/-
Chairman

Dated: October 28, 2020
Place: Dhaka

Sd/-
Ahmed Zaker & Co.
Chartered Accountants

Advent Pharma Ltd.
Statement of Changes in Equity
For the year ended June 30, 2020

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2019	754,600,000	264,034,442	1,018,634,442
Net Profit for the period	-	117,054,459	117,054,459
Stock Dividend (2018-2019)	75,460,000	(75,460,000)	-
Cash Dividend (2018-2019)	-	(15,092,000)	(15,092,000)
Adjustment for Leased Assets		(6,622)	(6,622)
Balance as on June 30, 2020	830,060,000	290,530,279	1,120,590,279

Advent Pharma Ltd.
Statement of Changes in Equity
For the year ended June 30, 2019

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2018	686,000,000	187,950,804	873,950,804
Net Profit for the period	-	158,403,638	158,403,638
Stock Dividend (2017-2018)	68,600,000	(68,600,000)	-
Cash Dividend (2017-2018)	-	(13,720,000)	(13,720,000)
Balance as on June 30, 2019	754,600,000	264,034,442	1,018,634,442

The accompanying notes (01 to 38) form an integral part of this financial statement and are to be read in conjunction therewith.

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Sd/-
Managing Director

Sd/-
Chairman

Dated: October 28, 2020
Place: Dhaka

Sd/-
Ahmed Zaker & Co.
Chartered Accountants

Advent Pharma Ltd.
Statement of Cash Flows
For the year ended June 30, 2020

Particulars	Amount in Taka	
	July 01, 2019 to June 30, 2020	July 01, 2018 to June 30, 2019
A. CASH FLOWS FROM OPERATING ACTIVITIES:		
Cash Receipts from Customers & Others	505,459,395	582,069,022
Cash Paid to Suppliers	(252,134,363)	(286,209,895)
Cash paid to Employees	(42,439,218)	(43,536,757)
Cash paid to Others	(34,171,639)	(35,849,097)
Tax Paid During This period	(6,618,029)	(11,920,491)
Net cash generated from operating activities	170,096,145	204,552,782
B. CASH FLOWS FROM INVESTING ACTIVITIES:		
Paid for Acquisition of Property, Plant & Equipment	(55,602,347)	(185,990,007)
Paid for Capital Work -in- Progress (construction)	(156,822,461)	(87,276,054)
Investment in FDR	40,000,000	(65,000,000)
LC margin for Machineries	-	(80,906)
Proceeds from disposal of Fixed Assets	-	250,767
Net cash used for investing activities	(172,424,808)	(338,096,200)
C. CASH FLOWS FROM FINANCING ACTIVITIES:		
Short Term Borrowings- Received/(Payment)	16,122,455	(12,947,151)
Long Term Borrowings-Received/(Payment)	(2,598,623)	(4,339,950)
Financial Expenses Paid	(4,233,596)	(6,054,194)
Cash Dividend Paid	(8,713,293)	(5,471,182)
Lease Payment	(632,500)	-
Refund to IPO Applicants	(20,000)	(295,035)
Net cash provided by financing activities	(75,558)	(29,107,512)
D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	(2,404,220)	(162,650,930)
E. Cash & Cash equivalents at the beginning of the year	8,742,883	171,393,813
F. Cash & Cash equivalents at the end of the year (D+E)	6,338,662	8,742,883
G. Net Operating Cash Flows Per Share	31.00	2.05
		2.46

The accompanying notes (01 to 38) form an integral part of this financial statement and are to be read in conjunction therewith.

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Sd/-
Managing Director

Sd/-
Chairman

Dated: October 28, 2020
Place: Dhaka

Sd/-
Ahmed Zaker & Co.
Chartered Accountants

Advent Pharma Limited
Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the year ended 30 June-2020

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016.

The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

3.01 Basis of Measurement of Elements of Financial Position

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 1987 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the year.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial instruments: Presentation
IAS 33	Earnings per Share
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segment
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases

3.02 Going Concern Assumption

The company has adequate resources to continue its operation for the foreseeable future. As such, the directors intended to adopt the going concern basis in preparing the financial statements. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business.

3.03 Structure, Content and Presentation of Financial Statements

Being the general purpose financial statements, the presentation of these financial statements is in accordance with the guidelines provided by IAS 1 Presentation of Financial Statements. The financial statements comprises the following;

- i) Statement of Financial Position as at June 30, 2020
- ii) Statement of Profit or Loss and other comprehensive income for the year ended June 30, 2020
- iii) Statement of Changes in Equity for the year ended June 30, 2020
- iv) Statement of cash flows for the year ended June 30, 2020
- v) Notes, comprising a summary of significant accounting policies and other explanatory information as at and for the year ended June 30, 2020

3.04 Reporting Currency and level of precision

The figure in the financial statements has been presented in Bangladesh Taka Currency and has been Rounded off to the nearest Taka where necessary.

3.05 Reporting Period

The period of the financial statements covers 12(Twelve) months from 01 July 2019 to 30 June 2020.

3.06 Revenue

"As per IFRS-15: "Revenue from Contracts form Customers" an entity shall account for a contract with a customer only when all of the following criteria are met:

- (a) The parties to the contract have approved the contract (in writing , orally or in accordance with other customary business practices) and are committed to perform their respective obligations ;
- (b) The entity can identify each party 's rights regarding the goods or services to be transferred ;
- (c) The entity can identify the payment terms for the goods or services to be transferred ;
- (d) The contract has commercial substance (i.e. the risk , timing or amount of the entity `s future cash flows is expected to change as a result of the contract); and
- (e) It is probable that the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer."

3.07 Property, Plant and Equipment

Initial Recognition and measurement

Property, plant and equipment have been capitalized at cost of acquisition and subsequently stated at cost less accumulated depreciation in compliance with the requirements of IAS 16 Property, Plant and Equipment. The cost of acquisition of an asset comprises its import/ purchase price including non refundable duty taxes and any other directly attributable incidental cost of bringing the assets for its intended use.

Depreciation on Fixed Assets

In accordance with the provisions of IAS 16 Property, Plant and Equipment. Depreciation charged on an asset when the assets are available for use. Depreciation is charged on all fixed assets on reducing balance method. The Rate of depreciation for this year as below:

Particulars	30-Jun-2020	30-Jun-2019
Land	-	-
Land Development	2.5%	2.50%
Factory Building	2.5%	2.5%
Plant & Machinery	5%	5%
Sub-Station	10%	10%
Motor Vehicle	15%	15%
Furniture & Fixture	10%	10%
Solar Panel	10%	10%
Generator	10%	10%
Air Conditioner	5%	5%
Office Equipment	10%	10%
HVAC System	5%	5%
Labrotory Equipment	5%	5%
Product development Equipment	5%	5%
ETP	5%	5%
Books & Journals	15%	15%

3.08 Cash and Cash equivalents

Cash and cash equivalents comprise cash in hand, demand deposits and short term deposit, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

3.09 Inventories

Inventories are carried at the lower of cost or net realizable value as prescribed by IAS 2 Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

3.10 Events after the Reporting Period

Events after the Reporting Period that provide additional information about the companies position at the date of statement of Financial position are reflected in the Financial Statements. Events after the reporting period that are non adjusting events are disclosed in the notes when material.

3.11 Statement of Cash Flows

The Statement of Cash Flows is prepared in accordance with Bangladesh Accounting Standards IAS 7 Statement of Cash Flows and cash flows from the operating activities have been presented under direct method considering the provision of paragraph 19 of IAS 7 which provides that Entities are encouraged to report cash flows from operating activities using the direct method.

3.12 Related Party Disclosures

The company in normal course of business carried out a number of transactions with related parties that fall within the definition of related party as prescribed by IAS 24 Related Party Disclosures. This has been disclosed in a separate note to the financial statements.

3.13 Earnings Per Share

The company calculates Earnings Per Share (EPS) in accordance with the requirement of IAS 33 Earnings Per Share, which has been shown on the face of the Statement of Profit or Loss and other Comprehensive Income.

Basic earnings

This represents earnings for the year ended June 30, 2020 attributable to the ordinary shareholders.

Basic earnings per share

This has been calculated dividing the basic earning by the weighted average number of shares outstanding during the year.

Diluted earnings per share

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary shares during the year ended 30 June, 2020.

3.14 Impairment of Assets

I) Financial Assets

Accounts receivable and others receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default of delinquency by a debtor, indicates that a debtor of issuer will enter bankruptcy etc.

II) Non-Financial assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impaired loss is recognized immediately in statement of comprehensive income unless the asset is carried at revalued amount. Any impaired loss of a revalued asset treated as a revaluation decrease.

All fixed and financial assets have been reviewed and it was confirmed that no such assets have been impaired during the year and for this reason no provision has been made for impairment of assets.

3.15 Provisions

In accordance with the guidelines as prescribed by IAS 37 "Provisions, Contingent Liabilities and Contingent Assets", provisions are recognized in the following situations:

- a) when the company has an obligation (legal or constructive) as a result of past events;
- b) when it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- c) when reliable estimates can be made of the amount of the obligation.

3.16 Income Tax

Current Tax

Provision for taxation has been made as per rates prescribed in Finance Act 2020 and the Income Tax Ordinance 1984 on the profit made by the company.

Deferred Tax

The company accounts for deferred tax as per IAS 12 Income Taxes. Deferred Tax is arising due to temporary difference in between carrying amount of book value of assets and liabilities and its tax base. The tax rate prevailing at the balance sheet date is used to determine deferred tax.

3.17 Workers Profit Participation Fund (WPPF)

The company has created a fund for workers " Workers profit participation fund (WPPF)" as per Bangladesh labor Act 2006 (amendments 2013) by 5% of profit after charging such expenses.

3.18 VAT

Company Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non vatable items as per S.R.O No. 144-AIN/2020/105-VAT, dated: June 11, 2020.

3.19 Comparative Information

Comparative information has been disclosed in the respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statement.

3.20 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IFRS-9 Financial Instruments' Recognition and Measurement.

Financial Assets

Financial assets of the company include cash and cash equivalents, equity instrument to another entity, Trade receivables and other receivables. The company initially recognize a financial asset in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognize a financial asset when, and only when; the contractual rights to the cash flows from the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.

Financial Liabilities

"The company initially recognize a financial liability in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognize a financial liability from its statement of financial position when, and only when, it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. "

3.21 Employee Benefits

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set delineated in the respective deeds. The company has accounted for and disclosed employees benefits in compliance with the provisions of IAS 19 Employee Benefits. The cost of employee benefit is charged off as revenue expenditure in the period to which the contributions relate.

The Company's employee benefits include the following:

Short Term Employee Benefits

Short term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured on an undiscontinued basis are expensed as the related service is provided.

Worker's profit participation fund(WPPF)

The company recognized WPPF at the rate of 5% on profit after charging such expenses before tax and payment is made to the workers as per provisions of Bangladesh Labor Act 2006 (amendments 2013).

3.22 Operating Segments:

"As required by IFRS-8 "Operating Segments", if an entity operates business activities that may earn revenues or incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which discrete financial information is available. The company consider the operation on aggregate basis and manage the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed."

3.23 Risk Management:

The management of the company is overall responsible for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risk for its use of financial instrument.

Credit Risk
Liquidity Risk
Market Risk

Credit Risk:

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. As at 30 June, 2020 there has no credit risk against receivables.

Management perception:

To mitigate the the credit risk the management of the company follows robust credit controll and collection polices. The company has dedicated credit collection team who are responsible for any dues and they have been demonstrating remarkable performance in collecting receivables as per company's credit and collection policy.

Liquidity Risk:

Liquidity risk is defined as the risk that the company will not be able to settle or meet its financial obligations on time or at a resunable price.

Management perception:

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and streessed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/ fund to make the expected payment within due date.

Market Risk:

Market risk is refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arrises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

Management perception:

Management is fully aware of the market risk, and act accordingly. Market of animel health products in Bangladesh is growing rapidly. Moreover the company has a strong marketing and brand management to increase the customer base and customer loyalty.

3.24 Authorisation for Issue

The financial statements were authorised for issue by the board of Directors of the Company on 28 October, 2020

		Amount in Taka	
		30-June-2020	30-June-2019
4.00 Property, Plant and Equipment			
A. Cost			
Opening Balance	927,415,596	648,882,223	
Add: Addition during the year	286,988,605	280,723,373	
Less: Disposal during the year	-	(2,190,000)	
	1,214,404,201	927,415,596	
B. Accumulated Depreciation			
Opening Balance	82,685,733	58,329,267	
Add: Depreciation charged during the year	33,117,323	24,632,842	
Less: Adjustment during the year	-	(276,376)	
	115,803,056	82,685,733	
Written down Value (A-B)	1,098,601,145	844,729,863	
Details are shown in Annexure-A.			
5.00 Capital Work In Progress (Building Construction)			
Opening Balance	86,451,054	94,733,366	
Addition during the year	150,778,461	240,757,598	
Transfer to Factory Building	(231,305,352)	(249,039,910)	
Closing Balance	5,924,163	86,451,054	
6.00 Right of use Assets:			
Beginning Balance	1,602,786	-	
Depreciation Expenses	(582,831)	-	
Closing Balance	1,019,955	-	
7.00 Inventories			
Finished Goods (Note-23.00)	24,923,097	22,786,458	
Raw Materials (Note-23.01)	22,320,203	27,308,790	
Packing Materials (Note-23.02.01)	6,055,256	6,779,356	
Spare Parts (Note-23.02.2)	185,452	388,658	
Work In Process (Note-23.00)	14,402,451	13,546,890	
Total	67,886,459	70,810,152	
8.00 Trade & Other Receivables			
Trade Receivable	118,236,156	78,850,747	
Total	118,236,156	78,850,747	
Ageing of Trade Receivable			
More than six months	-	-	
Less than six months	118,236,156	78,850,747	
	118,236,156	78,850,747	

During the year accounts receivable tk. 118,236,156. A substantial number of total dues of Tk. 118,236,156 is doubtful of recovery, but no provision has been made in these financial statements for the doubtful receivable amount.

The classification of receivables as required by the Schedule XI of the Companies Act, 1994 are given below:

Receivables considered good and in respect of which the company is fully secured.	-	-
Receivables considered good for which the company holds no security other than the debtor's personal security.	118,236,156	78,850,747
Receivables considered doubtful or bad.	-	-
Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
Receivables due by companies under the same management.	-	-
The maximum amount due by directors or other officer of the company at any time during the year.	-	-
Total	118,236,156	78,850,747

		Amount in Taka	
		30-June-2020	30-June-2019
9.00	Advances, Deposits & Pre-payments		
	Advances (Note # 9.01)	27,856,609	34,831,299
	Deposits (Note # 9.02)	1,129,724	1,129,724
	Prepayments (Note # 9.03)	43,523	25,260
	VAT Current Account	4,741,626	2,075,007
	Total	33,771,482	38,061,290
9.01	Advances		
	Advance against Tax (9.01.01)	20,827,608	33,788,346
	Advance against Salary	6,000	35,000
	Advance against Construction	6,869,000	825,000
	Advance against Raw Materials	154,001	102,047
	Advance LC margin for Laboratory Equipment	-	80,906
	Total	27,856,609	34,831,299
9.01.01	Advance against Tax		
	Opening Balance	33,788,346	21,867,855
	Add: Paid During the year(Note-9.01.02)	6,618,029	11,920,491
	Less: Adjustment During the year(Note-9.01.03)	(19,578,767)	-
	Total	20,827,608	33,788,346
9.01.02	Tax paid during the year		
	For the Income Year 2013	-	237,000
	For the Income Year 2014	-	266,000
	For the Income Year 2015	-	292,000
	For the Income Year 2013,2014,2015,2016(Six Month)	2,019,703	-
	For the Income Year 2017-2018	-	1,283,361
	Others	4,598,326	9,842,130
	Total	6,618,029	11,920,491
9.01.03	Advance tax adjustment during the year:		
	For the Income year 2013	4,885,968	-
	For the Income year 2014	6,273,749	-
	For the Income year 2015	7,661,078	-
	For the Income year 2016(Jan.-June)	757,972	-
	Total	19,578,767	-
9.02	Deposits		
	Security Deposit - Electricity	550,424	550,424
	Security Deposit -Titas Gas Transmission & Distribution Co. Ltd.	183,000	183,000
	Security against-House Rent	391,000	391,000
	Security Deposit -BTCL.	5,300	5,300
	Total	1,129,724	1,129,724
9.03	Prepayments		
	Prepaid Fire Insurance:		
	Opening Balance	25,260	25,260
	Add: Advance paid during the year	174,104	101,049
	Less: Charged during the year	(155,841)	(101,049)
	Closing Balance	43,523	25,260

		Amount in Taka	
		30-June-2020	30-June-2019
10.00 Investment in FDR			
<u>Name of Financial Institution</u>			
Midland Bank Ltd.	FDR No.: 0019761	40,000,000	40,000,000
Phoenix Finance & Investments Ltd.	TDR No.: 23977/18	-	30,000,000
IFIC Bank Ltd.	FDR No.: 1299962	-	10,000,000
Total		40,000,000	80,000,000
11.00 Cash & Cash Equivalents			
Cash in hand (Note-11.01)		135,502	231,781
Cash at bank (Note-11.02)		6,203,160	8,511,102
Total		6,338,662	8,742,883
11.01 Cash in Hand			
Head Office		65,587	207,370
Depots		69,915	24,411
		135,502	231,781
Cash in hand has been certified by the management of the company.			
11.02 Cash at Bank (Note- 11.02.01)		6,203,160	8,511,102
11.02.01 Cash at Bank			
<u>Bank Name</u>			
Islami Bank Bangladesh Ltd.	A/C No. # 283517	265,542	72,830
Dutch Bangla Bank Ltd.	A/C No. # 129775	688,718	1,134,212
Janata Bank Ltd.	A/C No. # 10035785	197,721	173,198
IFIC Bank Ltd.	A/C No. # 327-041	4,028,654	5,338,665
IFIC Bank Ltd.	A/C No. # 327-001	43,178	1,275,496
IFIC Bank Ltd.	A/C No. # 327-003	81,294	126,750
Shahjalal Islami Bank Ltd.	A/C No. # 000-7339	22,810	165,794
Midland Bank Ltd.	A/C No. # 000-6230	696,445	91,149
BRAC Bank Ltd.	A/C No. # 150001	94,826	104,122
BRAC Bank Ltd.	A/C No. # 150002	83,972	28,885
Total		6,203,160	8,511,102
12.00 Share Capital			
<u>Authorized Capital :</u>			
100,000,000 ordinary shares of Tk. 10.00 each		1,000,000,000	1,000,000,000
<u>Issued, Subscribed & Paid-up Capital :</u>			
754,60,000 ordinary shares of Tk. 10.00 each		830,060,000	754,600,000
830,06,000 ordinary shares of Tk. 10.00 each			

Share holding position of Shareholders:

Category of Share Holders	No. of Share Holding		Percentage of Shareholding		Amount in Taka	
	30-Jun-20	30-Jun-19	30-Jun-20	30-Jun-19	30-Jun-20	30-Jun-19
Director & Sponsor	26,096,675	23,724,250	31.44%	31.44%	260,966,750	237,242,500
Institutional	16,219,372	14,920,238	19.54%	19.77%	162,193,724	149,202,380
Public	40,689,953	36,815,512	49.02%	48.79%	406,899,526	368,155,120
Total	83,006,000	75,460,000	100%	100.00%	830,060,000	754,600,000

The distribution schedule showing the number of shareholders and their share holding in percentage has been disclosed below:

Range of Holding	As per Folio		As per BO ID		Total Share Holdings	%
	No. of Holders	Holdings	No. of Holders	Holdings		
Up to 500 Shares	-		1,330	211,532	211,532	0.25%
501 to 5,000 Shares	-		1,821	3,188,008	3,188,008	3.84%
5,001 to 10,000 Shares	-		348	2,597,216	2,597,216	3.13%
10,001 to 20,000 Shares	-		218	3,102,268	3,102,268	3.74%
20,001 to 30,000 Shares	-		89	2,223,021	2,223,021	2.68%
30,001 to 40,000 Shares	-		33	1,125,898	1,125,898	1.36%
40,001 to 50,000 Shares	-		26	1,218,552	1,218,552	1.47%
50,001 to 100,000 Shares	-		66	4,896,610	4,896,610	5.90%
100,001 to 1,000,000 Shares	-		87	22,899,075	22,899,075	27.59%
Over 1,000,000 Shares	1	1,400,000	15	40,143,820	41,543,820	50.05%
Total	1	1,400,000	4,033	81,606,000	83,006,000	100%

13.00 Retained Earnings

Balance brought forward
Add: Profit for the year
Stock Dividend
Cash Dividend
Adjustment for Leased
Balance carried forward

Amount in Taka	
30-June-2020	30-June-2019
264,034,442	187,950,804
117,054,459	158,403,638
(75,460,000)	(68,600,000)
(15,092,000)	(13,720,000)
(6,622)	-
290,530,279	264,034,442

14.00 Long Term Borrowings Net of Current Portion

Islami Bank Bangladesh Ltd., A/C # 082015
Islami Bank Bangladesh Ltd., A/C # 100814
Total
Less: Current Portion of long Term loan
Less: Accrued Interest on Long Term Loan
Net Amount

19,544,093	21,278,375
5,464,264	6,050,313
25,008,357	27,328,688
(7,912,963)	(7,912,963)
(579,219)	(300,927)
16,516,175	19,114,798

Terms and conditions

This represent the present outstanding balance of the above Long term loans(Project Loan) taken for Construction Works and purchase of Machinery. The above loans are secured by land with building and Existing Machinery. The rate of interest of this loans are varying from 9% -15%.

15.00 Short Term Borrowing

Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch
Midland Bank Ltd., Dilkusha Branch

-	796,034
-	1,859,467
-	1,175,869
-	1,826,217
-	1,800,165
1,098,720	-
1,291,649	-
2,008,929	-
2,155,038	-
3,317,632	-
1,878,529	-

		Amount in Taka	
		30-June-2020	30-June-2019
Midland Bank Ltd.,	Dilkusha Branch	877,541	-
Midland Bank Ltd.,	Dilkusha Branch	4,770,953	-
Midland Bank Ltd.,	Dilkusha Branch	3,226,757	
Midland Bank Ltd.,	Dilkusha Branch	3,162,479	
Total Amount		23,788,227	7,457,752
Less: Accrued Interest on Short Term Loan		(430,151)	(222,130)
Net Amount		23,358,077	7,235,622

Terms & Conditions

This represent the present outstanding balance of the above short term loans(working capital Loan) taken for purchase of Raw materials. The above loans are secured by land with building and Existing Machinery. The rate of interest of this loans are varying from 9% -15%.

16.00 Deferred Tax Liabilities

Opening Balance	66,999,086	43,259,181
Add: Provision made during the year (Note-16.01)	34,429,158	23,739,905
Closing Balance	101,428,244	66,999,086

16.01 Deferred tax liabilities as at June 30, 2020 is arrived as follows :

Written Down Value of PPE as per Accounting Base	1,098,601,145	844,729,863
Adjustment of WPPF	-	(11,982,914)
Written Down Value Considering WPPF	1,098,601,145	832,746,948
Written Down Value as per Third Schedule	(692,888,168)	(564,750,605)
Net Temporary Difference	405,712,977	267,996,343
Income Tax Rate	25%	25%
Deferred Tax Liability	101,428,244	66,999,086
Openning Deferred Tax Liability	(66,999,086)	(43,259,181)
Deferred Tax Expenses	34,429,158	23,739,905

17.00 Trade and other payables

Payable to Suppliers & Others:

Chemi Trade	1,404,225	1,383,150
Mars Trading	162,100	938,000
Annex International	210,670	-
AR Plastic Industries	-	84,674
Asia Plastic Container	659,041	241,500
Bismillah Plastic	60,000	-
Daily Industry	8,000	
Digital Sign Pack	741,933	623,147
Free Mason International	-	10,830
G Mack Corporation	30,000	-
Jamuna Corporation	1,338,850	40,700
M.A Polymer Industries	180,850	-
Matador Ball Pen Industries	45,700	
Max Accessories	34,000	
Metro Foils Ltd.	21,275	-
Modhubon Courier Service	7,000	
Moon International	-	7,200
Mousumi Traders	102,000	-
M/S Alamgir & Sons	120,380	-
M/S Homeland	187,585	-
M/S Mina Traders	516,500	
M/S Siyam Enterprise	913,740	330,000

		Amount in Taka	
		30-June-2020	30-June-2019
	M/S Shefa Trading	-	131,940
	M/S Sonali Center Pvt. Ltd.	-	22,447
	New Progressive Traders	-	53,220
	Oxide Chemical Industry	15,520	-
	Pakeza Graphics & Design & Printing	130,145	86,700
	Pharmatex Trading	790,000	-
	Pharmalink Engineering Technology	25,000	90,000
	Protidiner Sangbad	8,000	-
	Ripon Works Motor	55,088	50,260
	Rupayan Karim Tower	15,345	-
	Saumica Printing	10,530	-
	Six Sigma Group	838,360	-
	Sky Foils Ltd.	-	95,667
	S.M. Enterprise	181,400	152,884
	Total Can & Closer Ltd.	455,400	39,675
	Cash Dividend Payable	14,627,525	8,248,818
	Total	23,896,162	12,630,812
18.00	Liability for Leases net of current Maturity:		
	Beginning Balance	1,609,407	-
	Add: Interest Expenses	164,869	-
	Less: Payment	632,500	-
	Closing Balance	1,141,776	-
	Less: Liabilities for lease-current maturity	(649,231)	-
	Total	492,545	-
19.00	Liabilities for expenses		
	Electricity Bill	204,140	236,101
	Salary and Wages	3,032,450	2,905,162
	Director Remuneration	97,000	97,000
	Telephone & Mobile bill	12,495	1,657
	Accrued Interest (Note-19.01)	1,009,370	523,057
	TDS Payable	15,260	12,840
	Office Rent	-	57,500
	Audit Fees	230,000	230,000
	Legal, License, Renewals & Professional fee	1,510,198	20,000
	Total	6,110,913	4,083,317
19.01	Accrued Interest on Loan		
	Accrued Interest on Long Term Loan (Note-19.01.01)	579,219	300,927
	Accrued Interest on Short Term Loan (Note-19.01.02)	430,151	222,130
	Total Amount	1,009,370	523,057
19.01.01	Accrued Interest on Long Term Loan		
	Opening Balance	300,927	108,299
	Interest Charged during the year	3,062,781	3,943,278
	Payment made during the year	(2,784,489)	(3,750,650)
	Closing Balance	579,219	300,927

		Amount in Taka	
		30-June-2020	30-June-2019
19.01.02	Accrued Interest on Short Term Loan		
	Opening Balance	222,130	727,761
	Interest Charged during the year	1,376,917	1,465,286
	Payment made during the year	(1,168,896)	(1,970,917)
	Closing Balance	430,151	222,130
20.00	Liability for Contribution to WPPF		
	Opening Balance	11,982,914	6,115,435
	Add: Provision for WPPF for the year (Note-20.01)	8,075,461	10,598,030
	Add: Interest on W.P.P.F fund used	1,286,195	-
	Less: Paid during the year	-	(4,730,551)
	Total	21,344,569	11,982,914
20.01	Provision for WPPF for the year		
	5 % of profit beforeTax	8,075,461	10,598,030
	Total	8,075,461	10,598,030
21.00	Provision for Current Tax		
	Opening Balance	58,922,680	29,105,618
	Add: Provision for tax during the year (Note-21.01)	10,025,596	29,817,062
	Less: Paid during the year/Adjustment (Note-9.01.03)	(19,578,767)	-
	Total	49,369,509	58,922,680
21.01	Provision for Tax during the year		
	Accounting Profit before Tax	161,509,212	211,960,605
	Add: Other Inadmissible Allowances		
	Accounting Depreciation	33,117,323	24,632,842
	Provision for WPPF	-	10,598,030
	Other Income	(10,817,225)	(6,935,771)
	Loss on disposal of Fixed Assets	-	1,662,857
	Less: Items for Separate Consideration		
	Depreciation as per 3rd Schedule	(158,851,042)	(125,459,940)
	Payment for WPPF	-	(4,730,551)
	Loss as per Third Schedule	-	(395,091)
	Total Taxable Income	24,958,268	111,332,981
	Rate	25%	25%
	Total Tax Expenses/Current Tax	6,239,567	27,833,245
	Tax on other income	3,786,029	2,427,520
	Adjustment for previous year:		
	For the Income year 2013	-	(2,127,626)
	For the Income year 2014	-	2,129,756
	For the Income year 2015	-	1,799,178
	For the Income year 2016(Jan.-June)	-	(2,245,010)
	Total Tax Payable	10,025,596	29,817,062

		Amount in Taka	
		July 01, 2019 to June 30, 2020	July 01, 2018 to June 30, 2019
22.00	Turnover		
	Sales Revenue from Sale of Finished Goods:		
	Gross Sales(Note: 22.01)	535,061,262	603,555,589
	Less : VAT on Sales	1,033,683	1,589,092
	Net Sales	534,027,579	601,966,497
22.01	Gross Sales		
	Sales Revenue from Sale of Finished Goods		
		Gross Sales	VAT@15%
		Net Sales	Net Sales
	Vatable Sales	7,924,921	1,033,683
	Non Vatable Sales	527,136,341	-
	Total	535,061,262	1,033,683
		534,027,579	601,966,497
23.0	Cost of Sales		
	Raw Materials Consumed (Note-23.01)	251,729,434	271,746,199
	Manufacturing Overhead (Note-23.02)	59,520,720	50,766,448
		311,250,154	322,512,647
	Add: Opening Work in process	13,546,890	14,274,867
	Less: Closing Work in process	(14,402,451)	(13,546,890)
	Cost of Goods manufactured	310,394,593	323,240,624
	Add: Opening stock of finished Goods	22,786,458	19,265,698
	Cost of Goods Available for Sale	333,181,051	342,506,322
	Less: Closing stock of finished Goods	(24,923,097)	(22,786,458)
	Less: Sample Distribution	(1,281,602)	(1,573,288)
	Cost of Sales	306,976,352	318,146,576
23.01	Raw Materials Consumed		
	Opening Stock of Raw Materials	27,308,790	24,398,106
	Add: Raw Materials Purchased (Note-23.01.01)	246,740,847	274,656,883
	Raw Materials available for Consumption	274,049,637	299,054,989
	Less: Closing Stock of Raw Materials	(22,320,203)	(27,308,790)
	Raw Material Consumption	251,729,434	271,746,199
23.01.01	Raw Materials Purchase:		
	Local Purchase	203,605,942	264,352,802
	Foreign Purchase	43,134,905	10,304,081
	Total Purchase	246,740,847	274,656,883
23.02	Manufacturing Overhead		
	Wages and Salary	9,256,520	9,165,350
	Festival Bonus	1,017,027	999,050
	Overtime	1,332,105	1,429,950
	Packaging Materials Consumed (Note # 23.02.01)	9,676,995	7,280,677
	Spare Parts Consumed (Note # 23.02.02)	1,440,171	2,663,267
	Repair & Maintenance	758,349	1,110,942
	Electricity Bill (Factory)	1,371,612	1,785,975
	Disel & Fuel	734,338	848,748
	Electric & Sanitary Goods	400,600	649,527
	Fire Insurance Premium	155,841	101,049

		Amount in Taka	
		July 01, 2019 to June 30, 2020	July 01, 2018 to June 30, 2019
Canteen Expenses		1,400,781	1,132,133
Laboratory Expenses		188,633	329,220
Cleaning & Washing		233,636	144,319
Internet bill		28,800	29,800
Mobile & Telephone bill		29,670	32,100
Uniform		98,063	186,710
Depreciation (Annexure-A)		31,397,579	22,877,631
Total		59,520,720	50,766,448
23.02.01 Packaging Materials Consumed			
Opening Stock of Packaging Materials		6,779,356	5,372,560
Add: Purchase during the year		8,952,895	8,687,473
Less: Closing Stock of Packaging Materials		(6,055,256)	(6,779,356)
Packaging Materials Consumed		9,676,995	7,280,677
23.02.02 Spare Parts Consumed			
Opening Stock of Spare Parts		388,658	370,452
Add: Purchase during the year		1,236,965	2,681,473
Less: Closing Stock of Spare Parts		(185,452)	(388,658)
Spare Parts Consumed		1,440,171	2,663,267
24.00 Administrative Expenses			
Salary & Allowance		11,483,982	11,604,329
Director Remuneration (Note # 34.01)		1,200,000	1,200,000
Conveyance		277,590	185,655
Subscription, Gift & Donation		61,750	170,900
Festival Bonus		629,175	1,070,225
Office Rent including VAT		-	690,000
Board meeting attendance fees (Note # 34.01)		270,000	315,000
Cleaning & Sanitation		30,056	163,204
Credit Rating Fee		50,000	50,000
Electricity Bill		168,876	122,016
Entertainment		407,624	609,564
Garage Rent		24,400	12,500
Legal, License & Renewal & Professional fee		2,243,747	1,653,375
Research & Product Development		2,230,000	678,480
Miscellaneous Expense		1,348,068	1,559,767
Newspaper & Magazine		4,316	7,249
Postage, Stamps & Courier		73,989	98,018
Printing & Stationery		529,694	648,939
Office Maintenance		224,475	258,152
Training Allowance		17,760	88,410
Vehicle Repair & Maintenance		664,017	158,391
Fuel & Gas		361,857	614,579
Telephone & Mobile		206,065	137,044
Internet bill		109,000	92,250
Annual General Meeting Expenses		274,145	328,815
Audit Fees Including VAT		230,000	230,000
Interest expenses on the Lease Liability		164,869	-
Depreciation Charge for the Right-of-Use Asset		582,831	-
Depreciation (Annexure-A)		1,719,744	1,755,211
Total		25,588,030	24,502,073

		Amount in Taka	
		July 01, 2019 to June 30, 2020	July 01, 2018 to June 30, 2019
25.00	Selling & Marketing Expenses		
	Salary & Allowance	16,555,217	17,092,270
	Travelling & Conveyance	5,008,117	4,953,349
	Festival Bonus	851,480	956,725
	Advertisement	106,498	331,955
	Marketing Promotion	4,854,704	4,038,750
	Distribution Cost	8,032,027	7,344,599
	Sample Distribution	1,281,602	1,573,288
	Total	36,689,645	36,290,936
26.00	Financial Expenses		
	Bank Charges	280,211	332,626
	Interest on Loan	4,439,698	5,408,565
	Interest on W.P.P.F Fund used	1,286,195	-
	Total	6,006,104	5,741,191
27.00	Other Income		
	Interest on FDR	8,487,500	4,716,792
	Bank Interest	344,032	646,724
	Sales of Wastage(Others)	928,267	1,572,255
	Toll Manufacturing Income	1,057,426	-
	Total	10,817,225	6,935,771
28.00	Other Loss		
	Loss on disposal of Fixed Assets	-	1,662,857
	Total	-	1,662,857
		Yearly Product	
		30-June-2020	30-June-2019
29.00	Earnings Per Share		
	Basic Earnings per Share :		
	Profit after tax	117,054,459	158,403,638
	Weighted average number of ordinary shares outstanding Note - 29.1	83,006,000	75,460,000
	Basic Earnings per Share	1.41	2.10
	Adjusted Earnings per Share :		
	Profit after tax	117,054,459	158,403,638
	Weighted average number of ordinary shares outstanding Note - 29.1	83,006,000	83,006,000
	Basic Earnings per Share(Adjusted)	1.41	1.91
	Diluted Earnings Per Share		
	Profit after tax	117,054,459	158,403,638
	Weighted average number of ordinary shares outstanding Note - 29.1	83,006,000	83,006,000
	Diluted Earnings Per Share	1.41	1.91

As there are no shares under option, Basic & Diluted earning per share are same for the year. This has been calculated in compliance with the requirements of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the year

Yearly Product	
30-June-2020	30-June-2019

29.01 Calculation of Weighted Average Number of Shares

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Yearly Product (Weighted Average)	
Shares at beginning	75,460,000	July-19 to June-20	366	27,618,360,000	75,460,000	68,600,000
Stock Dividend-2018 @ 10%					-	6,860,000
Stock Dividend -2019@ 10%	7,546,000	July-19 to June-20	366	2,761,836,000	7,546,000	7,546,000
Total	83,006,000			30,380,196,000	83,006,000	83,006,000

30.00 Net Asset Value (NAV) per Share

	30-Jun-2020	30-Jun-2019
Total Asset	1,371,778,022	1,207,645,989
Less: Total outside Liability	251,187,743	189,011,547
Net Asset	1,120,590,279	1,018,634,441
Number of ordinary shares outstanding	83,006,000	75,460,000
Net Assets Value (NAV) per Share	13.50	13.50

31.00 Net Operating Cash Flows per Share(NOCFPS)

	30-Jun-2020	30-Jun-2019
Net Cash Generated From Operating Activities	170,096,145	204,552,782
Weighted Average Number of Shares Outstanding	83,006,000	83,006,000
Net Operating Cash Flows per Share(NOCFPS) (Adjusted)	2.05	2.46

32.00 Reconciliation of Net Profit with Cash flows from Operating Activities:

	30-Jun-2020	30-Jun-2019
Profit before Tax	161,509,212	211,960,605
Adjustment for:		
Depreciation on property, plant and equipment	33,117,323	24,632,842
Adjustment for depreciation of the Right Use of Assets	582,832	-
Interest expenses on Lease	164,869	-
Financial Expenses	6,006,104	5,741,191
Loss on disposal of Fixed Assets	-	1,662,857
	201,380,340	243,997,495
(Increase)/Decrease in Accounts Receivable	(39,385,409)	(26,833,246)
(Increase)/Decrease in Inventory	2,923,693	(7,128,469)
Increase/(Decrease) in Trade and Other Payables	4,886,643	58,241
Decrease/(Increase) in Advance, Deposit & Prepayments	(2,707,836)	147,273
Increase in Liabilities for Expenses	1,541,283	364,500
(Increase)/Decrease in Liability for contribution to W.P.P.F	8,075,461	5,867,479
	176,714,174	216,473,273
Less: Income Tax Paid	(6,618,029)	(11,920,491)
Net Cash Generated from Operating Activities	170,096,145	204,552,782

33.00 Utilization of IPO Fund

Utilization position of IPO proceeds upto 30 June, 2020 was as under:

Purpose as per Prospectus	As per Prospectus	Utilized upto 30 June, 2018	Utilized during 2018-2019	Utilized during 2019- 2020	Total Unutilized
Acquisition of Machineries & Equipment	81,430,800	-	29,924,522	51,506,278	-
Construction of Building and Other Civil Works	100,069,200	1,027,800	92,089,910	6,951,490	-
IPO Expenses	18,500,000	18,198,305	-	301,695	-
Total	200,000,000	19,226,105	122,014,432	58,759,463	-

The company raised Tk. 200,000,000 divided into 20,000,000 ordinary shares of Tk. 10 each through IPO on March 13, 2018. The company utilized Tk. 81,430,800 for the purpose of acquisition of Machineries and Equipment, Tk. 100,069,200 for the purpose of construction of Building and other Civil works and Tk. 18,500,000 for IPO expenses up to June 30, 2020 as certified by independent auditor, AHMAD & AKHTAR, Chartered Accountants, Habib Sarwar & Co., Chartered Accountants and Artisan, Chartered Accountants.

The utilization for the purpose of construction of building and other civil works has been recognized as capital work in progress in note # 5, Acquisition of Machineries and Equipments has been recognized in note # 04, and the IPO expenses included in the printing and stationer expenses to the financial statements.

34.00 Related parties Transaction:

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

34.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation.

a) Short-term employee benefits :

The amount of transaction for remuneration and board meeting fee during the year from 1st July 2019 to 30th June 2020 are as follows:

Name	Designation	Remuneration	Board meeting fee
A.K.M. Shafiqul Alam	Chairman	-	30,000
Wajhi Ahmed	Managing Director	1,200,000	30,000
Kazi Rina Alam	Director	-	30,000
Faria Binta Alam	Director	-	30,000
Md. Tazul Islam	Director	-	30,000
Mohammad Towhidul Islam	Nominee Director	-	30,000
Asif Iqbal Chowdhury	Nominee Director	-	30,000
Mohammed Salim	Independent Director	-	30,000
Shekh Karimuzzaman	Independent Director	-	30,000
Total		1,200,000	270,000

b) Post employment benefits: Nil

c) Other long term benefits: Nil

d) Termination benefits: Nil

e) Share-based payment: Nil

35.00 Disclosure as per Companies Act, 1994:

35.01 Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3:

Employee position of the company as at June 30, 2020:

Salary (Monthly)	Officer & Staff		Worker	Total Employees
	Factory	Head Office		
Below Tk. 3,000	-	-	-	-
Above Tk. 3,000	50	187	53	290
For the year ended 30.06.2020	50	187	53	290

35.02 Attendance Status of Board Meeting of Directors

During the year Six Board Meetings were held. The attendance status of the meetings are as follows:

Name of Directors	Duration	Position	Meeting Held	Attended	Total Fee
A.K.M. Shafiqul Alam	01.07.19 to 30.06.20	Chairman	6	6	30,000
Wajhi Ahmed	01.07.19 to 30.06.20	Managing Director	6	6	30,000
Kazi Rina Alam	01.07.19 to 30.06.20	Director	6	6	30,000
Faria Binta Alam	01.07.19 to 30.06.20	Director	6	6	30,000
Md. Tazul Islam	01.07.19 to 30.06.20	Director	6	6	30,000
Mohammad Towhidul Islam	01.07.19 to 30.06.20	Nominee Director	6	6	30,000
Asif Iqbal Chowdhury	01.07.19 to 30.06.20	Nominee Director	6	6	30,000
Mohammed Salim	01.07.19 to 30.06.20	Independent Director	6	6	30,000
Shekh Karimuzzaman	01.07.19 to 30.06.20	Independent Director	6	6	30,000
Total					270,000

35.03 Disclosure as per requirement of Schedule XI, Part II, Para 4

Payments to Managing Director and Directors by the Company during the year:

Sl. No.	Particulars	30-Jun-20
(a)	Managerial remuneration paid or payable during the year to the directors, including managing director, a managing agent or manager;	1,230,000
(b)	Expenses reimbursed to the managing agent;	Nil
(C)	Commission or other remuneration payable separately to managing agent or his associate;	Nil
(d)	Commission or other remuneration payable separately to managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company;	Nil
(e)	The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year;	Nil
(f)	Any other perquisites or benefits in cash or in kind;	Nil
(g)	Other allowances and commission including guarantee commission;	Nil
(h)	Pensions etc.-	Nil
	(i) Pensions	Nil
	(ii) Gratuities	Nil
	(iii) Payments from a provident funds, in excess of own subscription and interest thereon	Nil
	(iv) Compensation for loss of office	Nil
	(v) Consideration in connection with retirement from office.	Nil

35.04 Disclosure as per requirement of Schedule XI, Part II, Para 7:

Details of Production Capacity Utilization for the year July-2019 to June-2020

Particulars	Unit	License Capacity	Installed Capacity Per Annum	Actual Production per annum	Percentage of Capacity Utilization
Bolus Products	Pcs	N/A	15,876,000	2,678,820	17%
Powder Products	Kg	N/A	1,181,250	621,624	53%
Liquid Products	Liter	N/A	1,388,016	845,839	61%

35.05 Disclosure as per requirement of Schedule XI, Part II, Para 8 :

(a) Value of imports calculated on C.I.F basis by the company during the year 2019-2020 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

S.L	Particulars	Import Amount in BDT
i	Raw Materials	43,134,905
ii	Packing Materials	-
iii	Components of Spare parts	-
iv	Capital Goods	1,502,509

(b) The Company did not have any expenditure in foreign currency during the financial year on account of Royalty, Know-how, Professional consultancy fees, Interest and other matters.

(c) Value of both imported and Indigenous raw materials, Spare parts and components consumption thereon were as follows:

Particulars	Total Consumption	Imported Value(in BDT)	(%)	Indigenous Value(in BDT)	(%)
Raw Materials	251,729,434	36,977,756	14.69%	214,751,678	85%
Packing Materials	9,676,995	-	0%	9,676,995	100%
Spare Parts	1,440,171	-	0%	1,440,171	100%
Total	262,846,600	36,977,756		225,868,844	

(d) No amount is remitted during the year in foreign currencies on account of dividend with a specific mention of the number of non-residents shareholders, the number of shares held by them on which the dividends were due and the year to which the dividends, related.

(e) Earnings in foreign exchange classified under the following heads as follows:

- i) No export made during the year;
- ii) No royalty, know-how, professional and consultation fees were received;
- iii) No Interest and Dividend received;
- iv) No Other income received.

36.00 Contingent Liabilities

There is no sum for which the company is contingently liable as on 30.06.2020.

37.00 Events after the Reporting Period

Following events occurred since the balance date:

(a) The board of directors recommended 10% stock dividend at the Board meeting held on October 28, 2020 for the year ended June 30, 2020. This dividend is subject to final approval by the shareholders at the forthcoming Annual General Meeting (AGM) of the company.

(b) Except for the fact stated above, no circumstances have arisen since the balance sheet date which would require adjustment to, or disclosure in, the financial statements or notes thereto.

38.00 Significant Deviation

Advent Pharma Ltd. Is veterinary medicine producer. Due to COVID-19 pandemic and flood, our sales has decreased and materials price has increased in the market for interruption of Import. On the other hand carrying cost also has increased. In this year we got approval another 17 new products from drug administration and Department of Live Stock Services. For this we have spent some amount of money for product development. All of this reason net profit after tax has decreased, earnings per share and net operating cash flow per share has also decreased in the same line.

Advent Pharma Ltd.

Schedule of Property, Plant and Equipment
As at June 30, 2020

Annexure-A									
(Amount in Taka)									
Particulars	Cost			Rate of Dep.	Depreciation		Adjustment during the year	Balance as on 30-June-2020	Written down value as on 30-June-2020
	Balance as on 01-July-2019	Addition during the Year	Disposal during the Year		Balance as on 01-July-2019	Charged during the year			
Land	3,783,816	-	-	0%	-	-	-	-	3,783,816
Land Development	9,454,530	-	-	2.5%	579,164	221,884	-	801,048	8,653,482
Factory Building	527,536,942	231,305,352	-	2.5%	21,301,784	13,137,765	-	34,439,549	724,402,745
Plant & Machinery	219,601,006	53,434,378	-	5%	32,200,835	11,593,923	-	43,794,758	229,240,626
Sub-Station	6,694,722	-	-	10%	2,263,127	443,160	-	2,706,287	3,988,435
Motor Vehicle	6,097,576	-	-	15%	2,682,804	512,216	-	3,195,020	2,902,556
Furniture & Fixture	6,625,880	1,434,005	-	10%	1,882,099	557,736	-	2,439,835	5,620,050
Solar Panel	2,004,740	-	-	10%	622,907	138,183	-	761,090	1,243,650
Generator	627,520	-	-	10%	304,838	32,268	-	337,106	290,414
Air Conditioner	3,807,120	447,000	-	5%	709,269	175,530	-	884,799	3,369,321
Office Equipment	6,063,443	367,870	-	10%	1,566,748	474,262	-	2,041,010	4,390,303
HVAC System	44,536,240	-	-	5%	6,184,506	1,917,587	-	8,102,093	36,434,147
Laboratory Equipment	51,322,810	-	-	5%	7,056,954	2,213,293	-	9,270,247	42,052,563
Product Development Equipment	20,725,781	-	-	5%	2,818,714	895,353	-	3,714,067	17,011,714
ETP	18,488,470	-	-	5%	2,497,870	799,530	-	3,297,400	15,191,070
Books & Journals	45,000	-	-	15%	14,114	4,633	-	18,747	26,253
Total	927,415,596	286,988,605	-		82,685,733	33,117,323	-	115,803,056	1,098,601,145
Balance as at June 30, 2019	648,882,223	280,723,373	2,190,000		58,329,267	24,632,842	276,376	82,685,733	844,729,863

Allocation of Depreciation:

Administrative cost	1,719,744
Factory cost	31,397,579
Total	33,117,323

Advent Pharma Ltd.

Schedule of Stock
As at June 30, 2020

Finished Goods

Annexure-B

Name of Items	Unit	30-Jun-20		30-Jun-19	
Non Vatable Goods		Quantity	Amount	Quantity	Amount
Advit DB Premix-100 gm	Sachet	-	-	646	12,080
Advit DB Premix-500 gm	Sachet	-	-	1,587	127,150
Advit DB Premix-1 kg	Bucket	852	160,176	1,501	225,976
Advit CP Suspension -500 ml	Bottle	1893	166,584	1,209	89,127
Advit CP Suspension -1 ltr.	Bottle	996	151,392	1,241	158,041
Advit CP Suspension -5 ltr.	Jar	1210	774,400	1,171	627,773
Adzinc Syrup - 100 ml	Bottle	7816	187,584	2,716	54,456
Adzinc Syrup - 500 ml	Bottle	1564	137,632	1,450	106,691
Adzinc Syrup - 1 ltr.	Bottle	3607	577,120	2,477	331,423
Adzinc Syrup - 3 ltr.	Bottle	1605	719,040	1,233	462,498
Adlyte Powder -100 gm	Sachet	-	-	1,034	13,856
Adlyte Powder -500 gm	Sachet	-	-	1,856	99,482
Adlyte Powder -1 kg	Sachet	1142	109,632	1,037	83,375
Advit(B+C)-100 gm	Sachet	-	-	1,302	41,950
Advit(B+C)-500 gm	Sachet	-	-	1,056	141,631
Advit WS-100 gm	Sachet	-	-	650	100,003
Advit GC-500 gm	Sachet	1107	75,276	2,657	151,183
Advit GC-1 kg	Sachet	-	-	1,895	202,992
Advit C-100 gm	Sachet	-	-	1,745	193,084
Advit C-500 gm	Sachet	1798	560,976	1,847	720,330
Advit CP Plus Bolus	Bolus	1824	196,992	3,754	176,063
Advit D Plus -100 ml	Bottle	3640	203,840	1,735	81,077
Advit AD3E-100 ml	Bottle	-	-	1,544	134,621
Advit AD3E-500 ml	Bottle	-	-	1,572	621,726
Adzoril Solution-100 ml	Bottle	621	183,816	-	-
Adbovi Powder-125 gm	Sachet	3566	513,504	1,851	223,138
Adcal P Powder-500 gm	Sachet	1667	333,400	1,098	183,970
Adzyme Powder-100 gm	Sachet	2894	324,128	1,924	180,317
Cough of Oral Solution-100 ml	Bottle	3031	230,356	3,872	246,337
Cough of Oral Solution-500 ml	Bottle	1826	671,968	2,946	907,810
Cough of Oral Solution-1 Ltr.	Bottle	1221	859,584	1,605	946,228
Advit E-Sel-100 MI	Bottle	1426	96,968	1,950	110,760
Feron Vet-500 MI	Bottle	2255	180,400	1,590	106,689
Feron Vet-1 Ltr.	Bottle	1471	223,592	2,439	327,314
ABC -100 MI	Bottle	3473	250,056	3,060	184,671
ABC -500 MI	Bottle	1476	436,896	2,997	743,016
ABC -1 Ltr.	Bottle	929	516,524	1,645	766,027
Lever on-100 MI	Bottle	1973	110,488	2,186	102,436
Lever on-500 MI	Bottle	1381	342,488	1,055	219,071
Lever on-1 Ltr.	Bottle	1519	1,042,642	1,462	572,958

Nephrosol-100 ml	Bottle	2777	422,104	2,573	488,870
Nephrosol-500 ml	Bottle	1745	1,256,400	1,865	1,678,500
Egg Bost-100 gm	Sachet	3245	337,480	2,448	318,240
Egg Bost-500 gm	Container	1455	727,500	1,275	796,875
Power Fat-1 kg	Sachet	1957	430,540	8,605	1,585,470
Oramin Solution-100 ml	Bottle	4390	386,320	3,557	391,270
Oramin Solution-500 ml	Bottle	2023	825,384	2,282	1,163,820
Oxi D Bolus	Container	2338	448,896	5,617	926,805
Advit B Complex-100 ml	Bottle	1665	113,220	2,650	145,750
Advit B Complex-500 ml	Bottle	1426	444,912	1,752	455,520
Adzinc B-100 ml	Bottle	3167	202,688	2,420	125,840
Adzinc B-500 ml	Bottle	1470	329,280	900	220,500
Adzyme-100 ml	Bottle	2596	228,448	-	-
Adzyme-500 ml	Bottle	1038	415,200	-	-
Toxosorb-100 ml	Bottle	2587	238,004	-	-
Toxosorb-500 ml	Bottle	1011	416,532	-	-
Acipuire Plus-100 ml	Bottle	2487	169,116	-	-
Acipuire Plus-500 ml	Bottle	1119	331,224	-	-
Grenphos Dcp Super-1 kg	Sachet	752	42,112	-	-
Nutarin-500 ml	Bottle	390	290,160	-	-
Nutarin-100 ml	Bottle	1160	185,600	-	-
Superior Syn Biotech-100 ml	Bottle	1039	91,432	-	-
Superior Syn Biotech-500 ml	Bottle	519	211,752	-	-
Utrosol -500 ml	Bottle	754	144,768	-	-
Germ Kill 80 -100 ml	Bottle	423	60,912	-	-
SubTotal			19,087,438		19,074,790

Variable Goods	Unit	30-Jun-20		30-Jun-19	
		Quantity	Amount	Quantity	Amount
Advomica Powder-20 gm	Sachet	6299	464,917	7,270	45,074
Aadcipcin Solution-100 ml	Bottle	1717	241,671	1,268	149,523
Aadcipcin Solution-500 ml	Bottle	306	199,461	1,937	1,012,315
Adlinsin Powder-500 gm	Container	353	317,638	-	-
Adrizole Bolus	Box	1545	151,323	1,017	83,445
Apetonic Bolus	Box	3426	281,699	1,852	127,437
Adcet Bolus	Box	-	-	6,506	145,734
Adprozine Bolus	Box	-	-	6,862	683,249
Adtetra Powder-100 gm	Sachet	2060	997,040	886	38,302
Adprolim Plus Powder-100 gm	Sachet	1463	238,481	1,054	143,808
Adzyl Bolus	Box	3736	217,017	1,616	117,338
Keto Pain Bolus(5x4)	Box	822	65,477	2,803	365,595
Keto Pain Bolus(10x4)	Box	933	112,124	913	275,881
Aadcipcin Bolus(10x2)	Box	2169	521,775	973	253,827
TCL Vet(5x4)	Box	2145	518,524	894	270,140
Adtetra Powder-500 gm	Container	1412	323,789	-	-
Neo Super Vet-100 gm	Sachet	995	175,470	-	-

Neo Super Vet-500 gm	Container	432	344,622	-	-
Levo Super-100 ml	Bottle	1787	270,237	-	-
Tilfos-100 ml	Bottle	815	394,395	-	-
SubTotal			5,835,659		3,711,668

Grand Total			24,923,097		22,786,458
--------------------	--	--	-------------------	--	-------------------

Raw Materials

Name of Items	Unit	30-Jun-20		30-Jun-19	
		Quantity	Amount	Quantity	Amount
Acetic Acid Glacial	Kg	90.00	14,400	20.00	11,200
Aerosil-200, BP	Kg	239.72	167,804	235.02	164,514
Albendazol	Kg	9.59	38,168	530.05	795,075
Amonium Bi Carbonate	Kg	294.00	9,408	432.00	35,424
Amprolium HCL	Kg	36.00	113,400	129.35	426,855
Ascorbic Acid (Vitamin C)	Kg	229.29	166,235	752.80	572,128
Avicel-PH 101, BP	Kg	228.00	61,104	1,723.40	461,871
Avicel-PH 102, BP	Kg	14.00	4,620	64.00	21,120
Avicel RC 591, BP	Kg	65.00	34,450	205.00	108,650
Adzyme Liquid	Ltr.	1,250.00	596,250	-	-
Acipure Plus	Ltr.	6,100.00	1,506,639	-	-
Benzyl Alcohol, BP	Kg	110.14	44,056	313.64	125,456
Benzyl Benzoate	Kg	0.61	290	10.62	5,045
Biotin 2 %	Kg	8.22	17,673	8.67	18,641
Butylated Hydroxytoluene(Powder)	Kg	0.19	48	10.19	19,106
Butylated Hydroxytoluene(Liquid)	Kg	-	-	8.31	58,195
Calcium Chloride Dihydrate	Kg	309.94	16,737	763.00	38,150
Calcium D Panthothenate	Kg	68.64	308,880	422	1,393,161
Calcium Lactate Pantahydrate, BP	Kg	225.00	54,000	225.00	54,000
Calcium Propionate	Kg	596.91	140,871	36.74	12,859
Calcium Premix	Kg	597.82	10,761	609.41	12,188
Cetrimide	Kg	23.27	31,415	25.00	33,750
Choline Bitartrate, BP	Kg	19.94	51,445	2.93	11,134
Cholistin Sulphate	Kg	-	-	137	232,900
Chocolate Brown Colour	Kg	0.95	1,520	1.66	2,656
Cholin Choride	Kg	527.50	60,663	26.99	2,834
Chlohexidine Gluconate Liquide	Kg	4.20	5,880	5.50	7,425
Ciprofloxacin Hydrochloride, USP	Kg	38.23	133,805	114.15	299,644
Citric Acid, Monohydrate, BP	Kg	152.90	16,819	165.69	19,883
Citric Acid Anhydrous	Kg	71.09	7,464	142.03	15,623
CMC Sodium, BP	Kg	83.50	33,818	58.11	29,055
Calcium Gloconate	Kg	8.60	15,910	18.60	34,410
Cobalt Gluconate	Kg	0.36	2,520	10.78	19,943
Cobalt Sulphate, BP	Kg	24.27	38,347	50.31	135,837
Color FD & C Red # 40, LAKE	Kg	1.00	3,500	1.00	3,500
Color FD & C Allora Red # 40, Ph, Grade	Kg	1.52	5,320	21.99	76,965
Color Egg Yellow	Kg	-	-	1.39	1,663

Color Erythrosin	Kg	20.31	182,790	14.99	11,467
Copper Sulphate	Kg	23.29	5,823	41.60	31,826
Clorsulon USP	Kg	50.00	618,600	-	-
Clove Oil	Kg	1.07	4,708	1.49	298
Cyanocobalamin, Vitamin B12(100%) BP	Kg	0.09	45,000	0.015	7,500
Cyanocobalamin, Vitamin B12(1%) BP	Kg	4.41	39,690	2.23	23,415
Dark Chocolate Colour	Kg	1.00	1,600	1.00	1,600
Dextrose Anhydrous, BP	Kg	2,183.77	207,458	4,075.69	354,585
Di Calcium Phosphate Dihydrate, BP	Kg	22,995.60	984,212	512.00	71,680
DCP Anhydrous	Kg	270.00	38,448	1,234.20	172,788
Dried Ferrous Sulphate, BP	Kg	394.48	55,227	284.86	24,213
Disodium Hydrogen Phosphate Anhydrous	Kg	108.64	23,901	382.02	66,854
DL-Methionine	Kg		-	548.74	153,647
Essence of Banana, PH, Grade	Kg	82.80	57,960	36.08	28,864
Essence of Sweet Orange Flavour, Ph Grade	Kg	38.40	26,880	26.00	20,800
Essence of Pineapple, Ph Grade	Kg	32.45	22,715	32.05	25,640
Essence of Strawberry Flavour	Kg	179.55	125,685	17.71	14,168
Essence of Raspberry Flavour	Kg	60.30	42,210	23.20	18,560
Essence of Lemon Sparkle	Kg		-	0.09	144
Eucalyptus Oil	Kg	4.50	16,650	0.63	1,134
EDTA Disodium Solt	Kg	12.12	35,754	0.42	168
Egg Yellow Colour	Kg	21.06	25,272	2.66	3,192
FD & C Yellow # 10	Kg	1.03	3,595	2.60	9,100
Ferrous Sulphate Hepthahydrate	Kg	17.06	512	36.44	1,093
Folic Acid	Kg	0.49	3,577	66.31	464,170
Genger Powder	Kg	53.40	10,680	19.60	7,840
Gention Powder	Kg	61.57	16,562	27.69	11,076
Glycerin, BP	Kg	3,667.24	359,390	495.34	48,543
Gelatin	Kg	45.50	13,195		
Haltox (Antioxident)	Kg	22.40	3,696	37.60	6,204
Inositol	Kg	26.99	40,485	10.99	14,287
Iso Propyle Alcohol	Kg		-	34.00	5,780
Ivermectin	Kg	10.00	217,680	-	-
Justica Adha	Ltr.	14.10	14,946	83.75	88,943
Ketoprofen	Kg		-	59.78	466,284
Lactic Acid, BP(80%)	Kg	230.46	46,092	362.00	74,210
Lactose Mono	Kg	351.20	71,996	108.42	21,684
Lequid Paraffin	Kg	132.66	11,276	132.66	11,276
Lemon Sweet Flavour	Kg	0.80	924	1.00	1,200
Lemon Yellow Colour, Ph. Grade	Kg	2.64	3,168	2.94	3,528
Levamisole Hydrochloride	Kg	6.72	34,944	131.52	400,393
Levender Oil	Kg	0.18	504	0.24	672
L-Lysine	Kg	31.92	3,767	394	52,530
Ludipress	Kg	25.68	43,656	25.68	43,656
Levofloxacin Hemihydrate USP	Kg	29.48	103,180	-	-
Magnesium Oxide, Light	Kg	239.45	95,780	155.15	50,424

Magnesium Stearate, BP	Kg	112.34	18,536	190.97	31,510
Mazie Strach	Kg	2,175.76	121,843	759.06	64,520
Manganese Sulphate	Kg	35.66	4,101	465.76	60,549
Magnesium Sulphate	Kg	60.48	1,512	484.14	12,104
Manitol	Kg	0.95	399	10.95	4,599
Methyl Paraben(Methyl Hydroxy, Benzoate)	Kg	148.34	96,421	31.58	20,527
Methyl Paraben(Sodium)	Kg	150.90	120,116	16.55	11,585
Metronedazole	Kg	78.87	99,376	192.50	231,000
Mint Flavour	Kg	1.00	1,000	21.00	21,000
MP Zyme	Kg	295.00	73,750	455.00	113,750
Niacinamide	Kg	384.41	384,410	154.99	105,393
Neomycin Sulphate	Kg	200.00	463,400	562.41	956,097
Nux Vomica Powder	Kg	234.50	29,313	232.10	69,630
Nytric Acid Liquide	Kg	390	27,300	390.00	27,300
Nutarin liquid	Kg	2,650	1,937,680	-	-
Oxytetracycline HCL	Kg	-	-	726.62	637,558
Polyethelene Glycol(PEG 6000)	Kg	47.65	13,342	315.40	110,390
Polyethelene Glycol(PEG 400)	Kg	-	-	8.90	3,738
Paracetamol, BP	Kg	-	-	688.42	289,136
Polysorbate (Tween 80)	Kg	999.10	249,775	156.00	40,560
Polyoxyl Castrol Oil	Kg	72.90	24,786	176.69	60,075
Potacium Chloride, BP	Kg	132.04	9,243	465.10	23,255
Potassium Iodide, GR Grade	Kg	0.44	4,400	2.64	2,640
Povidone-K 30, BP	Kg	254.02	112,785	1,490.32	661,926
Promethazine HCL	Kg	2.39	14,818	91.53	530,874
Phosphoric Acid 85%	Ltr.	89.60	13,888	12.64	35,392
Propilene Glycol(P.G)	Kg	4,336.00	932,240	877.00	162,245
Propyl Paraben(Propyl Hydroxy Benzoate)	Kg	106.11	95,499	16.51	14,859
Propyl Paraben Sodium	Kg	12.00	10,800	12.53	11,904
Purified Talcum, BP	Kg	196.12	16,866	57.20	4,576
Pyrodoxine Hydrochloride, (Vit. B6)	Kg	22.94	79,602	124.93	812,045
Propyle gallate	Kg	0.49	6,566		
Rasbery Red Colour	Kg	54.13	108,260	12.03	21,654
Rivoflavin, (Vit, B2)	Kg	39.14	215,270	308.40	1,696,200
Rivoflavin, Sodium 5 Phosphate(Vit, B2)	Kg	9.19	99,252	35.16	351,600
Sodium Benzoate	Kg	91.78	14,685	56.77	8,516
Sodium Bicarbonate, BP	Kg	1,474.40	64,874	913.05	38,348
Sodium Chloride, BP	Kg	385.36	12,332	712.16	22,789
Sodium Cytrate Dihydrate, BP	Kg	76.20	8,001	120.00	13,200
Sodium Floride	Kg	20.39	81,560	1.40	5,600
Sodium Hydroxied Crystal, BP	Kg	32.53	2,082	1,036.00	113,960
Sodium Molybdate Dihydrate, GR Grade	Kg	1.00	12,537	1.67	23,380
Sodium Saccharin, BP	Kg	106.06	89,621	51.25	35,363
Sodium Selinate Anhydrous	Kg	0.96	11,520	11.47	137,640
Sodium Strach Gyclolate	Kg	366.10	98,847	947.62	306,413
Sorbitor 70%	Kg	4,502	504,224	583.00	48,972

Strawberry Flavour(Powder)	Kg	62.30	43,610	4.70	4,700
Sucrose, Food Grade	Kg	1,100	61,600	2,500	132,500
Sulphadiazine	Kg	-	-	150.00	251,690
Sulphadiazine Sodium	Kg	-	-	54.65	101,628
Sulphadimidine	Kg	5.20	4,649	106.24	94,954
Sulphapyridine	Kg	212.00	593,600	211.63	355,775
Sulpha Quinoxaline Sodium	Kg		-	65.63	101,822
Superior Prozymes	Ltr.	1,950	984,107	-	-
Superior Syn Biotech	Ltr.	5,600	1,945,216	-	-
TCP	Kg	24.98	1,499	1,425.55	95,897
Thaym Oil	Kg	0.74	1,628	10.87	23,914
Thaymol	Kg	0.44	528	10.76	12,912
Threonine	Kg	24.96	3,994	102.49	17,423
Thiamine HCL, BP(Vit.B1)	Kg	59.17	249,816	129.74	843,310
Thiamine Mononytrate, BP(Vit.B1)	Kg	22.87	79,359	120.55	723,300
Triclabendazole	Kg	72.43	463,987	425.20	1,843,268
Trimethoprime Powder	Kg	-	-	121.04	279,838
Turtaric Acid	Kg	19.90	6,965	176.34	61,717
Tylosin Tartrate, BP	Kg	-	-	498.33	2,391,984
Toxosorb	Ltr.	4,100	1,578,500	-	-
Tolfenamic Acid	Kg	20	200,000	-	-
Utrosol	Ltr.	-	-	9,803	1,323,244
Vegetable Fat	Kg	12,507	1,091,236	4,726	444,244
Vitamin A Acetate, USP (5 lac i.u./gm)	Kg	19.87	147,038	124.91	849,388
Vitamin A Palmitate Oil, USP (17 lac i.u./gm)Kg		16.67	295,059	16.99	322,810
Vitamin D3(5 lac)	Kg	49.71	253,521	117.13	468,520
Vitamin D3(Oily Form,5 lac)	Kg	23.00	333,500	4.91	69,722
Vitamin E Liquid	Kg	46.95	126,765	22.87	67,467
Vitamin E 50%	Kg	35.46	42,552	26.12	23,508
Vitamin K3	Kg	18.99	26,586	21.25	29,750
Vanila Flavour	Kg	4.80	3,360	11.20	8,960
Xantham Gum	Kg	0.90	450	-	-
Zinc Sulphate Monohydrate, BP	Kg	292.24	116,896	547.14	300,927
Dry Lemon Flavour	Kg	1.00	1,000	11.00	11,000
Dry Raspberry Flavour	Kg	0.95	950	10.95	10,950
Dry Orange Flavour	Kg	1.00	1,000	11.00	11,000

Grand Total			22,320,203		27,308,790
--------------------	--	--	-------------------	--	-------------------

Packing materials

Name of Items	Unit	30-Jun-20		30-Jun-19	
		Quantity	Amount	Quantity	Amount
Master Carton-A	Pcs	287	8,323	3,167	85,509
Master Carton-B	Pcs	905	19,005	2,245	44,900
Master Carton-C	Pcs	6,740	155,020	3,258	70,047
Master Carton-D	Pcs	509	10,689	3,509	73,689
Master Carton-E	Pcs	608	10,032	2,318	35,929

Master Carton-F	Pcs	274	7,946	3,364	97,556
Master Carton-G	Pcs	480	9,600	2,072	41,440
Master Carton-H	Pcs	642	18,297	1,914	52,635
Master Carton-I	Pcs	620	11,470	2,928	51,240
Master Carton-J	Pcs	760	16,720	2,021	44,462
Master Carton-K	Pcs	1,911	59,241	1,025	33,825
Master Carton-L	Pcs	1,851	40,722	2,020	42,420
Master Carton-M	Pcs	506	12,144	1,630	39,120
Master Carton-N	Pcs	625	21,250	950	30,875
Master Carton-O	Pcs	635	14,923	1,958	44,055
Master Carton-P	Pcs	507	7,352	1,534	22,243
Master Carton-Q	Pcs	1,267	31,042		
Sub Total			453,775		809,945

Sticker Label:	Unit	Quantity	Amount	Quantity	Amount
Adzinc Syrup-100 ml	Pcs	24,621	19,697	6,209	4,657
Adzinc Syrup-500 ml	Pcs	467	957	4,436	8,428
Adzinc Syrup-1 Ltr.	Pcs	1,525	3,599	8,610	18,942
Adzinc Syrup-3 Ltr.	Pcs	700	3,556	2,000	9,500
Advit CP Suspension-500 ml	Pcs	500	650	6,410	8,333
Advit CP Suspension-1 Ltr.	Pcs	4,885	7,816	8,004	12,006
Advit CP Suspension-5 Ltr.	Pcs	868	5,902	1,535	10,438
Adcicip Oral Solution-100 ml	Pcs	3,457	2,696	1,589	1,192
Advit D Plus-100 ml	Pcs	4,975	5,323	8,525	8,525
Advomica Powder-20 gm Sachet	Pcs	2,125	2,125	2,125	2,125
Advit DB Powder-500 gm	Pcs	900	1,710	1,900	3,610
Advit DB Powder-1 kg	Pcs	3,709	10,385	1,395	3,906
Adcicip Solution-500 ml	Pcs	2,801	8,683	5,076	15,736
Adtetra Powder-100 gm	Pcs	5,993	19,777	2,747	9,065
Adtetra Powder-500 gm	Pcs	1,413	3,391	-	-
AD3E Solution -100 ml	Pcs	1,126	788	1,126	788
AD3E Solution -500 ml	Pcs	5,000	9,000	5,000	9,000
Adzuril Syrup-100 ml	Pcs	4,167	4,584	-	-
Adzyme Powder-100 gm	Pcs	6,545	26,835	4,589	18,815
Advit DB Powder-Small Label	Pcs	6,480	5,184	9,171	7,337
Round Label for DB-1 kg	Pcs	4,068	4,068	1,910	1,910
Sticker Label-250 gm	Pcs	17,716	5,315	17,716	5,315
Advit E-Sel- 100 ml	Pcs	5,720	4,004	4,975	3,483
Cough of Oral Solution-100 ml	Pcs	10,181	7,941	7,092	5,532
Cough of Oral Solution-500 ml	Pcs	6,098	20,733	5,281	12,674
Cough of Oral Solution-1 Ltr.	Pcs	2,101	8,404	1,023	2,813
ABC 1 Ltr.	Pcs	2,863	7,873	4,982	13,701
ABC 500 ml	Pcs	2,899	10,552	7,571	25,741
ABC 100 ml	Pcs	9,182	7,713	6,340	4,945
Advit C-500 gm	Pcs	1,800	6,120	1,800	6,120
Liver on 1 Ltr.	Pcs	2,254	9,647	3,051	8,390

Liver on 500 ml	Pcs	2,071	7,538	2,942	10,003
Liver on 100 ml	Pcs	9,035	7,047	4,376	3,413
Feron Vet 500 ml	Pcs	3,125	11,375	4,420	15,028
Feron Vet 1 Ltr.	Pcs	3,777	16,166	4,108	16,432
Neprosol 500 ml	Pcs	4,422	15,035	2,984	5,371
Neprosol 100 ml	Pcs	5,135	4,005	2,840	2,130
Power Fat 1 kg	Pcs	797	5,101	6,284	37,704
Adcal P-500 gm	Pcs	700	2,555	2,946	10,753
Egg Bost-100 gm	Pcs	5,828	20,107	2,633	9,084
Egg Bost-500 gm	Pcs	1,551	5,661	3,195	11,662
Oxi D Bolus	Pcs	2,636	3,110	4,350	4,785
Oramin 500 MI	Pcs	2,836	7,090	3,510	8,775
Oramin 100 MI	Pcs	7,509	5,857	2,936	2,290
Advit B Complex-100 MI	Pcs	3,074	2,398	2,993	2,335
Advit B Complex-500 MI	Pcs	1,298	4,413	2,392	8,133
Adzinc B-100 MI	Pcs	9,398	7,330	2,954	2,304
Adzinc B-500 MI	Pcs	6,108	11,605	2,880	5,472
Utrosol-500 MI	Pcs	795	1,511	10,000	19,000
Neo Super-100 gm	Pcs	5,009	13,524	-	-
Neo Super-500 gm	Pcs	1,488	5,134	-	-
Germ Kill 80-500 ml	Pcs	2,823	9,598	-	-
Germ Kill 80-100 ml	Pcs	1,956	1,526	-	-
Sticker Label Adzyme 500ml	Pcs	2,443	8,306	-	-
Sticker Label Adzyme 100ml	Pcs	6,345	4,949	-	-
Sticker Label Toxosorb 500ml	Pcs	1,804	6,567	-	-
Sticker Label Toxosorb 100ml	Pcs	3,085	2,591	-	-
Sticker Label Acipure Plus 500ml	Pcs	1,828	6,654	-	-
Sticker Label Acipure Plus 100ml	Pcs	2,996	2,517	-	-
St. Label Nutarin 100ml	Pcs	3,656	3,071	-	-
St. Label Nutarin 500ml	Pcs	2,597	9,453	-	-
St. Label Superior Syn Biotech 100ml	Pcs	3,457	2,904	-	-
St. Label Superior Syn Biotech 500ml	Pcs	2,487	9,053	-	-
St. Label Greenphos DCP 1 kg	Pcs	2,994	19,162	-	-
St. Label Nor Super 100ml	Pcs	3,000	2,520	-	-
St. Label Levo Super 100ml	Pcs	996	837	-	-
St. Label Tilfhos 100ml	Pcs	2,686	2,256	-	-
Sub Total			483,555		417,701

Sachet:	Unit	Quantity	Amount	Quantity	Amount
Adlyte Powder-100 gm	Pcs	29,292	87,876	31,192	93,576
Adlyte Powder-500 gm	Pcs	35,518	177,590	31,118	155,590
Adlyte Powder-1 kg	Pcs	8,968	59,637	10,693	71,108
Advit GC Powder-500 gm	Pcs	8,096	40,480	14,611	73,055
Advit GC Powder-1 kg	Pcs	21,998	146,287	20,398	135,647
Advit WS Powder-100 gm	Pcs	50,393	151,179	51,493	154,479
Advit C Powder-100 gm	Pcs	35,857	107,571	37,507	112,521

Advit DB powder-100 gm	Pcs	31,284	93,852	31,284	93,852
Advit (B+C) Powder-100 gm	Pcs	49,508	148,524	50,808	152,424
Advit (B+C) Powder-500 gm	Pcs	30,574	152,870	31,274	156,370
Unprinted Sachet-100 gm(Milky White)	Pcs	11,173	30,726	13,133	36,116
Advomica Powder-20 gm	Pcs	2,713	2,984	20,318	22,350
Un Printed Sachet-Advomica 20 gm	Pcs	1,415	1,726	-	-
Adbovi Powder-125 gm	Pcs	8,681	29,081	19,449	65,154
Adcal P Powder-500 gm	Pcs	14,662	75,509	14,866	76,560
Advit 3 Powder	Pcs	19,084	63,359	19,984	65,947
Adprolim Plus-100 gm	Pcs	5,079	14,729	10,076	29,220
Printed Alu Sachet-500 gm	Pcs	16,974	78,759	19,767	90,928
Printed Alu Sachet-1 kg	Pcs	22,518	135,108	11,006	66,036
Unprinted Sachet for DB -500 gm	Pcs	728	1,325	9,728	18,483
Sub Total			1,599,173		1,669,416

Insert:	Unit	Quantity	Amount	Quantity	Amount
Adcet Bolus	Pcs	11,300	2,260	18,862	3,772
Apetonic Bolus	Pcs	5,503	1,101	18,161	3,632
Adcipcin Oral Solution -100 ml	Pcs	7,338	2,201	9,905	2,476
Adtetra Bolus	Pcs	4,274	855	9,274	1,855
Adrizole Bolus	Pcs	12,40	2,480	12,333	3,083
Adzinc Bolus	Pcs	6,482	778	6,482	778
Advit CP Plus Bolus	Pcs	11,579	2,316	19,763	3,953
Adsulph Bolus	Pcs	6,600	1,320	-	-
Adzuril-100 ml	Pcs	9,133	1,827	-	-
Adzyl Bolus	Pcs	17,937	3,587	10,683	2,137
Adprozine Bolus	Pcs	8,337	2,501	13,070	3,921
Keto Pain Bolus(5x4)	Pcs	7,230	2,169	10,395	3,119
Adcipcin Bolus	Pcs	9,378	2,813	11,272	3,382
TCL Bolus	Pcs	7,857	2,357	10,251	3,075
Sub Total			28,565		35,183

Inner Carton/Box:	Unit	Quantity	Amount	Quantity	Amount
Adcet Bolus	Pcs	1,112	2,335	8,365	17,567
Apetonic Bolus	Pcs	5,491	24,984	5,543	25,221
Adrizole Bolus	Pcs	16,854	42,978	5,566	14,193
Advit CP Plus Bolus	Pcs	4,063	18,284	5,495	24,728
Advit D Plus Oral Solution-100 ml	Pcs	5,089	11,705	9,708	22,328
Advomica Powder-20 gm	Pcs	3,652	18,260	6,774	27,096
Adzinc Bolus	Pcs	1,465	2,491	1,465	2,491
Adtetra Bolus	Pcs	8,092	20,230	8,092	20,230
Adcipcin Oral Solution-100 ml	Pcs	2,061	6,183	5,286	15,858
Adcipcin Oral Solution-500 ml	Pcs	1,794	14,352	4,063	32,504
Adsulph Bolus	Pcs	6,361	16,221	-	-
Adzuril Syrup- 100 ml	Pcs	4,392	13,176	-	-
Adprolim Plus-100 gm	Pcs	738	8,856	6,252	75,024
Cough Off-100 ml	Pcs	12,827	33,350	6,300	16,380

Adzyl Bolus	Pcs	4,355	12,194	6,867	19,228
Neprosol 100 ml	Pcs	7,370	17,688	4,681	11,234
Adprozine Bolus	Pcs	5,642	20,875	8,531	31,565
Keto Pain Bolus(5x4)	Pcs	7,764	21,739	7,086	19,841
Keto Pain Bolus(10x4)	Pcs	11,520	42,624	6,975	25,808
Adcipcin Bolus(10x2)	Pcs	11,494	32,183	7,270	20,356
TCL Bolus(5x4)	Pcs	11,749	30,547	8,172	21,247
Levo Super-100 ml	Pcs	1,050	2,709		
Nor Super-100 ml	Pcs	3,050	7,869		
Tilfos-100 ml	Pcs	2,437	6,287		
Sub Total			428,120		442,899

Bottle & Accessoriet	Unit	Quantity	Amount	Quantity	Amount
HDPE Bottle with Handle & Cap 1000 ml	Pcs	81	1,377	4,938	83,946
HDPE Bottle with Handle & Cap 500 ml	Pcs	2,353	29,413	6,679	83,488
HDPE Bottle with Handle & Cap 1000 ml	Pcs	9,873	167,841	6,937	117,929
HDPE Bottle with Handle & Cap 500 ml	Pcs	8,374	104,675	7,380	92,250
HDPE Bottle with Handle & Cap -3 Ltr.	Pcs	1,573	58,201	3,080	113,960
HDPE Bottle Round with Cap 500 ml	Pcs	31	512	5,730	92,253
100 ml pet bottle(Amber)	Pcs	81,348	280,651	16,632	69,355
100 ml pet bottle(Milky White)	Pcs	48,095	165,928	18,606	64,191
100 ml pet bottle(Transperant)	Pcs	63,144	217,847	11,259	38,844
500 ml pet bottle(Milky White)	Pcs		-	9,063	125,069
1000 ml pet bottle(Milky White)	Pcs	2,963	64,445	2,508	54,549
500 ml pet bottle(Transparent)	Pcs	5,463	68,288	3,492	41,904
1000 ml pet bottle(Transparent)	Pcs	4,658	97,818	5,518	115,878
500 ml pet bottle(Transparent) with red cap	Pcs		-	9,015	108,180
Plastic Bucket-1 kg(White)	Pcs	1,945	49,598	3,621	92,336
Plastic Container-500 gm	Pcs	746	10,444	2,746	35,698
Plastic Container-500 gm(Round)	Pcs	1,698	23,772	5,870	82,180
Plastic Container-500 gm(Square)	Pcs	785	18,055	5,160	118,680
Plastic Container-100 gm(Square)	Pcs	3,489	22,679	2,463	16,010
Blue Jar-5 Ltr.	Pcs	283	34,172	-	-
5 Ltr. Jar(New)	Pcs	4,472	313,040	1,132	79,240
Measuring Cup 15 ml	Pcs	46,906	16,886	21,630	7,787
EP Liner for 500 ml Container	Pcs	1,980	1,188	1,980	1,188
HDPE Bottle with purple ring 500 ml	Pcs	4,271	79,014	16,288	301,328
PP Cap 28 mm	Pcs	90,091	99,100	36,553	45,691
Sub Total			1,924,941		1,981,934

PVC Flim:	Unit	Quantity	Amount	Quantity	Amount
PVC Sheet (180 mm x 350 mic)-Glass Clear	Kg	809	125,395	440.51	68,279
PVC Sheet (204 mm x 350 mic)-Glass Clear	Kg	903	139,965	910.00	141,050
PVC Sheet (204 mm x 350 mic)-Milky White	Kg	1,128	219,960	1,528.20	297,999
Sub Total			485,320		507,328

Aluminium Bottom Foil	Unit	Quantity	Amount	Quantity	Amount
Alu Alu Bottom Sheet (137 mm)	Kg	467.48	203,354	61	26,522
Sub Total			203,354		26,522

Aluminium Foil:	Unit	Quantity	Amount	Quantity	Amount
Adcet Bolus	Kg	8.63	6,473	95.38	71,535
Adrizul Bolus	Kg	11.59	8,345	50.70	43,602
Adsulph Bolus	Kg	31.70	27,262	-	-
Adtetra Bolus	Kg	16.79	14,439	26.79	23,039
Adzinc Bolus	Kg	3.47	2,984	3.47	2,984
Adzyl Bolus	Kg	17.60	12,672	72.41	54,308
Advit CP Plus Bolus	Kg	0.50	375	67.00	57,620
Apetonic Bolus(137 mm)	Kg	38.38	29,169	49.00	36,750
Adprozine Bolus	Kg	30.27	23,005	51.15	38,874
Keto Pain Bolus	Kg	68.33	51,931	49.55	37,658
Adcipcin Bolus	Kg	21.65	16,454	33.60	25,536
TCL Bolus	Kg	6.00	4,560	38.91	29,572
Alu Foil Advomica 20gm	Kg	95.99	38,398	-	-
Alu Foil Adprolim Plus 100gm	Kg	107.20	42,880	-	-
Sub Total			278,947		421,478

Aluminium Disk:	Unit	Quantity	Amount	Quantity	Amount
Aluminium Disk-1 Ltr.	Kg	7.50	9,000	36.20	36,200
Aluminium Disk -500 ml for big Cap	Kg	28.50	34,200	29.00	29,000
Aluminium Disk for 500 ml narrow Cap	Kg	6.00	6,000	26.26	26,260
Alu Disk-2"	Kg	11.05	11,050	63.00	63,000
Alu Disk-3"	Kg	26.00	26,000	46.00	46,000
Alu Disk-3.5"	Kg	10.10	10,100	40.50	40,500
Alu Disk-4"	Kg	9.70	11,640	31.39	31,390
Sub Total			107,990		272,350

Miscellaneous:	Unit	Quantity	Amount	Quantity	Amount
Gum Tape # 2.5"	Pcs	1,190	35,700	2,995	89,850
Scotch Tape # 1/2"	Pcs	580	4,490	1,450	11,600
Cotton Thread	Pcs	285	17,100	1,320	92,400
Cable Tie	Pcs	-	-	1,500	750
Cotton	Kg	0.10	43	-	-
White Poly Bag # 7"-9"	Kg	1.00	220	-	-
White Poly Bag # 14"-18"	Kg	3.80	836	-	-
White Poly Bag # 14"-10"	Kg	3.40	748	-	-
Cutting Board	Pcs	9,520	2,380	-	-
Sub Total			61,517		194,600

Grand Total			6,055,256		6,779,356
--------------------	--	--	------------------	--	------------------

Advent Pharma Ltd.
Trade & Other Receivables
As at June 30, 2020

Annexure-C

Particulars	30-Jun-20	30-Jun-19
4 Star Poultry Feed Center(Cox's Bazar)	3,144	-
4 Star Poultry Feed Centre (Cox's Bazar) CP	-	184,271
A B Drugs	471,087	-
Abdul Halim (Mymensing)	316,000	-
Abdullah Medicare	292,937	-
Abdullah Medicine House (CP)	342,563	55,663
Abdullah Pharmacy (Joupurhat)	4,268	-
Abdullah Pharmacy(Ullahpara)	-	3,470
Abdullah Poultry	3,214	-
Abdullah Poultry Feed	72,110	77,582
Abdullah Poultry (Polashbari)	2,134	-
Abdur-Rob Medicine Corner(Manda)	7,743	-
Abida Medical Hall	300,776	14,695
Abid Poultry(Eleas)	275,600	-
Abir Pharmacy	520,352	8,352
Abir Pharmacy (Korchatpur)	10,301	-
Abir Pharmacy (Manikgonj)	357,607	-
A.B Pharmacy(Jhenaidha)	2,828	-
Abraham Poultry Feed(Nawabganj)	7,857	-
Abu Sayed Medical (Shahjadpur)	4,000	-
Adhunik Prani Chikitsaloy	229,250	245,250
Adil Pharmacy (Palashbari)	1,722	-
A.D Medicine Corner	386,754	166,453
Adnan Enterprize(Zohorul)	102,458	102,458
Adnan Poultry & Feed	379,310	204,310
Adorsho Pharmacy(Birampur)	264,542	278,542
Adorsho Pharmacy(Tanore)	205,744	207,856
Adorsho Poshu Chikishaloy(Robiul)	48,179	-
Adorsho Poshu Jogoth (Rezwanul)	4,992	-
Adorsho Poultry (Jhenaidha) Cp	15,860	-
Adorsho Veterinary(Gobindoganj)	9,215	5,008
Adorsho Veterinary (Zakir Hasan)	1,970	-
Advanced Chemical Ind. Ltd.	1,443,832	-
Afrin Dairy & Poultry (B. Baria)	34,423	57,816
Afsana Poultry Feed	333,840	155,240
Afzal Enterprize(Jhikorgacha)	2,388	-
Ahanaf Poultry Feed & Medicine(CP)	373,383	242,470
Ahasan Poultry(Cp)Satkhira	27,736	-
Ahmed Pharmacy(Salanga)	2,376	-
Ahmed Veterinary (Kaliganj) CP	305,805	486,408

	30-Jun-20	30-Jun-19
A.H Poultry	325,000	-
Ahsan Pharmacy (Rangpur)	8,131	-
Akash Pharmacy(Tanore) (CP)	300,369	224,665
Akbor Pharmacy (Matin)	6,746	-
Akhi Amin Pharmacy	59,788	3,642
Akhi Arnika Enterprise	8,356	-
Akhi Boiler House	158,548	206,548
Akhi Pharmacy(Thakurgaon)	-	1,344
Akhiraz Veterinary (Adamdighi)	8,861	-
Akhter Sha Poultry Feed (Manjurul)	17,738	-
A.K Medical Store	177,963	177,963
Akondo Pharmacy(Kalai)	154,004	156,980
Akota Agrose Trading	301,365	314,365
Akota Pharmacy (Natore)	316,140	326,540
Akota Poultry (Amir)	-	32,890
Akota Poultry Feed(Baneshor)	161,465	178,965
Akota Poultry, Narayangonj	337,280	-
Akram Medical Hall	388,800	-
Akter Poultry	113,908	-
Akter Poultry(Kapasias)	326,998	315,698
Alam Dairy Farm(Dhaka)	185,600	-
Alamgir Eashat Pharmacy (Kishorgonj) CP	301,458	301,458
Alamgir Pharmacy(Panchagarh)	-	2,256
Alamgir Poultry Feed	331,500	324,156
Alamin Pharmacy	278,965	278,965
Alamin Pharmacy(Kurigram)	-	305,781
Al Amin Pharmacy(Yeakub)	188,800	-
Alamin Poultry & Fish Center	253,014	253,014
Alamin Poultry(Kishoreganj)	463,490	-
Alamin Poultry(Narayanganj)	192,200	-
Alamin Store (Khulna)	5,791	-
Al-Amin Store (Potuakhali)	40,169	-
Alam Medical Hall (Kishorganj)	268,793	268,793
Alam Medical Hall (Phultala)	3,136	-
Alam Pharmacy	35,420	46,220
Al- Arafapoultry Feed & Medicine	360,245	360,245
Alauddin Dairy Farm	188,344	-
Alaxo Traders	170,428	-
Al-Bakara Medical Store(Palashbari)	7,527	-
Al-Baraka Pharmacy (Jessore)	26,166	-
Al-Bashir Pharmacy (Hatibandha)	3,104	-
Al Fala Pharmacy	102,345	102,345
Al-Fala Pharmacy(Nalitabari)	48,652	-
Al-Fate Pharmacy (Magura)	29,209	-
Alfia Agro Feed & Medicine Point	188,878	-

	30-Jun-20	30-Jun-19
Al-Haz Veterinary(Kurigram)	4,528	-
Ali Argo Farm (Krishno)	233,573	-
Alif Medicine (Birampur) Cp	31,183	-
Alif Medicine House(Birampur)	15,552	-
Alif Poultry Feed	199,461	199,752
Alif Poultry (Gazipur)	26,880	-
Al Jahara Pharmacy	10,696	-
Al-Jahara Pharmacy(Korchatpur)	9,250	-
Almas Poultry Feed(Jhenaidah)	304,500	304,500
Al-Modina Pharmacy (Mohammad Ali)	21,159	-
Alvida Poultry & Feed (Bhairab) CP	141,701	55,507
Amanur Veterinary Corner(Ghatail)	6,136	-
Amin Feed & Veterinary (Lalmonirhat)	10,686	-
Amin Medical Hall	150,221	-
Amir Dairy Pharmacy	21,620	-
Anawar Pharmacy (Raju Khan)	44,012	-
Anisa Poultry	9,200	-
Anowar Enterprize	6,224	-
Anower Medical Hall(Ekhtear)	11,900	-
Anwara Pharmacy (Meherpur) Cp	4,170	-
Anwara Pharmacy (Rajshahi)	7,296	-
Anwar Dairy(Lalmonirhat)	2,180	-
Anwar Pharmacy	3,657	-
Apon Veterinary Medicine Corner(Dhaka)	1,302	-
Arafat Vetrinary (Sahin Mia)	8,935	-
Araf Poultry (Rofiqul)	2,463	-
Arif Hossain (Khulna)	2,003	-
Arif Pharmacy(Bogra)	1,054	-
Arif Pharmacy(Jhikorgacha)	6,257	-
Armi Veterinary(Birampur)	13,200	-
Aroggo Veterinary (Kaliganj)	6,342	-
Asaia Veterinary	2,885	-
Asha Pharmacy (Pabna) CP	277,860	-
Ashar Alo Veterinary (Monirul)	6,616	-
Ashik Poultry(Gaibandha)(CP)	539,321	253,125
Ashim Veterinary (Gaibandha) CP	6,500	129,419
Ashim Veterinary Hall(CP)	164,058	-
Asiya Traders(Naogaon)(Cp)	113,490	-
Atiq Enterprize (Biplob)	1,555	-
Aungikar Poultry	1,000	-
Ayesha Poultry (Aminul)	4,888	-
Azad Veterinary	3,654	-
Azizul Pharmacy (Panchagar)	10,639	-
Aziz Veterinary (Ullahpara)	2,509	-
A Z Traders (Krishno)	2,304	-

	30-Jun-20	30-Jun-19
Baba Loknath Medicine	3,000	-
Babu Khamari	369,139	134,580
Babul Enterprise	265,300	265,300
Babul Pharmacy(Manikganj-2)(Selim)	555,428	324,815
Babul Traders	665,378	325,480
Babu Pharmacy(Pabna)	296,302	388,302
Badhon Poultry (Kishoreganj)Cp	303,500	-
Badhon Poultry (Solonga)	10,331	-
Badsha Medical Hall(Sarishabari)	2,142	-
Bagabari Pharmacy	105,420	105,420
Baganbari Medicine Corner	1,870	-
Bahar Medical Hall(Tangail)	221,452	221,452
Bakku Poultry Feed	131,400	225,400
Bangali Veterinary	226,541	226,541
Bangla Bazar Poultry, Narayanganj	107,357	102,345
Bangladesh Pharmacy	55,230	55,230
Bangladesh Veterinary	235,610	235,610
Bangladesh Veterinary (Rezwanul)	2,880	-
Bappi-Kiron Poultry Feed(CP)	203,206	356,306
Bappi Poultry Feed(Badorkandi)	3,832	-
Barouli Poultry Feed	6,961	-
Basar Pharmacy	204,568	204,568
Bashar Pharmacy (Sajedur)	135,690	135,690
Beauty Pharmacy (Anamul)	245,687	245,687
Bengol Agro Veterinary(Shibpur)	5,849	-
Bhai Bhai Enterprize(Ghatail)	7,776	-
Bhai Bhai Medical Hall (Joynal)	302,145	302,145
Bhai Bhai Medical Hall(Sakhipur)	3,550	-
Bhai Bhai Pharmacy(Bonpara)	246,429	245,874
Bhai Bhai Pharmacy(Boraigram)	210,545	204,785
Bhai Bhai Pharmacy (Chuadanga)	170,015	165,892
Bhai Bhai Pharmacy (Delowar)	87,816	88,974
Bhai Bhai Pharmacy(Dhamrai)	201,855	221,452
Bhai Bhai Pharmacy(Lalpur)	1,174	-
Bhai Bhai Poultry(B.Barua)	92,353	88,965
Bhai Bhai Poultry & Dairy (Rezwanul)	68,819	75,624
Bhai Bhai Poultry Feed (Chuadanga)	3,000	-
Bhai Bhai Poultry Feed(Cox's Bazar)	4,082	-
Bhai Bhai Poultry Feed (Delowar)	1,958	-
Bhai Bhai Poultry(Monohordi-2)	97,320	101,452
Bhai Bhai Poultry (Sreepur)	13,483	-
Bhai Bhai Traders(Adamdighi)	20,251	-
Bhai Bhai Veterinary(Ranisonkoil)	37,731	-
Bhai Bhai Veterinary (Zakir)	11,814	-
Bhai Bon Enterprize (Polash)	31,602	-

	30-Jun-20	30-Jun-19
Bhai Bon Pharmacy (Joypurhat) CP	281,907	360,081
Bhai Bon Veterinary (Birampur)	1,984	-
Bhuiya Poultry (Bhairab)	9,227	-
Biddut Medical Hall	228,037	236,420
Biddut Pharmacy (Manda)	1,328	-
Bijoy Poultry Firm	212,478	215,478
Bina Pharmacy(Ishwardi)	214,587	214,587
Biplob Pharmacy (Hatibandha)	2,231	-
Birol Pharmacy	3,436	-
Bismillah Feed & Medicine	360,245	360,245
Bismillah Medical Hall (Khulna)	2,182	-
Bismillah Medical Hall(Sherpur)	324,568	324,568
Bismillah Medicine Corner(CP)	253,400	201,458
Bismillah Medicine House (Cp) (Nayon)	165,691	-
Bismillah Medicine House (Domar) (Acqua) CP	211,525	215,125
Bismillah Medicine House(Domar) CP	111,276	165,784
Bismillah Medicine Point (Mymensingh)	22,074	-
Bismillah Pharmacy (Biplob)	55,958	62,458
Bismillah Pharmacy(Khulna)	5,808	-
Bismillah Pharmacy (Kustia) Cp	88,800	-
Bismillah Pharmacy (Magura)	15,718	-
Bismillah Pharmacy (Mahadi)	6,443	-
Bismillah Pharmacy (Sirajganj)	7,532	-
Bismillah Pharmacy(Ullahpara)	7,594	-
Bismillah Poultry Complex(Kahalu)(CP)	233,178	125,478
Bismillah Poultry & Feed Center	158,462	158,462
Bismillah Poultry Feed & Medicine(Matin)	5,288	-
Bismillah Poultry Feed (Rangpur)	6,240	-
Bismillah Veterinary (Ishwardi)	13,145	-
Bismilla Poultry Feed	19,280	-
Biswash Pharmacy(Shoilkupa) Cp	256,994	-
Biswash Poultry Complex (Phultala)	3,952	-
Biswas Medicine(CP)	78,562	78,562
Biswas Medicine (Kumarkhali)	31,564	-
Biswas Poultry Feed (Korchatpur)	9,454	-
Bohorpur Pharmacy (Rajbari)	4,369	-
Boisakhi Poultry (Kishorganj)	1,000	-
Bokkar Veterinary Store(Rangpur)	9,543	-
Bondhu Poultry Feed (Jhenaidah)	10,864	-
Borna Pharmacy	2,578	-
BOROITULI ENTERPRIZE	21,707	-
Brack Projonon Kendro (Sarishabari)	2,553	-
Brothers Poultry	106,548	106,548
Brothers Poultry,(Manikgonj)	12,480	-
Buffalo Dairy & Poultry (Pirgonj)	4,736	-

	30-Jun-20	30-Jun-19
Chandan Pharmacy	58,796	58,796
Chanmiah Pharmacy	166,354	166,354
Chatmohor Poultry(CP)	282,483	350,183
Chatmohor Poultry (Saju) Cp	147,964	350,182
Cholonbil Pharmacy (Natore)	25,781	-
Chowdhury Pharmacy(Dhaka)	145,789	145,789
Chowdhury Traders(Gobindaganj)	412,540	412,540
Cipy Pharmacy (Birganj)	7,887	-
City Pharmacy (Jewel)	210,354	210,354
Dairy Feed & Medicine Ghor	190,210	386,210
Dairy Poultry Medicine Corner	194,420	213,420
Darussalam Medical Hall	-	54,365
Dash Medicine Corner	206,547	206,547
Datta Pharmacy, Chapainawabganj	265,479	265,479
Daynight Pharmacy	203,412	203,412
Debnath Veterinary(Gobindoganj)	7,532	-
Deb Pharmacy (Jhenaidha)	6,381	-
Delowar Veterinary (Manda)	1,968	-
Dewan & Brothers Enperprise	107,203	96,124
Dewan Pharmacy(Joypurhat)	345,874	345,874
Diana Poultry(Eleas)	134,143	228,143
Digital Poultry	18,004	-
Digital Poultry(CP)	179,058	96,458
Dipa Pharmacy (Jalil)	74,589	74,589
Doctors Veterinary	195,779	301,479
Domar Poultry Network	305,497	305,497
Dr. Abu Bokker Siddiki(Nilphamari) Cp	328,990	-
Dr. Asraf (Asaduzzaman)	5,303	-
Dr. Joban Medical Hall(Monirul)	168,754	198,763
Dr. Mezan Pharmacy (Delowar)	9,868	-
Dr.Mojibar Rahman(Charghat)	5,654	-
Dr. Monjur (Biplob)	3,599	-
Dr. Mozammel Pharmacy(Krishno) Cp	185,677	-
Dr. Nuruzzaman (Lalmonirhat)	7,053	-
DR. Nurzzaman(Asaduzzaman)	6,092	-
Dr. Ripon(Assaduzaman)	8,022	-
Dr Roni(Jamalpur)	3,656	-
Dr Sadequl	3,049	-
Dr. Saiful Islam (Lalmonirhat)	10,173	-
Dr. Samsuddin(Pirgonj)	6,327	-
Dr.Shoriful	4,630	-
Dr. Sumonto Rai (Birganj)	4,154	-
Dr. Wahid (Nazmul)	6,944	-
Dui Bhai Pharmacy	211,458	211,458
Dyanamic Pharmacy(Hafizul)	11,516	-

	30-Jun-20	30-Jun-19
Dynamic Pharmacy	123,658	123,658
Dynamic Pharmacy (Kalialoir)	1,301	-
Elit Drug House (Borguna)	12,571	-
Eman Pharmacy(Pirganj)	163,686	173,185
Emon-Onik Pharmacy	16,416	-
Emon Pharmacy (Lalmonirhat)	197,995	265,995
Emon Pharmacy (Lalmonirhat) CP	218,806	265,994
Emon Poultry (Mithapukur) (CP)	258,690	-
Emon Poultry (Rangpur)	2,634	-
Esha Enterprise	156,324	156,324
Eva Poultry Feed & Medicine (Hatibandha)	224,587	224,587
Fahad Enterprize (Aslam)	1,000	-
Fahim Poultry Feed & Medicine	1,960	-
Fardin Poultry Feed	18,051	-
Farhan Poultry Feed	98,746	98,746
Fariya Pharmacy	218,246	235,483
Faruk Medical Store	103,074	111,736
Faruk Medicine Corner	155,687	155,687
Faruk Pharmacy	225,478	225,478
Faruk Pharmacy (Adamdighi)	15,334	-
Faruk Pharmacy(Domar)	4,719	-
Farzana Pharmacy	131,247	131,247
Fatema Medical Hall	35,622	-
Fatema Medicine Supply	245,871	245,871
Fatema Pharmacy(Julhas)	30,432	-
Faumif Traders	252,500	452,136
Faumif Traders(Hilli)CP	292,385	21,901
Fayza Poultry	242,871	245,871
Fencey Pharmacy(Panchagor)	6,791	-
Ferdous Medical Hall	131,449	135,487
Feroz Poultry (Narsingdi)	-	74,778
Five Brothers Poultry	201,478	201,478
Fokir Veterinary	485,652	485,652
Forida Pharmacy (Sirajganj) CP	122,586	102,851
Forid Pharmacy(Jamalpur)	5,925	-
Forid Pharmacy(Joypurhat)	301,472	301,472
Forkan Veterinary Store	248,756	248,756
Foysal Pharmacy (Saju)	7,948	-
Fozila Pharmacy	11,496	-
Fozlu Pharmacy (Cp)	66,789	66,789
Fozlu Pharmacy(Panchagarh)	261,922	328,711
Friends Poultry(Kapasias)	3,547	-
Friends Poultry (Nilphamari)	5,068	-
Friends Traders(Ishwardi)	306,547	306,547
Friend Traders (Pabna)	6,201	-

	30-Jun-20	30-Jun-19
Fuad Veterinary (Gobindaganj)	19,071	-
Galib Poultry (Hafizul)	12,541	-
Galib Poultry (Kaliakoir) CP	354,564	66,628
Galib Poultry (Lalmonirhat)	140,902	145,879
Gayan Poultry(Satkhira)(Cp)	107,572	-
Gaziul Pharmacy (Naogaon)	41,242	-
General Poultry Feed (Sakhipur)	203,499	203,499
Giyash Pharmacy	46,324	46,324
Gobadi Pushu Corner	220,302	236,129
Goffar Poultry (Rupsha)	16,055	-
Golden Poultry	441,100	52,369
Gourohori Medical Hall	245,783	245,783
Gourohori Medical Hall (Nalitabari)	3,155	-
Habiba Veterinary	14,592	-
Habibul Store	301,478	301,478
Habibur Rahman(Sakhipur)	1,072	-
Hafiza Poultry & Fish Center	301,247	301,247
Hafizul Pharmacy	145,786	145,786
Halima Pharmacy	88,335	108,796
Halima Poultry(Satjhira)	7,600	-
Halima Poultry(Satkhira)	10,311	-
Halima Veterinary (Palashbari)	1,162	-
Halim Pharmacy (Aslam)	4,999	-
Hamida Pharmacy (Hilli)	31,258	-
Hamid Poshu Chikishaloy	210,789	304,789
Hamidul Poultry Corner	1,416	-
Hanif Pharmacy(Hakimpur)	201,689	201,689
Hanim Medicine	335,489	335,489
Happy Pharmacy (Mithapukur)	19,315	-
Harun Pharmacy	312,584	312,584
Hasan Pharmacy (Mohammad Ali)	4,844	-
Hasan Poultry Feed	13,452	13,452
Hasan Poultry (Noakhali)	4,119	-
Hashu Poultry Feed (Baneshwar)	278,450	278,450
Hazi Medicine Corner (Saju)	4,517	-
Hazi Pharmacy (Monirul) CP	225,173	294,182
Hazi Veterinary(Bhangura)	298,812	312,489
Helal Poultry	150,476	113,247
Hira Pharmacy (Hatibandha)	3,384	-
Hiru Poultry (Milon)	8,673	-
Hitler Pharmacy	288,135	288,135
H & M Enterprize	99,756	99,756
Hobby Pharmacy	219,475	219,475
Hoimonti Traders	219,383	245,783
Horidash Pharmacy(Sarishabari)	246,795	246,795
Hridoy Pharmacy (Bheramara)	4,424	-
Hridoy Poultry Feed & Medicine Centre	2,160	-
Ikbāl & Brothers (Shamim)	1,280	-
Ikra Medical Hall	106,451	106,451
Ima Uday Pharmacy(Nawabganj)	5,182	-
Insaf Veterinary (Santhia)	33,102	46,396
Islamia Poultry Feed (Delowar)	4,872	-

	30-Jun-20	30-Jun-19
Fuad Veterinary (Gobindaganj)	19,071	-
Galib Poultry (Hafizul)	12,541	-
Galib Poultry (Kaliakoir) CP	354,564	66,628
Galib Poultry (Lalmonirhat)	140,902	145,879
Gayan Poultry(Satkhira)(Cp)	107,572	-
Gaziul Pharmacy (Naogaon)	41,242	-
Islam Pharmacy	85,478	103,478
Islam Poultry	5,564	-
Islam Poultry Feed	324,785	324,785
Islam Traders	185,195	227,407
Islam Traders (CP)	60,329	60,329
Islam Veterinary (Asaduzzaman)	17,338	-
Israt Pharmacy(Palashbari)	4,320	-
Jafor Pharmacy (Jhikorgacha)	26,725	-
Jahanara Pharmacy	30,533	-
Jahangir Medical Hall(Mustafiz)	305,478	305,478
Jalal Pharmacy	235,478	235,478
Jalil Medical(Paikgacha)	10,704	-
Jamal Traders(Eleas)	218,893	265,893
Jaman Pharmacy(Kumarkhali)	19,427	-
Jaman Pharmacy(Pirgonj)	4,774	-
Jaman Tarders (Solonga)	6,775	-
Jamira Pharmacy(Phultala)	3,952	-
Janani Poultry	485,247	485,247
Jannat Poultry Feed (Nobinagar)	11,200	-
Jannat Traders(Hatibandha)	4,656	-
Jannatul Pharmacy(Panchagarh)	360,269	355,471
Jannatul Pharmacy (Shahjadpur)	24,937	-
Jarit Veterinary (Palashbari)	12,062	-
Jarnalit Pharmacy	201,345	201,345
Jasim Dairy Farm	148,596	148,596
Jesmin Pharmacy (Biplob)	3,999	-
Jewel Poultry (Nalitabari)	14,532	-
Jhora Enterprize	6,198	-
Jhorna Traders(Lalmonirhat)	3,095	-
Jiniya Pharmacy (Hatibandha)	9,126	-
Jisan Poultry Farm	303,500	-
Jobbar Pharmacy (Manik)	220,312	250,312
Jobbar Pharmacy (Manik) CP	288,173	250,312
Jom Jom Pharmacy (Chuadanga)	1,552	-
Jonokollan Pharmacy(Narshingdi)	321,458	321,458
Jononi Pharmacy(Domar)	485,245	485,245
Jononi Pharmacy (Hatibandha)	9,378	-
Jononi Pharmacy (Raiganj)	2,227	-
Jononi Poshu Chikishaloy(Jessore)	19,764	-

	30-Jun-20	30-Jun-19
Jononi Traders (Birampur) CP	91,739	223,713
Jonony Pharmacy(Kustia)	17,519	-
Jonota Medical Hall(Bera)	305,478	305,478
Jonota Poshu Chikishaloy	328,745	328,745
Joshim Pharmacy	203,145	203,145
Joshim Poultry Feed	343,003	347,896
Jotimoy Pharmacy(Hakimpur)	25,854	-
Joti Pharmacy	374,598	374,598
Joya Medicine Corner (Delowar)	13,013	-
Joya Poultry Feed & Medicine(Delowar)CP	283,800	59,710
Joy Veterinary (Asaduzzaman)	9,049	-
Jui Pharmacy (Saju)	253,150	248,695
Kader Pharmacy (Magura)	37,241	-
Kadira Pharmacy	1,087	-
Kalam Poultry Feed (Chapai) CP	177,459	223,578
Kalam Poultry Feed(Chapainawabganj)	147,856	147,856
Kamal Pharmacy(Dhaka)	33,843	33,843
Karim Pharmacy(Nilphamari)	277,045	278,965
Kashem Veterinary (Manda)	12,125	-
Kawsar Dairy Farm	152,632	152,632
Kawsar Pharmacy(Hakimpur)(CP)	301,478	301,478
Kazi Poultry(Barguna)	4,611	-
Kazol Enterprize(Paba)	251,576	269,874
Kazol Veterinary(Ullahpara)	457,624	395,874
Keya Bagan Pharmacy (Jhenaidha)	-	112,117
Keya Bagan Pharmacy(Kaliganj) Cp	414,029	-
Keya Pharmacy (Ruhul)	8,451	-
Khadiza Prani Chikishaloy (Durgapur)	45,057	-
Khaleda Pharmacy (Satkhira)	3,100	-
Khan Pharmacy(Nobinagar)	11,162	-
Khan Pharmacy (Shahjadpur)	-	57,351
Khan Poultry Medicine	45,789	45,789
Khan Poultry (Tala)	4,484	-
Khoka Traders	152,369	152,369
Khondokar Medical Hall(Akbor)	343,904	351,200
Khondoker Traders (Manda)	8,554	-
Khosru Poultry & Medicine(Polash)	5,189	-
Khosru Veterinary House (Palash)	10,445	-
Kobir Pharmacy(Khulna)	43,766	-
Kobir Pharmacy (Panchagor)	10,531	-
Kobita Drugs House(Bagharpara)	27,555	-
Kofil Uddin Homio & Veterinary Medical Store	182,037	185,695
Konok Veterinary	198,582	201,458
Korchatpur Pharmacy	18,422	-
Korchatpur Pharmacy (Sobuj Khan)	15,902	-

	30-Jun-20	30-Jun-19
Kotha Medical Hall (Khulna)	5,056	-
Kotha Traders(Manda)	13,175	-
Krishan Medical Hall (Bhairab)	5,597	-
Krishi Utsho (Solonga)	8,332	-
Krishno Traders	200,883	203,145
Krishno Veterinary (Ullahpara)	3,394	22,072
K.R Medical Hall (Sarishabari)	2,460	-
Lalon Pharmacy (Asaduzzaman)	2,447	-
Lamiya Poultry	121,458	121,458
Lemon Pharmacy	358,410	358,410
Lemon Pharmacy(Panchagarh)	1,176	-
Lemon Veterinary (Hatibandha)	5,364	-
Lima Pharmacy	7,566	-
Liton Medical Store	410,253	410,253
Liton Pharmacy(Magura)	25,272	-
Liza Enterprize-2 (Narayanganj)	7,295	-
Liza Enterprize(Narayanganj)	100,385	103,589
Liza Pharmacy (Chapai) CP	320,833	345,789
Liza Poultry (Kayum)	102,300	-
Lota Store	8,832	-
Lotif Pharmacy	201,458	201,458
Lotif Pharmacy (Hatibandha)	1,329	-
Maa Baba Pharmacy (Kaliakair)	1,992	-
Maa Baba Pharmacy (Rubel Hasan)	1,075	-
Maa- Baba Pharmacy (Solonga)	4,598	-
Maa Baba Poultry	203,145	203,145
Maa Babar Doa Enterprize (Gazipur)	2,034	-
Maa Babar Doa(Panchagarh)	10,854	-
Maa Babar Doa Pharmacy(Mithapukur)	2,428	-
Maa Babar Doa Poultry	412,563	412,563
Maa Chikitshaloy(Bosunia)	186,874	245,874
Maa Enterprize(Mymensingh)	4,668	-
Maa Enterprize (Rajshahi)	17,770	-
Maa Fatema Pharmacy	239,664	245,789
Maa Medical Hall (Anamul)	201,457	201,457
Maa Medical Store(Bogra)	475,698	475,698
Maa Medicine Corner (Santhia)	452,368	452,368
Maa Pharmacy	353,167	352,147
Maa Pharmacy(Noakhali)	13,822	-
Maa Pharmacy(Panchagor)	7,646	-
Maa Pharmacy (Sirajganj)	4,800	-
Maa Poultry Corner(Tangail)	1,520	-
Maa Traders(Naryanganj)	343,739	356,840
Maa Veterinary(Anowar Manda)	7,421	-
Maa Veterinary Chikishaliy (Aslam)	6,954	-

	30-Jun-20	30-Jun-19
.Maa Veterinary Hall (Ullahpara)	1,980	-
Maa Veterinary Oushodh Gorh	201,457	201,457
Ma- Baba Pharmacy(Kalai)	5,059	-
Ma Babar Doa(Kaliakor)	14,293	-
Mahabub Traders (Lalmonirhat) Cp	134,519	-
Mahafuz Pharmacy	377,968	378,954
Mahatab Pharmacy	240,874	245,874
Mahedi Veterinary(PABNA)	3,949	-
Mahfuz Pharmacy (Kapasias)	338,516	345,697
Mahfuz Poultry(Kayum)	1,802	-
Mahfuz Veterinary (Saju)	345,162	354,126
Mahi Dairy Pharmacy	13,788	-
Mahi Enterprize(Jessore)	4,967	-
Mahiya Medicine(Bhangura)	4,623	-
Mahmuda Medicine Corner	7,458	-
Ma-Jannat Pharmacy(Magura)	32,445	-
Major Poultry Feed (Pirgonj)	8,510	-
Majumdar Drug House	17,240	-
Makka Poultry(Chatmohor)	381,173	379,659
M. Ali Poultry	1,149	-
Maltasha Poultry (Kishorganj)	69,809	29,216
Mama Vagina Pharmacy(Sakhipur)	7,796	-
Mamun Medical Hall (Kayum)	10,080	-
Mamun Medical Hall(Mymensingh)	3,815	-
Manaf Medical Hall	198,165	206,478
Mannan Poultry (RAJU) CP	311,928	514,377
Marziya Meical Hall (Sherpur)	3,921	-
Marziya Veterinary Store	1,016	-
Marziya Veterinary Store (Gobindaganj)	6,450	-
Master Feed Agrotec Limited	15,795,000	301,695
Master Pharmacy(Dinajpur)	359,667	365,781
Master Pharmacy (Shamin)	6,308	-
Master Poultry-2 (Took)	57,977	112,977
Master Poultry(Kotiadi) Cp	199,116	-
Master Veterinary (Nilphamary)	6,110	-
Master Veterinary (Santhia)	2,304	-
Masud Medical Hall(Askik)	410,753	412,578
Masud Pharmacy	412,563	412,563
Masud Poultry(Narsingdi)	33,323	-
Masud-Rana Pharmacy(Charghat)	15,066	-
Masum Khaddo Bondor (Panchagor)	7,313	-
Masum Traders (Hiru)	340,156	345,879
Matin Pharmacy(Panchagor)	9,710	-
Matiur Pharmacy	385,410	385,410
M.A Veterinary (Palashbari)	4,753	-

	30-Jun-20	30-Jun-19
Maya Pharmacy (Pabna) 2	1,771	-
Mayer Doa (Gazipur)	78,007	-
Mayer Doa Medicine Corner(Gaibandha)	4,012	-
Mayer Doa Pharmacy(Panchagarh)	6,816	-
Mayer Doa Pharmacy(Sarishabari)	8,779	-
Mayer Doa Poultry (Cox's Bazar)	6,208	-
Mayer Doa Poultry Feed (Chapai) CP	358,000	-
Mayer Doa Poultry Feed(Chapainawabganj)	19,233	-
Mayer Doa Poultry Feed (Pirojpur)	11,889	-
Mayer Doa Poultry (Narayanganj)	9,341	-
Mazeda Pharmacy	365,214	365,214
Mazeda Pharmacy(Thakurgaon)	7,558	-
Md. Jalal (Aslam)	12,222	-
Md. Zakir Hossain	1,180	-
Md. Zakir Hossain (Rajshahi)	19,952	-
Medicate Corner(Sakhipur)	3,100	-
Medicine Cornar (Jashore)	10,814	-
Medicine House (Mohammad Ali)	22,760	-
Medicine House(Satkhira)	1,354	-
Meghna Poultry (Narayanganj)	23,616	-
Mehedi Hasan Pharmacy (Matin)	255,716	247,896
Merina Pharmacy	347,596	347,596
M. Hossain Poultry(Bera)	1,914	-
Milon Enterprise(Rangpur)	243,659	243,659
Milon Pharmacy (Rezwanul)	1,853	-
Mim Medical Store (Pirgonj)	5,926	-
Mim- Megha Veterinary(Kurigram)	4,713	-
Mim Pharmacy	2,304	-
Mim Pharmacy(Gaibandha)	61,696	72,896
Miraj Poultry(Kumarkhali) Cp	119,532	-
Mitu Pharmacy(Nawabganj)	5,005	-
Miya Pharmacy(Kushtia)	3,000	35,875
Mizan Veterinary (Iswardi)	4,240	-
M.K Pharmacy(Panchagarh)	6,257	-
Modern Pharmacy(Rajshahi)	83,254	88,654
Modern Veterinary (Robiul)	85,984	92,354
Modhu Pharmacy (Jewel) CP	262,325	197,143
Modhu Pharmacy(Thakurgaon)	197,143	197,143
Modina Poultry (B.Barua)	42,675	-
Modina Veterinary (Rezwanul)	419,979	432,125
Mohammadia Pharmacy(Kishorganj)	1,285	-
Mohin Traders (Hatibandha)	12,028	-
Mohona Pharmacy(Dhamrai)	14,536	-
Mohona Pharmacy (Manda)	1,148	-
Mollah Pharmacy(Narsingdi)	126,336	126,336

	30-Jun-20	30-Jun-19
Mollah Veterinary (Natore)	18,650	-
Molla Medicine Corner (Delowar)	6,764	-
Mollik Medical Hall(Phultala)	1,920	-
Mollik Poultry Feed & Feed Centre(CP)	278,160	276,178
Mondol Medical Hall (Sarishabari)	1,409	-
Moni Mukta Pharmacy	9,400	-
Moni Poultry Feed (Delowar)	14,054	-
Monira Pharmacy (Biplob) Cp	287,479	-
Monira Pharmacy(Pabna)	131,441	301,654
Monir Drug House (Jessore)	10,038	-
Monir Oushodhaloy	4,840	-
Monirul Pharmacy (Birganj)	2,378	-
Monju Medical(Jhikorgacha)	50,156	-
Monosha Pharmacy(Monirul)	215,278	462,314
Moon Pharmacy (Monjurul)	3,048	-
Moriom Poultry	3,568	-
Morium Nur Poultry Feed (B-Baria)	6,032	-
Mosharof Poultry Center (Sakhipur)(Faruk)	8,078	-
Mostafizur Poultry Complex (Kapasias)	1,477	-
Moyna Treaders (Satkhira)	7,200	-
M. R Pharmacy(Dhamrai)	4,204	-
M.R Poultry Feed	13,763	-
Mrs. Abdul Karim Poshu Oshudhaloy	8,332	-
M.S Aditto Agro (Krishno)	56,347	30,064
M/s Amin Pharmacy(Korchatpur)	6,165	-
M.S Ashik Poultry Feed & Chick	3,540	-
M.S Bhai Bhai Poultry(Manikganj)(CP)	1,715	-
M.S Bipu Bech Bondor(Robiul)	6,344	43,164
M.S Bismilla Poultry Feed and Medicine(Sarishabari)	2,712	-
M/s Bonani Pharmacy(Rajbari)	32,939	-
M/s Bondhon Poultry Feed & Medicine(Belabo)	2,978	-
M.S Borol Poultry (Sathia)	19,520	19,564
M/S Delowar Veterinary (Manda)	6,413	-
M.S Eifad Enterprize	5,000	-
M/S Golden Drug House (Dhaka)	2,498	-
M.S Hamida Pharmacy (Birganj)	186,317	243,317
M.S Hamida Pharmacy (Birganj) CP	50,945	243,317
Ms.Hasina Pharmacy(Jashore)	6,527	-
M.S Islam Enterprize	12,896	-
Ms Jaman Pharmacy (Krishno)	45,737	39,197
M/s Jemin Traders (Ranisonkoil)(Cp)	127,876	-
M/s Joaddar Poultry (Jhenaidha)	8,162	-
M/s Jonota Poultry&Medical Hall(Ullahpara)	6,093	-
M/S Kazi Poultry Feed & Chick (Jhenaidha)	20,172	-
M/S Kobir Poultry Feed	36,952	63,241

	30-Jun-20	30-Jun-19
M.S Maa Baba Pharmacy(B.Baria)	2,193	-
M/s Mollah Pharmacy(Jessore)	13,650	-
M.S Monu Poultry Feed & Medicine(Akbor)	1,272	-
M.S Muradh Traders (Rangpur) CP	101,066	146,335
M.S Nazat Pharmacy	11,584	-
M/S Nihan Veterinary & Pharmacy(Jhenaidha)	13,998	-
M.S Nirman Poultry Complex	4,539	-
M/S Orpita Traders (Sahin Mia)	5,610	-
M/S Paul Traders (Jhikorgacha)	23,957	-
M/S Pollob Medicine Corner (Jhenaidha)	6,708	-
M.S Progoti Poultry Medicine & Feed	43,175	31,245
M/S Rakib Enterprize	3,615	-
M/s Ranisha Poultry Feed & Medicine(Belabo)	9,853	-
M/S Rashed Traders(Nawabganj)	2,296	-
M/S Rico Poultry Feed	2,447	-
M/s R.K Poultry	18,791	-
M. S Runu Poultry (Maona)	9,455	-
M/S Sadikur Poultry Feed	32,555	-
M.S Santo Pharmacy	14,770	-
M/s Shah Chondropuri Medicine Corner(Cp)	19,412	-
Ms Sheba Prani Chikitshaloy (Kishorganj)	1,281	-
Ms Shoan Poultry (Pirgonj)	1,061	-
M/s Suprovath Poultry (Jhenaidha)	1,075	-
M.S Talukdar Poultry	198,254	363,254
M.S Tamanna Poultry(CP)	114,624	290,124
M/s Tuhin Poultry & Medicine Corner(Cp)	155,123	-
M.S Unik Enterprize (Raju)	2,395	-
Muklas Veterinary	359,812	456,812
Mukta Veterinary	196,784	271,784
Mukta Veterinary(Bhangura)(CP)	250,996	-
Muktijuddha Pharmacy(Panchagor)	4,692	-
Mukul Medical Hall (Delowar)	4,142	-
Mukul Veterinary Pharmacy (Polashbari)	7,403	-
Munshi Medical(Malek)	232,872	249,872
Murad Veterinary (Jhenaidha)	3,802	-
Musa Pharmacy(Razib)	4,563	-
Musa Traders	262,354	266,354
Mustakin Traders(Bhangura)	7,416	54,186
Mustak Veterinary	7,355	-
Mustofa Dairy & Poultry(Lalmonirhat)	19,585	-
Naba Pharmacy	318,796	358,796
Nabila Poultry Feed & Medicine Corner	1,000	-
Nabil Medicine Corner (Ghatail)	1,427	-
Naf Veterinary Hospital	-	10,314
Nahar Pharmacy (Bogra)	328,607	401,247

	30-Jun-20	30-Jun-19
Nahian Poultry Feed (Bhairab)	25,913	30,625
Nahian Poultry Feed (Moniruzzaman)	5,031	-
Nahid Pharmacy (Sirajganj)	8,091	-
Nakshi Pharmacy(Thakurgaon)	321,300	-
Nalta Poultry (Satkhira)	8,560	-
Nasim Veterinary Store(Gaibandha)	240,041	247,563
Nasir Pharmacy(Abdul Manik)	-	99,214
Nayem Pharmacy(Rajshahi)	332,982	352,123
Nayem Veterinary	13,807	-
Nayem Veterinary (Bhangura)	35,322	40,986
Nazmoon Pharmacy	304,854	339,854
Nazmul Pharmacy (Panchagor)	4,119	-
Nazmul Traders(Dinajpur)(CP)	91,728	235,684
Nesarabad Poultry (Pirojpur) CP	443,143	-
New Abir Traders (Dhaka)	107,540	132,540
New Star Drug(Jewel)	5,753	-
Nilnodia Pharmacy	1,110	-
Niloy Poultry Feed(Kayum)	1,312	-
Niloy Vet Pharmacy	301,540	336,540
Niven Veterinary(Pabna)	295,552	309,652
Nobirul Pharmacy(Gabtoli)	5,226	-
Nokshi Pharmacy (Jewel)	190,501	324,570
Nondita R-71 Poultry Feed (Rangpur)	-	20,591
Nur-Alam Pharmacy (Panchagor)	6,144	-
Nurian Veterinary Corner (Cox's Bazar)	3,686	-
Nurjahan Medical Hall	1,112	-
Nur Medical (Jhenaidha)	5,584	-
Nur-Mohammod Veterinary (Belkuchi)	7,100	-
Nurnobi Pharmacy (Palashbari)	3,125	-
Nur Poultry(Gazipur)(CP)	384,845	81,245
Nurul Amin Poultry(Palashbari)(Cp)	7,346	-
Nurul Veterinary(Pabna)	337,890	365,890
Nusrat Agro Medicine Corner (Kaliakor)	4,932	-
Obidul Pharmacy (Birganj)	4,159	-
Omar Pharmacy	198,245	244,150
Omi Poultry Feed & Medicine Center	96,509	123,458
Omol Medicine Store	1,976	-
Ongkon Pharmacy (Lalmonrhat)	1,878	-
Onika Pharmacy (Biplob)	1,059	-
Ontor Enterprize(Manda)	2,802	-
Onuradha Traders (Nalitabari)	22,005	-
Opu Pharmacy(Jewel)	191,945	204,587
Othoi Medical Hall(Barguna)	40,753	-
Oushodh Bitan	226,302	232,158
Oushodh Gorh	416,843	409,547

	30-Jun-20	30-Jun-19
Oushudh Bitan	5,432	-
Ovi Poultry	17,639	-
Padma Poshu Chikishaloy	80,041	87,541
Pakhi Ghor (B.Barria) CP	408,702	74,989
Palong Poultry Feed & Medicine Center	323,910	365,890
Pata Pharmacy (Mohammad Ali)	1,041	-
Pavel Medical (Kaliakair) Cp	53,315	-
Payker Pharmacy (Gabtali)	-	51,008
Payker Pharmacy(Gabtali) Cp	499,222	-
Payker Pharmacy(Gabtali) (Acqua)	51,008	51,008
Pekua Veterinary Corner (Coz's Bazar)	3,196	-
Piash Poultry Feed Corner(Hatibandha)	3,104	-
Pirgacha Agro Service	87,039	103,982
Polash Pharmacy (Kotchandpur)	2,062	-
Polash Pharmacy (Sirajgonj)	10,046	-
Polash Shemul Pharmacy	85,345	120,345
Poli Agrovat (Asaduzzaman)	9,737	-
Polli Sheba Pharmacy (Rangpur)	1,892	-
Polton Pharmacy	2,825	-
Polton Pharmacy(Aslam)	2,415	-
Poltu Pharmacy(Jewel)	108,926	111,426
Popular Pharmacy(Chapai)	98,254	133,254
Popular Poultry (Kaliakair)	7,655	-
Poramanik Pharmacy(Adamdighi)	9,914	-
Poribarton Medicine(Cp)	69,676	-
Poshu Oshud Jogoth (Krishno)	141,623	146,123
Poshu Oshud Jogoth (Krishno) CP	488,900	146,123
Poshu Pakhi Medicine	249,159	263,159
Poshu Pusti Hall	15,600	-
Poshu Shastho (Krishno)	20,198	-
Poshu Shastho (Nilphamari)	1,041	-
Poshu Shastho Pharmacy(Jewel)	45,991	76,646
Poshu Shastho (Taraganj)	2,880	-
Poshu Sheba Kendro (Sultan)	2,789	-
Poshu Sheba Pharmacy (Bogra)	258,806	263,124
Potaka Pharmacy(Bera)	5,585	-
Poultry Corner (Institution)	338,700	-
Poultry Ghor(Paikgacha)	9,462	-
Poultry Plus(Meshkat)	2,886	-
Poultry View (Institution)	314,300	-
Poultry Village(Kaliakair)	31,091	-
Prani Oshudhaloy (Krishno)	329,659	345,875
Prani Sheba Oushudhaloy (Gazipur)	30,382	-
Protima Pharmacy(Mirzapur)	215,377	221,356
Puspita Veterinary (Shamim)	3,303	-

	30-Jun-20	30-Jun-19
Puspo Poultry & Feed	323,000	-
Rabiya Poultry (Rupsha)	19,467	-
Rabiya Veterinary(Gobindaganj)	10,446	-
Rafa Pharmacy (Pirgonj)	7,131	-
Rafi Poultry (Gazipur)	36,970	-
Rafiq Pharmacy	287,227	288,542
Rafi Veterinary (Ishwardi) Cp	125,060	-
Rafiza Pharmacy (Chapai)	-	38,058
Rahad & Murad Veterinary	9,373	-
Rahad Poultry (Sarishabari)	284,260	302,154
Rahamania Drug House(Ullahpara)	7,104	-
Rahima Pharmacy(Jessore)	26,415	-
Rahman Pharmacy(Cp)	109,097	-
Rahman Pharmacy(Thakurgaon)	226,273	254,630
Rahman Poultry	3,499	-
Rahul Pharmacy (Narsingdi)	4,600	56,040
Raihan Medical Hall	272,339	313,548
Raihan Pharmacy	289,145	302,145
Raisa Medicine (Kayum)	7,930	-
Raisa Veterinary (Nalitabari)	13,309	-
Rajmoni Poultry (Kishorganj)	1,743	-
Raju Pharmacy (Birganj)	3,725	-
Raju Pharmacy(Rajbari)(Cp)	192,551	-
Rakib Poultry Feed (Rajshahi)	15,108	-
Rakib Traders(Bogra)(CP)	212,578	224,578
Rana Feed Model Medicine Shop(Ghatail)	2,637	-
Rana Poultry (Kayum)	3,700	-
Rangdhonu Medicine Corner	365,324	365,324
Rangpur Poultry& Dairy	260,658	265,315
Rani Poultry Feed (Kayum)	5,623	-
Rasel Medical Hall(Tangail)	2,245	-
Rasel Poultry (Meskat)	6,613	-
Rasel Veterinary Store (Gaibandha) CP	372,578	89,752
Rashedul Veterinary (Ullahpara)	7,920	-
Rashida Pharmacy(Panchagor)	10,196	-
Razzak Veterinary	304,546	332,546
Ready Stock	147,341	156,841
Retu Pharmacy(Shahjadpur)	1,000	-
Rifadh Poultry Feed & Medicine	4,554	-
Rifad Pharmacy(Nayon)	8,249	-
Rifat Poultry Feed (Abdul Manik)	3,543	-
Rihad Veterinary (Gaibandha)	3,525	-
Rimi Poultry	203,489	235,489
Rimu Enterprize(Rupsha)	67,207	-
Ripon Enterprize(Baraigram)	2,731	-

	30-Jun-20	30-Jun-19
Ripon Medical Hall(Mymensingh)	165,437	201,458
Ripon Pharmacy (Korchatpur)	21,294	-
Ripon Pharmacy (Panchagor)	11,951	-
Rita Pharmacy	259,032	263,548
Riya Medical Hall (Ullahpara)	5,112	-
Riya Pharmacy	1,899	-
Riya Poultry (Moniruzzaman)	1,291	-
R.K Medicine Center (Delowar)	18,820	30,617
R.K Poultry (Nalitabari)	10,923	-
Robi Poultry(Lalmonirhat)	3,000	-
Robi Poultry (Lalmonirhat) CP	333,596	206,601
Robiul Pharmacy(Hatibandha)	14,633	-
Robiul Pharmacy (Natore)	7,714	-
Rogmukti Medical(Natore)	25,362	-
Rog Mukti Pharmacy	288,954	307,546
Rohid Pharmacy (Gabtoli)	30,502	-
Roies Veterinary (Sobuj Khan)	17,421	-
Roja Pharmacy(Naogaon)	31,141	-
Rokeya Medicine(Kayum)	21,122	-
Rokeya Pharmacy (Aslam)	3,517	-
Roktim Medical Hall (Zakir)	16,960	-
Roky Medicine Corner (Mithapukur)	1,728	-
Roman Poultry	131,643	135,684
Roni Pharmacy (Anowar)	13,612	-
Rotna Pharmacy(Taraganj)	2,920	-
Royal Pharmacy (Aslam)	13,105	-
Royel Pharmacy(Julhas)	20,454	-
Rubel Pharmacy(Rangpur) Cp	551,871	-
Rufaida Pharmacy (Pachbibibi)	3,849	-
Ruhi Poshu Chikishaloy (Nawabganj)	3,001	-
Rujdha Pharmacy	13,128	-
Rupa Medical(Gaibandha)(Cp)	142,318	-
Rupa Medical Store (Cp)	5,983	42,983
Rupa Medical Store (Gaibandha)	47,802	42,983
Rupa Veterinary (Mithapukur)	9,607	-
Rusha Pharmacy (Korchatpur)	17,452	-
Sabbir Enterprize(Nawabganj)	1,344	-
Sabbir Medical Store (Biplob)	10,032	-
Saddam Feed Traders	11,224	-
Sad Enterprize(CP)	194,461	254,682
Sadhona Pharmach(Magura)	28,027	-
Sadia Poultry(Kapasias)	14,898	-
Sadib Poultry (Bhairab)	4,226	-
Sadik Pharmacy (Joypurhat)	1,359	-
Sadik Pharmacy (Rubel Hasan)	1,843	-

	30-Jun-20	30-Jun-19
Sadik Veterinary (Manda)	16,633	-
Sadiqul Poultry(Chapainawabganj)	316,152	330,152
Sadiya Poultry Feed & Medicine(Belabo)	18,450	-
Safa Veterinary Care(Ghatail)	3,832	-
Sagor Medicine & Feed	6,116	-
Sagor Poultry Feed	292,876	302,148
Saha Poultry (Shibpur)	14,403	-
Saidul Muktakin Pharmacy(Nalitabari)	10,431	-
Saidul Traders(Matin)	5,892	-
Saiful Poultry(CP)	62,083	-
Saiful Poultry (Kapasias)	-	20,171
Saiful Traders (Bogra)	3,425	-
Saiful Veterinary (Kaliakair)	9,072	-
Sajeda Pharmacy (Adomdighi)	6,617	-
Saju Pharmacy(Robiul)	148,341	156,841
Salam Pharmacy(Rangpur)	26,847	-
Salma Medical Hall(Phultala)	8,406	-
Samia Pharmacy(Rajshahi)(Zohorul)	129,064	132,564
Samsunahar Pharmacy	189,658	201,658
Sanjida Pharmacy (Natore)	24,224	-
Sanjida Poultry (Nilphamari)	5,638	-
Sara Medicine Corner(Bhairab)	8,256	-
Sardar Pharmacy (Manda)	1,269	-
Sardder Pharmacy(Jessore)	27,616	-
Sarder Poultry & Feed	110,133	122,457
Sarkar Pharmacy(Narsingdi)	284,099	288,599
Sarkar Veterinary (Chatmohor)	9,216	-
Sarker Drug House(Akbor)	135,014	165,241
Sarker Medical Hall (Delowar)	3,274	-
Sarker Medical Hall(Ullahpara)	2,070	-
Sarker Pharmacy-2 (Bogra)	2,365	-
Sarker Pharmacy-2(Robiul)	3,204	-
Sarker Pharmacy (Bera)	4,920	-
Sarker Pharmacy (Bogra) CP	164,727	-
Sarker Pharmacy(Robiul)	31,005	-
Sarker Poultry(Gaibandha)	11,378	-
Sathi Pharmacy(CP)	266,161	237,458
Sathi Poultry & Dairy	320,814	323,314
Sathi Poultry & Dairy (Natore) CP	473,342	323,313
Sathi Poultry (Natore) 2	10,534	-
Satter Veterinary (Zakir)	7,073	-
Sayma Pharmacy	196,527	251,407
Sayma Pharmacy (Bonpara) CP	-	251,407
Seha Medical Hall	1,253	-
S Enterprize (Chapai)	2,539	31,657

	30-Jun-20	30-Jun-19
Seven Brothers	1,146	-
Seyam Enterprize - CP	129,344	132,844
Seyam Medical Hall	1,845	-
Seyam Medicine Corner (Sirajganj)	10,220	-
Seyam Pharmacy	288,969	301,245
Seyam Pharmacy(Natore)	7,764	-
Seyam Poultry (Ullahpara)	2,183	-
Seyam Veterinary(Bhangura)	5,962	-
Shadat Veterinary (Birampur)	1,940	-
Shahalom Veterinary	296,458	332,458
Shahida Pharmacy	10,885	-
Shahin Traders	114,524	286,524
Shahin Veterinary Hall (Ullahpara)	1,740	-
Shahitto Poultry Media	-	44,378
Shahjalal Medical Hall (Delowar)	7,716	-
Shahjalal Medicine (Kishorganj)	1,606	51,252
Shah Pharmacy(Rajbari)	9,973	-
Shajopori Poultry 2 (Chakoria)	3,168	-
Shakib Pharmacy (Kayum)	7,030	-
Shakib Pharmacy(Kushtia)	4,895	-
Shakib Poultry (Mithapukur)	8,352	-
Shakila Poultry Farm	1,394	-
Shamim Enterprise(Jessore)	5,554	-
Shamim Pharmacy(Kalai)	4,511	-
Shamim Poshu Chikitshaloy(Birampur)	17,485	-
Shamim Poultry Feed(Kurigram)	5,110	-
Shami Pharmacy (Cox's Bazar)	46,316	-
Shammi Medical Hall	13,276	-
Sheba Agro Medical Hall (Delowar)	8,144	-
Sheba Medical Hall (Rubel Hasan)	9,178	-
Sheba Pharmacy (Nilphamari)	21,668	-
Sheba Pharmacy (Shahjadpur)	33,883	-
Sheba Pharmacy(Shakhipur)	11,520	-
Sheba Poshu Chikishaloy (Kayum)	5,858	-
Shefa Pharmacy (Shamim)	4,648	-
Shefa Pharmacy(Taraganj)	4,692	-
Shescha Sheba Krittim Projonon Kendro	260,765	253,839
Shescha Sheba Krittim Projonon Kendro (CP)	-	253,839
Shiblu Medical Hall(Akbor)	280,914	301,245
Shikder Enterprise(Dhamrai)	38,676	-
Shiva Pharmacy (Hatibandha)	12,924	-
Shofiquel Poultry(Palashbari)	4,656	-
Shofiquel Veterinary (Hatibandha)	8,508	-
Shojib Traders(Bhangura)	19,044	-
Shokal Veterinary(Charghat)	11,058	-

	30-Jun-20	30-Jun-19
Shondhani Pharmacy(Hafizul)	19,651	-
Shopno Medicine Corner (Sarishabari)	7,490	-
Shoriful Pharmacy (Ullahpara)	7,567	-
Shorif Veterinary(CP)	374,236	-
Shorna Veterinary Hall (Joynal)	12,898	-
Showan Pharmacy(Dinajpur)	186,458	203,458
Shuli Pharmacy	135,387	145,682
Shuma Pharmacy	1,229	-
Shuvo Pharmacy(Robiul)	41,493	-
Siddik Enterprize	1,760	-
Siddik Traders (Hatibandha)	6,344	-
Sifath Pharmacy (Kayum)	1,243	-
Sikder Medical Hall (Rajbari)	21,407	-
S K Medicine (Kishorganj)	-	41,664
Sobuj Medical Hall	57,980	-
Sobuj Pharmacy(Birganj) Cp	139,937	-
Sohel Enterprize (Bogra)	2,447	-
Sohel Pharmacy	6,198	-
Sojib Medical Hall (Khulna)	12,144	-
Sojol Pharmacy (Moheshpur)	19,923	-
Sontos Medical Hall (Borguna)	64,700	-
Soronjit Kumar Bormon	3,958	-
Sorup Poultry Feed (Pirojpur)	22,891	-
Sotota Dairy (Feni)	3,104	-
Sotota Pharmacy(Tangail)	4,329	-
Sotota Poultry Feed (Delowar)	12,064	-
Sotota Poultry Feed(Sarishabari)	6,720	-
Sourov Pharmacy (Krishno)	4,316	-
Sowda Poultry(Shibpur)	9,234	-
Sownik Poultry Feed & Medicine	22,848	64,256
S Poultry (Birganj)	4,806	-
Srabon Poultry (Nalitabari)	8,650	-
S.S Pharmacy(Rangpur)	18,976	-
S.S Poultry(Dhaka)	3,419	-
S.S Poultry (Solonga)	19,909	-
S & S Veterinary Corner (Kaliakair)	8,720	-
Suchona Poultry(Samim)	7,200	-
Sufiya Medical (Feni)	22,126	-
Sujata Veterinary Hall (Phultala))	1,959	-
Sujon Veterinary Store	1,824	-
Sultan Pharmacy (Sarishabari)	6,280	-
Sultan Vet Medicine Corner(Ghatail)	8,674	-
Sumaiya Pharmacy (Dhamrai)	2,639	-
Sumiya Poultryfeed & Medicine	165,599	183,214
Sumon Pharmacy(Manda)	4,066	-

	30-Jun-20	30-Jun-19
.Sumon Pharmacy(Pirganj)	211,145	220,145
Sumon Traders	3,667	-
Sumuna Medical (Mahmudul)	5,812	-
Supriya Poultry Feed (Pirozpur)	14,214	-
Suvro Medical Hall	186,071	204,578
Tahiya Poultry	15,280	-
Taiabiya Medical Hall(Jamalpur)	242,697	245,876
Taj Veterinary (Natore)	9,943	-
Talukder Poultry(Ullahpara)	2,134	-
Tamim Poultry Feed & Medicine	80,000	133,423
Tanha Pharmacy(Naogaon)	2,784	-
Tanjit Pharmacy	145,454	145,872
Tansa Enterprize	10,868	-
Tanu Biswas Medicine, Chowgacha, Jessore	429,000	-
Taraganj Poultry	2,616	-
Tarek Enterprize(Ghatail)	14,431	-
Tarek Medical Hall (Sarishabari)	376,700	-
Tarek Pharmacy (Biplob)	-	31,904
Tarek Pharmacy (Cp)	-	31,904
Tarek Poultry Feed & Medicine	208,798	231,458
Tarisha Pharmacy (Rajshahi)	9,846	-
Tashim Agro	7,361	-
Tasiya Medical Hall (Sarishabari)	2,680	-
Tasnia Enterprize (Rupsha)	13,515	-
Tasnin Poultry	24,470	32,548
Taysha Poultry Feed & Medicine Corner(Mymensing)	-	35,430
Taz Poultry	231,578	242,578
Teen Bhai Enterprise	290,000	-
Three Brothers Poultry Feed & Medicine	11,210	-
Tisha Pharmacy(Gaibandha)	-	63,254
Tofazzol Pharmacy(Salaque)	-	77,893
Toma Poultry Feed & Medicine	427,900	-
Toma Tamanna Pharmacy(Bera)	3,017	-
Topu Medicine Hall	436,200	-
Torikul Poultry(Asaduzzaman)	5,670	-
Towhid Poultry Feed	19,100	31,547
Towhid Veterinary(Hatibandha)	4,365	-
Tuhin Enterprize (Birampur) CP	144,713	235,594
Tumpa Drug House (Bhairab)	8,801	-
Turag Veterinary Collection (Dhamrai)	2,894	-
Tushar Pharmacy(Bheramara)	6,254	-
Tutul Pharmacy (Anamul)	375,400	-
Tutul Traders(Gaibandha)CP	108,156	142,156
Tutul Veterinary(Pabna)	31,884	-
Uddyog Poultry	92,974	108,974

	30-Jun-20	30-Jun-19
Udoyon Poultry Feed (Bhairab)	36,243	37,752
Ullahpara Medical Hall(CP)	256,724	349,333
Ullahpara Medical Hall (Momin) Cp	60,468	-
Umme Habiba Poultry	11,087	-
Update Pharmacy(CP)	339,809	-
Updat Phatmacy (Farhad) (CP)	70,715	-
Upom Poultry	199,219	141,968
Upozila Veterinary Hospital (Kapasias)	279,464	-
Urmi Eti Poultry Feed (Mirzapur)	3,155	-
Uttara Pharmacy	108,356	142,356
Uttom Medicine Corner(Gazipur)	13,289	-
Uzzal Poultry	-	47,589
Vai Vai Pharmacy(Ranisankali)	395,640	-
Varoti Pharmacy	9,918	-
Vasha Pharmacy	77,458	101,458
Very Good Dairy & Agro Farm (Dhaka)	4,777	-
Veterinary Clinic	-	54,682
Veterinary Clinic(Mirzapur)	6,754	-
Veterinary Oushudh Ghor(Tariqul)	98,458	113,458
Veterinary Store(Shehab)	199,587	214,587
Vet Fish & Medicine Corner	156,289	165,789
Vula Pharmacy	-	66,879
Wahed Veterinary	3,187	-
WAZID VETERINARY	137,971	136,597
Yeakub Pharmacy(Manikganj)	99,707	87,456
Younus Enterprize	99,698	103,548
Yousuf Poultry (Narsingdi)	14,195	20,123
Zahin Traders	334,197	-
Zaidul Pharmacy	316,791	-
Zerin Poultry	219,336	245,876
Zerin Poultry Feed (Jhenaidha)	5,376	-
Zia Poultry & Medicine (Raipura)	-	20,835
Zihadh Veterinary(CP)	56,241	131,242
Zihadh Veterinary (Gobindoganj) Cp	185,652	-
Zillur Traders	446,400	-
Ziniya Pharmacy	478,774	-
Zohir Enterprise(Sumon)	180,587	214,587
Zohir Traders	264,291	268,791
Zohorul Pharmacy (Taraganj)	3,122	-
Total	118,236,156	78,850,747

Advent Pharma Ltd.

Schedule of Sales
As at June 30, 2020

Finished Goods

Annexure-D

Name of Items	Product Category	Unit	30-Jun-20		30-Jun-19	
			Quantity	Amount	Quantity	Amount
Adlyte Powder 100 gm	Powder	Sachet	2,358	47,160	282,699	5,653,980
Adlyte Powder 500 gm	Powder	Sachet	12,929	1,034,320	192,708	15,416,640
Adlyte Powder 1 kg	Powder	Sachet	30,725	3,687,000	198,705	23,844,600
Advit GC Powder 500 gm	Powder	Sachet	45,285	3,849,225	181,444	15,422,740
Advit GC Powder 1 kg	Powder	Sachet	31,572	5,051,520	153,023	24,483,680
Advit C Powder 100 gm	Powder	Sachet	6,256	1,032,240	144,598	23,858,670
Advit C Powder 500 gm	Powder	Sachet	18,737	7,307,430	490	191,100
Advit DB Powder 100 gm	Powder	Sachet	1,721	48,188	386,002	10,808,056
Advit DB Powder 500 gm	Powder	Container	12,636	1,579,500	217,176	27,147,000
Advit DB Powder 1 kg	Powder	Bucket	48,696	11,443,560	162,291	38,138,385
Advomica Powder 10x20gm	Powder	Box	11,131	1,026,945	11,826	1,091,070
Ad-Tetra 100 gm	Powder	Sachet	3,572	230,251	4,251	274,019
Adprolim Plus 100 gm	Powder	Sachet	3,441	701,138	1,192	242,882
Adlinsin 100 gm	Powder	Sachet	1,113	280,955	2,203	556,103
Adlinsin 500 gm	Powder	Container	-	-	617	693,989
Adlosin Powder-100 gm	Powder	Container	-	-	1,413	854,865
Adcipcin 100 ml	Liquid	Phyle	3,180	559,488	2,383	419,265
Adcipcin 500 ml	Liquid	Bottle	1,631	1,328,921	952	775,680
Adrizole Bolus	Bolus	Box	4,483	548,854	2,864	350,640
Adcet Bolus	Bolus	Box	9,789	326,953	7,132	238,209
Ad-Tetra Bolus	Bolus	Box	500	22,955	1,131	51,924
Adsulph Bolus	Bolus	Box	428	133,164	1,319	321,177
Adsulph-S Bolus	Bolus	Box	579	180,144	1,107	269,555
Apetonic Bolus	Bolus	Box	5,552	570,635	2,581	265,275
Adprozine Bolus(10x4)	Bolus	Box	6,862	683,249	2,157	214,772
Keto Pain Bolus(5x4)	Bolus	Box	1,981	297,586	1,850	277,907
Keto Pain Bolus(10x4)	Bolus	Box	-	-	760	228,334
TCL Vet Bolus(5x4)	Bolus	Box	-	-	1,746	527,589
Adcipcin Bolus(10x2)	Bolus	Box	-	-	709	213,196
Adbovi Powder 125 gm	Powder	Sachet	67,793	12,202,740	44,749	8,054,820
Adcal P 500 gm	Powder	Sachet	35,036	8,759,000	49,674	12,418,500
Adcal P 250 gm	Powder	Sachet	-	-	1,343	174,590
Adzyme Powder 100 gm	Powder	Sachet	75,426	10,559,640	52,910	7,407,400
Colis Vet 100 gm	Powder	Sachet	-	-	1,881	240,862
Colis Vet 500 gm	Powder	Container	-	-	1,333	759,277
Neocin Vet 100 gm	Powder	Sachet	-	-	1,025	225,951
Neocin Plus Vet 100 gm	Powder	Sachet	-	-	2,227	635,675
Egg Bost-100 gm	Powder	Sachet	52,011	6,761,430	17,796	2,313,480
Egg Bost-500 gm	Powder	Container	3,251	2,031,875	5,520	3,450,000
Power Fat-1 kg	Powder	Sachet	32,716	8,996,900	16,001	4,400,275

Name of Items	Product Category	Unit	30-Jun-20		30-Jun-19	
			Quantity	Amount	Quantity	Amount
Advit(B+C)-100 gm	Powder	Sachet	1,302	62,496	35,097	1,684,656
Advit(B+C)-500 gm	Powder	Sachet	1,056	211,200	14,255	2,851,000
Advit WS-100 gm	Powder	Sachet	650	149,500	7,093	1,631,390
Advit-3 Powder-100 gm	Powder	Sachet	-	-	992	74,400
Microfix 100 gm	Powder	Sachet	-	-	2,533	697,132
Advit CP Suspension 500 ml	Liquid	Bottle	54,349	5,978,390	249,681	27,464,910
Advit CP Suspension 1 ltr	Liquid	Bottle	66,855	12,702,452	179,382	34,082,580
Advit CP Suspension 5 ltr	Liquid	Jar	19,662	15,729,600	52,696	42,156,800
Adzinc Syrup - 100 ml	Liquid	Bottle	299,450	8,983,500	251,808	7,554,240
Adzinc Syrup - 500 ml	Liquid	Bottle	89,191	9,811,010	194,254	21,367,940
Adzinc Syrup - 1 Litre	Liquid	Bottle	126,605	25,321,000	176,169	35,233,800
Adzinc Syrup - 3 Litre	Liquid	Container	27,390	15,338,400	6,655	3,726,800
Advit - D Plus Solution -100 ml	Liquid	Bottle	132,789	9,295,230	144,749	10,132,430
Advit AD3E Solution 100 ml	Liquid	Bottle	1,544	200,720	43,849	5,700,370
Advit AD3E Solution 500 ml	Liquid	Bottle	9,726	5,738,340	28,632	16,892,880
Adzuril Solution 100 ml	Liquid	Bottle	47,407	17,540,590	1,929	713,730
Advit E-Sel 100 ml	Liquid	Phyle	55,805	5,580,500	68,633	5,833,805
Cough Off 100 ml	Liquid	Phyle	117,945	11,204,775	42,102	3,999,690
Cough Off 500 ml	Liquid	Jar	27,027	12,432,420	12,351	5,681,460
Cough Off 1 ltr.	Liquid	Jar	16,656	14,657,280	9,027	7,943,760
ABC Solution 100 ml	Liquid	Phyle	107,547	9,679,230	69,043	6,213,870
ABC Solution 500 ml	Liquid	Jar	54,434	20,140,580	27,261	10,086,570
ABC Solution 1 ltr.	Liquid	Jar	33,318	23,156,010	29,407	20,437,865
Feron Vet 500 ml	Liquid	Jar	52,302	5,230,200	61,002	6,100,200
Feron Vet 1 Ltr.	Liquid	Jar	37,512	7,127,280	49,742	9,450,980
Liver On 100 ml	Liquid	Phyle	117,629	8,234,030	110,390	7,727,300
Liver On 500 ml	Liquid	Jar	63,763	19,766,530	34,085	10,566,350
Liver On 1 ltr.	Liquid	Jar	30,725	17,974,125	30,759	17,994,015
Nephrosol 100 ml	Liquid	Phyle	65,467	12,438,730	22,147	4,207,930
Nephrosol 500 ml	Liquid	Phyle	14,494	13,044,600	6,218	5,596,200
Oramin Solution-100 ml	Liquid	Bottle	59,680	6,564,800	33,453	3,679,830
Oramin Solution-500 ml	Liquid	Bottle	27,593	14,072,430	11,377	5,802,270
Advit B Complex-100 ml	Liquid	Bottle	9,543	3,721,770	47,556	4,042,260
Advit B Complex-500 ml	Liquid	Bottle	24,838	2,111,230	28,055	10,941,450
Advit CP Plus Bolus (10*2)	Bolus	Box	2,100	147,000	-	-
Advit CP Plus Bolus (20*2)	Bolus	Box	38,760	5,232,600	77,484	10,460,340
Adzyle Bolus	Bolus	Box	20,295	1,473,620	2,322	168,600
Oxi D Bolus	Bolus	Container	71,273	17,105,520	644	154,560
Acipure Plus-100 MI	Liquid	Bottle	2,451	208,335	-	-
Acipure Plus-500 MI	Liquid	Bottle	857	317,090	-	-
Adzinc B -100 MI	Liquid	Bottle	19,629	1,570,320	-	-
Adzinc B -500 MI	Liquid	Bottle	13,943	3,904,040	-	-

Name of Items	Product Category	Unit	30-Jun-20		30-Jun-19	
			Quantity	Amount	Quantity	Amount
Adzyme-100 MI	Liquid	Bottle	7,536	828,960	-	-
Adzyme -500 MI	Liquid	Bottle	3,788	1,894,000	-	-
Germ Kill 80-(100 MI)	Liquid	Bottle	47,097	8,477,460	-	-
Germ Kill 80-(500 MI)	Liquid	Bottle	23,628	19,493,100	-	-
Greenphos DCP Super- 1kg	Powder	Sachet	899	62,930	-	-
Levo Super - 100 MI	Liquid	Bottle	1,433	270,880	-	-
Nutrain-100 MI	Liquid	Bottle	879	175,800	-	-
Nutrain-500 MI	Liquid	Bottle	347	322,710	-	-
Superior Syn Biotech-100 MI	Liquid	Bottle	1,433	157,630	-	-
Superior Syn Biotech-500 MI	Liquid	Bottle	483	246,330	-	-
Toxosorb-100 MI	Liquid	Bottle	3,019	347,185	-	-
Toxosorb-500 MI	Liquid	Bottle	1,645	847,175	-	-
Utrosol (500 ml)	Liquid	Bottle	26,502	6,360,480	-	-
L-Lisyne	Powder	Bag	164,000	23,958,500	-	-
Green Phose(MCP)	Powder	Bag	216,000	12,624,000	-	-
L-Threonine	Powder	Bag	18,000	2,520,000	-	-
Total				534,027,579	-	601,966,497



ADVENT PHARMA LIMITED

Corporate Office: Rupayan Karim Tower, level 10, 80, Kakrail VIP Road, Ramna, Dhaka-1000

PROXY FORM

I / We of being a shareholders of **Advent Pharma Limited** and entitle to vote, hereby appoint Mr./Mrs./Miss..... as my/our proxy to attend and vote for me/us and on my/our behalf at the 13th Annual General Meeting (AGM) of the Company will be held on virtual platform on Thursday, December 17, 2020 at 11.00 a.m.

(Signature of the Shareholder)

(Signature of Proxy)

Revenue
Stamp
Tk. 20.00

BO ID No.

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

No. of Shares held

Dated.....

Note:

- 1) This form of proxy, duly completed and signed must be deposited at least 48 hours before the meeting at the Company's registered office. Proxy is invalid if not signed and stamped as explained above.
- 2) Signature of the Shareholder must be in accordance with Specimen Signature recorded with the Company.



ADVENT PHARMA LIMITED

Corporate Office: Rupayan Karim Tower, level 10, 80, Kakrail VIP Road, Ramna, Dhaka-1000

ATTENDANCE SLIP

I hereby record my attendance at 13th Annual General Meeting of the Company being held on virtual platform on Thursday, December 17, 2020 at 11.00 a.m.

Name of the Member/Proxy.....

BO ID No.

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

No. of Shares held


Dated.....

(Signature of Proxy)

(Signature of the Shareholder)

Date

N.B. Shareholder attending meeting in person or by Proxy are requested to completed the Attendance slip and deposit same at the entrance of the meeting.



Corporate Office: Rupayan Karim Tower, Level # 10, 80, Kakrail, V.I.P. Road, Ramna, Dhaka-1000,
E-mail: adventpharmaltd.bd@gmail.com, **Web:** www.adventpharmabd.com